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Haematopoietic stem cell  transplantation (HSCT)  is an effective therapy for many malignant and non‐malignant diseases. However, adverse events such as  infections, Graft‐versus‐Host Disease (GvHD) and relapse limit the wider use  of  HSCT.  The  identification  of  factors  that  predict  the  outcome  of  the transplant can be a vital  tool  to offer patients better options  for  treatment. Since there is a significant immunological contribution to the outcome of the transplant,  it  is  of  interest  to  ask  to what  extent  the  immune  status  of  the patient prior to transplant might influence their subsequent recovery.   After  transplantation,  the  reconstitution  of  the  T  cell  compartment  in  the patient relies on both expansion of existing T cells and the production of new ones via the thymus; in older patients this latter process is compromised by age‐dependent thymic involution. Improvements in thymus function leading to  improvement  in  immune  reconstitution  after  an  HSCT  may  provide significant benefits, potentially reducing mortality  from both  infections and GvHD.  In  one  study  described  in  this  thesis,  an  improvement  in  T  cell reconstitution, in particular of the CD4 compartment, could be demonstrated after the administration of an LHRH agonist before transplantation from an allogeneic donor. Such an effect could not be demonstrated in an autologous setting.    This may  reflect  a differential  requirement  for  thymus  function  in the two transplant settings. In  additional  studies,  various  immune  parameters  including  T  cell  subsets and  cytokine  profiles  from  the  patient,  that  could  affect  the  transplant outcome were analysed. The findings indicate that high levels of regulatory T 




cells  (Tregs)  as well  as  high  levels  of  regulatory  cytokines  in  patients  pre‐transplant are  factors  that predict relapse after  transplantation.    It  is  likely that  these  act  by  suppressing  anti‐tumour  responses  in  the  patient.  These findings may provide a useful tool to stratify the patients into high and low risk  categories  prior  to  transplantation.
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HSCT    =   Haematopoietic Stem Cell Transplantation DLI    =   Donor Leukocyte Infusion GvHD     =   Graft versus Host Disease aGvHD   =   acute Graft versus Host Disease cGvHD   =    chronic Graft versus Host Disease UD     =   Unrelated Donor UD‐HSCT   =   Unrelated Donor Haematopoietic Stem Cell        Transplantation HLA     =    Human Leukocyte Antigen CMV     =   Cytomegalovirus GvL     =   Graft versus Leukaemia RIC     =    Reduce Intensity Conditioning NKT     =   Natural Killer T cells NK     =   Natural Killer cells PCR     =   Polymerase Chain Reaction qRT‐PCR  =   quantitative Real Time‐ Polymerase Chain Reaction TRECs   =   T‐cell Receptor Excision Circles TCR     =   T Cell Receptor  TCRβ     =   beta Chain of the TCR Tregs     =   Naturally occurring CD4+CD25hi Regulatory T cells CTLA‐4   =   Cytotoxic T Lymphocyte Associated Antigen 4 GITR     =   Glucocorticoid Induced Tumour Necrosis Factor        Receptor PD1     =   Programmed Death 1 IL‐4     =   Interleukin 4 IL‐10     =   Interleukin 10 TGFβ     =   Transforming Growth Factor β FOXP3   =   forkhead box transcription factor 3  DC     =   Dendritic Cell mDC     =   myeloid Dendritic Cells pDC     =   plasmacytoid Dendritic Cells TRM     =   Transplant related mortality MHC     =   Major Histocompatibility Complex INF‐γ   =   Interferon‐gamma TNF‐α  =   Tumour Necrosis Factor alpha GvT     =   Graft versus Tumour PTLD     =   Post‐transplant Lymphoproliferative Disorder EBV     =   Epstein Barr virus pTα   =   Pre T‐cell receptor RAG1     =   Recombination Activating protein APC     =   Antigen Presenting Cells RSS     =   Recombination Signal sequence TdT     =   Terminal deoxynucleotidyl Transferase enzyme CDR3     =   Complementarity Determining Region 3 Tr     =    Regulatory T cells Th3     =   Regulatory TGF‐β producers PBMC’s   =  Peripheral blood Mononuclear cells  




RMPI    =  Roswell Park Memorial Institute DMSO    =  Dimethyl sulphoxide  cDNA    =   complementary DNA M‐MLV  =  Moloney Murine Leukemia Virus PBS    =  Phosphate buffered saline FCS    =  Foetal calf serum mAb    =  monoclonal Antibodies FITC    =  Fluorescein PE    =  Phycoerythrin PerCP    =  Peridinin‐chlorophyll‐protein Complex  APC    =  Allophycocyanin FACS    =  Fluorescence Activated Cell Sorting dNTP’s  =  deoxynucleotide triphosphates  SDS    =  Sequencing detection system LB    =  Lysogeny broth agar TE    =  Tris‐EDTA buffer MgCl2   =  Magnesium chloride NaCl    =  Sodium chloride LiCl    =  Lithium chloride NTC    =  Non template control TfR    =  Transferrin receptor OD    =  Optical density CDR    =  Complementarity Determining Region OS    =  Overall Survival DFS    =  Disease Free Survival   








 Haematopoietic Stem Cell Transplantation (HSCT) 
 Haematopoietic  stem  cell  transplantation  (HSCT)  is  a  potentially  curative therapy  for  a  variety  of  life  threatening  diseases  of  the  haematopoietic system, including malignancies, primary immune deficiencies, bone marrow failure  syndromes  and  autoimmune  diseases  (van  den  Brink,  et  al.,  2004). The  principle  of  haematopoietic  stem  cell  transplantation  consists  of  the administration of high doses of chemotherapy and irradiation  (conditioning regimen) to eliminate leukaemic or abnormal cells, and at the same time, to provide a space for the new healthy system to repopulate from transplanted stem cells. However, often not all  the  leukaemic cells are eliminated by the conditioning  regimen,  and  those  cells  are  responsible  for  relapse  of  the primary tumour. For some years, it has been demonstrated that the infusion of  donor  T  cells,  so‐called  donor  lymphocyte  infusion  (DLI),  induces remission  in  patients who had  experienced  relapse,  providing  a  proof  that donor cells can have an antileukaemic effect capable of inducing a sustaining remission.    




Conditioning before HSCT  The conditioning regimen required prior to transplantation comprises both treatments,  to  eliminate  the  leukaemic  cells  from  the  recipient  and  also  to prepare the recipient’s immune system to tolerate and accept the new cells. This  can  be  achieved  with  the  use  of  high‐dose  chemotherapy  with  or without  irradiation  (myeloablative  conditioning)  or  lower  doses  of chemotherapy  and/or  lower  doses  of  irradiation  (non‐myeloablative conditioning) (Martin, et al., 2009).     
Types of haematopoietic stem cell transplant  Haematopoietic  stem cells  can be  collected  from either  the  recipient’s own stem  cell  population  or  can  be  obtained  from  sibling  or  unrelated  donors.  When  cells  are  obtained  from  the  recipient  it  is  known  as  an  autologous transplant. When cells are collected from other individual it  is known as an allogeneic transplant, and in such cases, the recipients need to receive drugs to prevent either rejection of the transplanted haematopoietic stem cells or the  development  of  graft  versus  host  disease  (GvHD).  To  avoid  adverse reactions such as GvHD, T cells can be removed from the graft with depleting anti‐T  cell  antibodies  (T‐cell  depletion)  or  a  stem  cell  population  can  be enriched (CD34 selection).  




Haematopoietic Stem cell transplantation from Unrelated Donors 
Although  the  curative effect of HSCT has been demonstrated,  two‐thirds of patients requiring an allogeneic HSCT do not have a matched sibling donor, thus HSCT from unrelated donors (UD) has considerably increased in recent years. As a result of novel approaches to HSCT that have  led to more rapid engraftment  and  immune  reconstitution,  a  reduction  in  morbidity  and mortality post‐transplant is seen, making the use of allogeneic HSCT from UD applicable  to  a wider  range  of  patients.  In  Europe more  than  one  third  of allogeneic  transplants  performed  employ  haematopoietic  stem  cells collected  from unrelated donors  (Storb,  et  al.,  2003). Nevertheless,  despite its  curative  potential,  HSCT  remains  associated  with  significant  morbidity and mortality that may outweigh the beneficial effect in some cases.  Different  studies  comparing HSCT  using  siblings  or  unrelated  donors  have shown  similar  results  with  respect  to  transplant  outcome,  including  the incidence of GvHD, incidence of relapse and overall survival.  In part, that the results are comparable has been associated with an improvement in tissue‐typing  techniques  (Remberger,  et  al.,  2008).  However,  although  the  HLA‐matching is essential for the success of HSCT, it does not prevent the major complications.  Thus,  there  must  be  other  non‐HLA  factors  affecting  the outcome  of  an  HSCT.  Some  of  those  non‐HLA  factors  are  minor Histocompatibility antigens and polymorphic immune response genes.   




Clinical factors affecting HSC transplant 
A  number  of  patient  and  donor  factors  need  to  be  taken  into  account  to select  appropriate  candidates  for  HSCT  from  unrelated  donors.  The major predictive  factor  for an UD HSCT  is  to have a suitable HLA‐matched donor. Although,  there  are  some  “permissive”  mismatches  that  can  be  analyse  in specific  clinical  situations,  the  desirable  situation  and  most  important  for transplant  success  is  to  have  a  10/10  match.  However,  there  are  other factors  that  have  been  studied  and  are  involved  in  UD‐HSCT  success,  as shown schematically in Figure 1.1.   
Figure 1.1. Patient and donor characteristics associated with haematopoietic transplant 
outcome.  










Although it is very important to consider donor characteristics in the context of an HSCT, there are also recipient factors that are needed to be taken into account  to be  able  to define  the most  suitable donor. The  recipient  factors that need to be analysed are:  1) The type of haematological or genetic disorder,  2) The status of the disease at the time of the transplant;  3) The pre‐transplant conditioning of the recipient;  4) The immunosuppressive prophylaxis; and  5) Whether or not the graft is T cell depleted (Singhal, et al., 2005).   Although the majority of allogeneic transplants from unrelated donors in the United Kingdom are performed with T cell depletion, other very  important factors  for  successful  transplant  in  the  case of non‐T  cell depletion are  the characteristics of the graft, particularly the dose of nucleated cells, the dose of  CD34+  cells,  the  doses  of  other  immunological  cells  such  as  NKT (specialised T cells  that express  the NK1.1 cell  surface molecule and which carry a unique T cell receptor containing an invariant alpha chain; such cells recognise  glycolipids  presented  by  the  CD1d  non  classical  MHC molecule) and NK cell (natural killer cells), dendritic cells, and the dose of CD4+CD25+ and CD8+CD25+ T cells in the graft.  All those cell subsets have been shown to influence  the  success  of  the  transplant  (Vela‐Ojeda,  et  al.,  2006)  (Baron  & Storb,  2005) therefore a detailed monitoring of the graft’s composition is an important tool to predict the success of the transplant. Even though all aforementioned factors play a pivotal role in the transplant outcome,  the  transplant outcomes are ultimately  largely  immune mediated events.  Despite  this,  to  date  little  is  known  about  whether  variations  in immune parameters pre‐transplantation can influence the overall transplant 




outcome.  Therefore  precise  identification  of  pre‐transplant  prognostic factors  in both patients  and donors,  affecting  the outcome after HSCT may help  to  identify  patients  who  are  more  likely  to  benefit  from  additional approaches such as immunotherapy (Zorn, et al., 2005).  
Immune factors affecting HSCT 
 Different  groups  have  suggested  several  factors  of  the  recipient’s  immune status  pre‐transplantation  that  have  a  predictive  effect  in  HSCT  outcome, such as:  1)  T  cell  subsets,  particularly  the  number  of  effector  CD4+  T  cells (Rosinski, et al., 2005);  2) Thymic function, analysed by recent thymic emigrants (Clave, et al., 2005);  3) Regulatory T cells (Zorn, 2006); and also  4)  The  pre‐transplant  levels  of  other  immune  cells  (Cohen,  et  al., 2002) (Jones, et al, 2003) (Arpinati, et al., 2007) (Scott, et al., 2008).  Here I will analyse some of these factors and correlate their influence on the transplant outcome. 
 
T cells subsets and Transplant outcome. Tumour  relapse  remains  the  major  cause  of  transplant  failure  due  to  the inability  of  the  immune  system  to mount  an  effective  and  successful  anti‐tumour response after transplantation. The  role  of  immune  effector  cells  in  tumour  biology  is  an  active  area  of research  and  evidence  has  been  accumulated  that  demonstrates  an  anti‐tumour  effect  involving  T  cells  in  the  allogeneic  transplant  setting.  Pre‐




transplant  CD4+  T  cells,  in  particular  CD4+ memory  T  cells  (CD4+CD45RA‐CD62L‐) in the recipient have been shown to correlate well with the outcome of HSCT independently of other known factors (Rosinski, et al., 2005). These reports suggest that the analysis of the CD4+ subset prior to transplantation might be used as a prognostic factor after transplant. Another  imperative  issue  for  transplant  success  is  the emergence of GvHD. Certain  T  cell  subsets,  particularly  those  expressing  the  activation marker CD25 correlate with the degree and incidence of GvHD. Stanzani et al (2004) reported that higher frequencies of both CD4+CD25+ and CD8+CD25+ T cells in  the  graft  were  seen  in  patients  with  acute  or  chronic  GvHD  when compared with those who did not experience GvHD. However, they could not define whether  these CD25+  cells were  regulatory or  activated T  cells,  and they  suggested  that  more  work  to  identify  regulatory  T  cells  was  needed (Stanzani, et al., 2004), to clarify their influence in HSCT outcome. Therefore, there is evidence to support that the recipient’s T cell profile prior to  transplantation might  influence  the  transplant outcome,  and  its  analysis therefore could be used as a predictive factor. 
 
 
Thymic function and transplant outcome. Another  major  factor  influencing  HSCT  outcome  is  thymic  function  (Zorn, 2006). The  thymus  is  the primary anatomic  site of T  cell development and the regeneration of an adequate T cell number and repertoire diversity are key elements in the recovery of immune competence (Stanzani, et al., 2004).  




Thymic  function  and  the  production  of  recent  thymic  emigrants  can  be evaluated  through  the  quantitation  of  T‐cell  receptor  excision  circles (TRECs)  by  Real‐Time  Polymerase  Chain  Reaction  (qRT‐PCR).  TRECs  arise from  the  rearrangement  event  that  deletes  the  TCR  delta  locus  during commitment of a T cell to the alpha/beta lineage; they are stable, and neither replicate  nor  degrade  during  cell  division  but  partition  into  one  daughter cell, and they decrease with age following thymic atrophy since they will be lost as a result of normal cell turnover and not replaced  (Douek, et al., 1998) (Talvensaari, et al., 2002).  After transplantation, TREC production is the best indicator  to  date  of  thymic  function  and  TREC  levels  correlate  well  with naïve T cell levels (Baron & Sandmaier, 2005) (Stanzani, et al., 2004). A number of  studies have  shown  that patients with better  thymic  function before transplantation have better early recovery of TREC number and TCRβ repertoire  diversity  than  patients  with  lower  thymic  function.  Therefore, TREC quantification may be useful in assessing risk prior to transplantation (Zorn, 2006)  (Zhang, et al., 1999)  (Douek, et al., 1998).   
Regulatory T cells and transplant outcome.  A  population  of  lymphocytes  with  immune  suppressive  capacity  has  been reported,  termed  regulatory  T  cells  (Tregs),  representing  5  to  10%  of  the normal T cell compartment in mice and humans (Sakaguchi, et al., 1985).  A precise  definition  of  these  cells  is  not  conclusive  as  yet,  however,  they  are naturally occurring, predominantly confined to the CD25hi subset of CD4+ T 




cells,  they  appear  to  preferentially  express  the  transcription  factor  FOXP3 along  with  varying  levels  of  cytotoxic  T  lymphocyte  associated  antigen  4 (CTLA‐4),  glucocorticoid  induced  tumour  necrosis  factor  receptor  (GITR), and programmed death 1 (PD‐1). Upon stimulation, they produce regulatory cytokines such as IL‐4, IL‐10 and transforming growth factor β (TGF‐β). Tregs  have  an  important  role  in  controlling  autoreactive  T  cells  and maintaining  peripheral  tolerance  to  self‐antigens,  however  their  role  in transplant outcome remains controversial (Sakaguchi, et al., 2001). A  potential  clinical  benefit  of  Tregs  in  controlling  GvHD  and  reducing  the complications  of  allogeneic  HSCT  has  been  suggested.  The  recent understanding  of  the  function  of  Tregs may  provide  a  tool  to  improve  the outcome  of HSCT  by  creating  a  balance  between GvHD  and GvL  effects.  In mice,  it  has  been  reported  that  a  high  number  of  CD4+CD25+  T  cells correlates with a delay in the development of GvHD (Yagi, et al., 2004). Also, in mice, it has also been reported that the infusion of CD4+CD25+ T cells can control even established GvHD (Sakaguchi, et al., 1985).  However,  the  role  in  humans  is  more  controversial,  with  different  results being obtained by different groups. Clark et al (2004) found an increase in the absolute number of CD4+CD25hi T cells  in  adult  patients  who  underwent  an  HSCT  from  sibling  donors  and developed GvHD (Clark, et al., 2004). Sanchez et al (2004) also reported that the  ratio  of  activated  CD4+  effector  cells/CD4+CD25+  cells  was  higher  in patients who developed chronic GvHD in comparison with patients who did not (Sanchez, et al., 2004).   




In  contrast,  Zorn  et  al  (2006)  found  a  decrease  in  the  frequency  of CD4+CD25+  T  cells  in  patients  with  chronic  GvHD  and  also  showed  a correlation  between  a  decrease  of  FoxP3  expression  in  peripheral  blood lymphocytes (PBL), measured by quantitative PCR,  in patients with chronic GvHD  (Zorn,  2006).  Miura  et  al  (2004)  also  showed  a  decrease  in  the expression  in  FoxP3  in  PBMC,  measured  by  quantitative  PCR,  in  patients with  acute  and  chronic  GvHD  (from  patients  who  underwent  HSCT  from sibling  donors  or  auto  HSCT),  and  also  showed  a  correlation  between  the expression of FoxP3 and the severity of GvHD (Miura, et al., 2004). However in contrast to both of the above, Mening et al (2005) reported that comparable numbers of CD4+CD25hi T cells and FoxP3 levels were found in patients who underwent HSCT from HLA identical siblings, with or without chronic GvHD (Meignin, et al., 2005). Clearly, more information is required to elucidate the role of Treg in humans.  
Other Immunological Cells and HSCT outcome Recently the impact of the pre‐transplant levels of other immunological cells on  HSCT  outcome  has  been  investigated.  In  particular,  the  levels  of  both major  types  of  dendritic  cells,  myeloid  (mDC)  and  plasmacytoid  (pDC) dendritic  cells  along  with  monocytes  (CD14+  cells)  have  been  studied. Dendritic  cells and monocytes were measured prior  to  the  initiation of  the conditioning  regimen  in both  related and unrelated  transplant. The  results suggested  that  higher  levels  of  CD14+  cells  prior  to  transplantation  were predictive  for  the onset of aGvHD  in patients  receiving a  transplant  from a related donor but no effect was seen with patients receiving transplant from an unrelated donor. On  the other hand,  the  levels of dendritic  cells did not 





















Major complications in HSCT  There are complications associated with the transplant procedure and those not  associated with  the  underlying  disease  are  denominated  as  transplant related  mortality  (TRM),  which  can  occur  early  post‐transplant.  The  TRM complication  can  be  classified  as  early  (occurring  within  the  first  90  day after  transplant)  or  late,  occurring  beyond  90  days  post‐transplantation. These  complications  are  often  related  more  to  the  conditioning  regimen used. Despite the fact that recent advances have improved the prognosis of HSCT, there  are  major  complications  such  as  graft  versus  host  disease  (GvHD), infections and relapse of the primary malignancy that are still major causes of  death  after  transplantation  and  are  a  limitation  on  the  wider  use  of unrelated  donors,  and  the  wider  application  of  Haematopoietic  stem  cell transplantation for non‐malignant diseases. 
Infections 
Although better diagnostic tools and better treatments have been developed over time, infectious complications after HSCT remain a major cause of death after  HSCT  (Gratwohl,  et  al.,  2005).  The  major  factor  involved  in  the development  of  infections  is  the  profound  immune  deficiency  following HSCT with full  immune reconstitution taking up to two years (Martin, et al, 2009). At least 10% of all deaths after HSCT are due to infections. The causes of  lethal  infections  are  divided  into  bacterial,  viral,  fungal  or  parasitic infections.  Other  pre‐transplant  factors  along  with  immune  reconstitution that  are  associated  with  infectious  complications  are  age  and  T‐cell 




depletion,  though  these  also  affect  the  rate  of  immune  reconstitution.  The impaired T cell reconstitution after HSCT has also been associated with other HSCT  complications,  in  particular with  the  incidence  of  GvHD  and  relapse and  is  therefore  a  major  cause  of  morbidity  and  mortality    (Giralt,  et  al., 1997)  (Kassim, et al., 2005).   
Graft Versus Host Disease (GvHD) and Transplant failure. 
Graft versus host disease (GvHD) is the major complication after allo‐HSCT. Acute  GvHD manifests  within  100  days  post‐transplant  and  is  induced  by donor  T‐cells  responding  to  mismatched  host  polymorphic histocompatibility antigens, whiles chronic GvHD manifests later (more than 100  days  post‐transplant)  and  has  some  features  of  autoimmune  diseases (Toubai, et al., 2008). Chronic GvHD can arise de novo or as an extension of aGvHD, and  it  is  thought  to be  induced also by donor T‐cells. However,  the exact mechanism of cGvHD remains unclear (Toubai, et al., 2008). The  physiopathology  of  GvHD  is  not  completely  understood;  however  it  is thought to be initiated by alloreactive donor T cells that recognise MHC class I and class II molecules on the surface of host cells (direct allorecognition), as well  as  host  peptides  presented  by  donor  dendritic  cells  (indirect allorecognition)  (Ferrara,  2000).  The  infiltration of  target  organs by donor leukocytes is one of the key processes in GvHD (Gratwohl, et al., 2005); the activation  and  expansion  of  these  donor  T  cells  leads  to  a  deregulation  in production of pro‐inflammatory cytokines  (e.g.  INF‐γ  and TNF‐α)  in both T 




effector cells  that  further damage affected tissues (Remberger, et al., 2008) (Madrigal, et al., 1999) (Madrigal, et al., 1997).  To  date,  the  most  effective  way  to  avoid  GvHD  in  unrelated  donor haematopoietic stem cell transplantation (UD‐HSCT) is T cell depletion of the graft  (Przepiorka,  et  al.,  1999)  (Przepiorka,  et  al.,  2001).  However,  this method  results  in  a  greater  incidence  of  graft  failure;  higher  risk  of opportunistic  infections;  tumour  relapse;  secondary  lymphoproliferative diseases, and delay in immune reconstitution  (Urbano‐Ispizua, et al., 2002) (Vela‐Ojeda, et al., 2006) (Baron, et al., 2005). On  the  other  hand,  there  is  an  association  between  GvHD  and  relapse,  as mentioned before, patients who receive infusions of grafts containing T cells show less recurrence of their disease, demonstrating that in addition to the conditioning  regimen  aimed  to  eliminate  the  leukaemic  cells,  an  immune reaction  occurs  mediated  by  donor  T  cells  that  is  important  for  the elimination  of  residual  tumour  cells.  This  is  the  so‐called  Graft  versus Tumour or Leukaemia (GvT or GvL) effect. Therefore, it is clear that donor T cells  have  an  impact  improving  engraftment  and  immune  reconstitution after  HSCT  (Baron  &  Storb,  2005).  For  several  decades  then,  the  main challenge of allogeneic HSCT has been the balancing of  these two reactions (GvT  versus  GvHD)  that  has  not  yet  been  achieved  (Baron  &  Sandmaier, 2005).   
Graft failure 
Finally, transplant failure occurs when the new haematopoietic system fails to  grow  successfully  in  the marrow  of  the  recipient.  This may  result  from 




insufficient  stem  cells  being  transplanted  or  from  recipient  immune responses directed against the donor haematopoietic cells.  
Relapse of the primary tumour 
Relapse  or  disease  recurrence  is  defined  as  the  presence  of  cytological molecular  or  genetic  markers  of  the  underlying  disease.  Relapse  of  the primary tumour remains the major cause of treatment failure, and can occur anytime  during  therapy  or  after HSCT.  In  fact,  20  to  50% of  patients with acute leukaemia relapse after an HSCT (Lee, et al., 2000). One factor that has been  associated  with  an  increase  incidence  of  relapse  is  the  stage  of  the disease at the time of transplant. A second, very important factor is whether or not the graft was T cell depleted, which relates to the presence or absence of  the  graft  versus  leukaemia  effect  (GvL)  (Lee,  et  al.,  2000).  It  has  been demonstrated, that after allogeneic HSCT from a fully HLA matched donor, T cells  from  the  donor  can  mount  an  alloresponse  against  minor histocompatibility antigens of the recipients. Those allogeneic responses can be  restricted  to  host  haematopoietic  cells  and  can  create  an  effective  anti‐tumour  response.  Such  GvT  response  is  also  known  as  the  Graft  versus Leukaemia  effect  (GvL)  and  prevents  the  patient’  suffering  relapse  of  the primary tumour (Horowitz, et al., 1990). More  recently  other  genetic  factors  have  been  associated  with  increase relapse rate, such as DP matching and the presence of polymorphisms in the NOD2/CAR15  gene,  particularly  in  T  cell  depleted  transplant  settings  (Mayor, et al., 2007).  




Post-transplant lymphoproliferative disorder (PTLD) 
Anther  important  complication  after  HSCT  is  a  group  of malignancies  that are  associated  with  Epstein‐Barr  virus  (EBV)  infection.  There  are  several factors associated with the induction of PTLD, EBV mismatch between donor and recipient, the use of T‐cell depletion therapy and genetic predisposition of the recipient. The overall incidence or PTLD is 2.5% in the first year post‐transplant. 
Transplant success 
 The  successful  hematopoietic  stem  cell  transplantation  (HSCT),  in  both autologous  and  allogeneic  settings,  requires  a  rapid  and  durable engraftment,  considered  successful  when  the  patient  achieves  neutrophil counts  >  500/ul  and platelet  counts  >  20,000/ul  (Gonçalves,  et  al.,  2009).   Engraftment  can  be  achieved  with  a  combination  of  the  high  dose chemo/radiotherapy,  transplant  conditioning  and  the  anti‐leukaemic  effect of  the  allogeneic  T  cells  in  the  graft,  and  it  can  be  analysed  by monitoring engraftment  and  reconstitution  of  the  immune  system  by  flow  cytometry and  TREC  quantification.  Also  it  is  in  this  context  important  to  study  the diversity of  the T cell population. The period  following HSCT  is a period of profound  immunodeficiency  associated  with  complications  such  as infections  and  relapse.  And  thus,  mechanisms  to  improve  immune reconstitution  have  become  an  area  of  great  interest.  New  drugs  that enhance  the  immune  reconstitution,  in  particular  the  T  cell  lineage  have been studied to improve the outcome after transplantation.   




Immune reconstitution following HSCT  Better  outcome  following HSCT depends on  the  complete  reconstitution of the  host’s  immune  system.  The  recovery  of  the  complete  immune  system after an HSCT follows different paths  for  the different cellular components. There is a relative fast recovery of cells of the innate immunity, and the first cells  to  recover  are monocytes  and NK  cells.  Although  the  levels  of  B  cells also  recover  rapidly,  the  levels  of  immunoglobulins  remain  low. The T  cell lineage remains low up to one year after transplantation, mainly due to a low level  of  CD4+  cells,  which  remain  low  up  to  2  years  post‐transplant. Consequently, there is an inversion on the CD4/CD8 ratio. That observation has been supported by TREC quantification, where a low TREC count can be found even a year after  transplant, and the  low TREC  level  is mainly  in  the CD4+ T cell compartment (Storek, et al., 2008). Also the diversity of the TCR diversity  remains  restricted  up  to  two  years  after  transplant,  which  may imply a limited response against antigens and an increased risk of infections.   
T cells reconstitution after HSCT  T  cells  can  reconstitute  through  two  different  mechanisms  after transplantation,  the  progenitor  haematopoietic  cells  can  reconstitute  the T lymphocyte population using the thymic dependent pathway or pre‐existing T lymphocytes can reconstitute normal levels using the thymic independent homeostatic pathway. The  thymic  independent  pathway  involves  an  expansion  of  pre‐existing naïve and memory T cells derived from mature T cells present in the donor 




graft, the limited numbers of these producing an oligoclonal expansion and a narrow T cell repertoire  (Bomberger, et al., 1998) (de Gast, et al., 1985). The thymic dependent pathway involves the development de novo of T cells in the recipient from the transplanted donor stem cells. During, this process T  cell  reconstitution  recapitulates  the  T  cell  ontogeny,  in  which  T  cell progenitors undergo a process of expansion, maturation and differentiation in the thymus. Clearly,  therefore, a  functional thymus is required   (Mackall, et al., 1993). The thymic dependent pathway has the advantage of generating long‐term naïve  T  cells  and  a  broader  TCR  repertoire  in  contrast with  the thymic  independent  pathway. However,  the  thymus  dependent  pathway  is age‐dependent  as  a  consequence  of  thymic  involution  with  increasing  age  (Bomberger,  et  al.,  1998)  (Weinberg,  et  al.,  1995)  (Mackall,  et  al.,  1995) (Storek, et al., 1995). The reconstitution by  the  thymic dependent pathway can  be  analysed  by  flow  cytometry.  Traditionally,  the  naïve  T  cells  can  be studied  by  the  expression  of  the  surface  marker  CD45RA  (Johannisson  & Festin,  1995).  However,  it  has  been  demonstrated  that  this  marker  is  not accurate  (Arlettaz,  et  al.,  1999).  The  best  way  at  present  to  analyse  the reconstitution  of  newly  generate  T  cells  is  by  quantification  of  the  T  cell excision circles (TRECs) by real‐time PCR (Fallen et al, 2003).  
T cell ontogeny 
 Lymphoid progenitors from haematopoietic cell precursors migrate from the bone marrow to the thymus where they begin a period of differentiation and complete  their  maturation.  The  thymic  microenvironment  directs  the 




differentiation (Haynes & Heinly, 1995).  In  the  thymus, T cells also acquire their specific markers: TCR α and β chains, CD3, CD4 and CD8, and they go through a period of thymic education, involving processes of the positive and negative selection (Starr, et al., 2003). The  thymus  is  a  multi‐lobed  organ  with  cortical  and  medullary  areas surrounded by  a  capsule.  Shown  schematically  in  Figure 1.3,  the  lymphoid progenitors  enter  the  subcapsular  cortical  area  in  which  cells  interact immediately  with  the  thymic  stroma;  during  that  period  cells  undergo  a period of extensive proliferation. As cells continue their differentiation they move from the cortex to the medulla, into a different microenvironment that promotes T cell maturation.  T  cell maturation  from  lymphoid  progenitors  can  be  analysed  through  the expression of different surface markers. The first marker expressed is CD2, when the cells have not rearranged their TCR genes (CD2+CD3‐) and they are also negative for the CD4 and CD8 markers (so‐called double negative period CD4‐CD8‐). Then T cell precursors will express the adhesion molecule CD44, followed  by  the  expression  of  the  α  chain  of  the  IL‐2  receptor  (CD25) (Haynes, et al., 1988).  As  T  cell  precursors  become  CD44low  CD25+  double  negative  cells,  they rearrange  their T  cell  receptor  loci.  From  the double negative phase  about 10‐20%  of  the  cells  will  rearrange  the  γδ  TCR,  to  complete  their differentiation as a γδ T cells, while the majority of the cells, about 80‐90% will  commit  to  rearranging  their  αβ  TCR,  becoming  αβ  T  cells.    In  this process  they  rearrange  the  TCR  β  chain  of  one  chromosome  and,  if  that rearrangement  fails  then  a  rearrangement  of  the  second  chromosome 































Positive selection The process of selection of  the T cell  specificity  takes place  in  two discrete stages during T cell development, as shown in Figure 1.4.  Positive selection occurs  when  double  positive  T  cells  bind  cortical  thymic  epithelial  cells expressing either Class I or Class II MHC molecules/peptide complexes with high  affinity  to  get  a  survival  signal,  allowing  them  to  continue  their maturation  process    (Owen  &  Moore,  1995).  Therefore,  positive  selection appears to be based on low reactivity with self‐peptides presented by MHC molecules  of  thymic  epithelium    (Hogquist  et  al.,  1994)  (Hogquist,  et  al., 1997).  
Negative selection Negative selection occurs when double positive T cells bind  to self derived APC  (macrophages and dendritic  cells)  expressing either Class  I  or Class  II MHC molecules/self peptide complexes with a high enough affinity to receive an apoptosis signal and therefore, clonal deletion (Viret & Janeway, 1999).  The  recognition of peptides bound  to  the MHC molecules  through negative and positive selection have an impact in shaping the T cell repertoire.      
 
   










T cell receptor (TCR) and T cell receptor rearrangement  T  cell  receptor  (TCR)  is  a membrane bound heterodimer  composed of  two polypeptide  chains  (αβ  or  γδ)  linked  by  a  disulphide  bond  and  associated with  a  non‐polymorphic  membrane  bound  complex  of  proteins  known collectively as CD3   (Clevers, et al., 1988) (Rudd, et al., 1994) (Weiss, et al., 1994). 95% of T cells express the αβ T cell receptor (TCRαβ) and only 5% of T cells express the alternative γδ T cell receptor (TCRγδ). The extracellular domains of  the TCR contain  a  constant  (C) domain and a variable (V) domain. The V domain  interacts with  the antigen and with  the major histocompatibility molecules and confers specificity to the T cell.  























The TCR loci  The TCR genes are  located on chromosomes 7 and 14. The genes encoding the  TCRδ  (TCRD)  chain  are  located  within  the  TCRα  (TCRA)  loci  on chromosome 14q11‐12, whereas  the TCRβ  (TCRB) and TCRγ  (TCRG) genes are  located  on  chromosome  7,  positions  q31‐35  and  p15,  respectively  (Caccia, et al., 1984) (Morton, et al., 1985) (Isobe, et al., 1985) (Wilson, et al., 1988) (Rabbitts, et al., 1985) (Le Franc, 2000). Each of the four genes must be assembled together during T cell ontogeny by somatic recombination and each  of  them  is  composed  of  a  variable  (V)  amino‐terminal  region  and  a constant (C) region. The variable region of the alpha locus (TCRα) contains V and  J  gene  segments  (Vα  and  Jα) while  the beta  locus  (TCRβ)  contains Dβ gene segments in addition to the Vβ and Jβ gene segments.  The  gamma  (γ)  and  delta  (δ)  chains  also  contain  the  variable  (V)  and  the constant  (C)  regions,  and  like  the  αβ  TCR  they  have  the  V  and  J  gene segments. The delta locus also contains the D segment. The multiple  non‐contiguous  V,  D  and  J  segments  undergo  rearrangement during  T  cell  development  to  form  the  complete  V  domain,  which  is responsible for antigen recognition.  The TCRA gene consists of 70 V gene segments, divided into 41 families, and at least 61 J segments consisting of 50 functional J genes and with a single C gene    (Roman‐Roman,  et  al.,  1991)  (Yoshikai,  et  al.,  1985)  (Kimura,  et  al., 1987) (Klein, et al., 1987).  The TCRB locus, shown in Figure 1.5, contains approximately 67 V genes of which 47 are functional and 19 are pseudogenes  (Rowen, et al., 1996). The functional genes are grouped into 23 families based upon greater than 75% 




nucleotide  similarity    (Toyonaga,  et  al.,  1985).  There  are  also  2  D  genes segments, 13 J segments, and 2 C genes. The D, J and C genes form two D‐J‐C clusters.  The  TCRG  consist  of  14  V  gene  segments  and  a  duplicate  J‐C  cluster,  one cluster containing three J genes and one C and the other one containing two J genes and one C gene. The TCRD locus is located within the TCRA locus between the AV and AJ gene segments (Le Franc, 2000). It is flanked by TCRD deleting elements (ΨJA and 
δREC), and during the commitment of the T cell to express αβ T cell receptor (TCR) the delta locus is eliminated by rearrangement between these deleting segments.    The  germline  encoded  TRCD  locus  contains  eight  V  segments, three D segments and four J segments.              





Figure 1.5. Locus representation of human TCRB locus on chromosome 7 (7q39).  Lefranc,  M.‐P.  and  Lefranc,  G.,  The  T  cell  receptor  FactsBook, Academic Press, London, 398 pages (2001)   
     
TCR Diversity  T cells have a unique ability to recognise a wide variety of non‐self antigens, which  is  necessary  for  their  immunological  function.  Therefore,  the generation  of  a  broad  TCR  diversity  is  very  important  to  allow  immune responses to many different infectious agents. The T cell receptor diversity is generated  during  T  cell  development  in  the  thymus  as  a  consequence  of different mechanisms: 




a)  Stochastic  TCR  gene  rearrangement:  different  V, D,  J  gene  segments  are brought  together  in  each  T  cell  progenitor  into  a  continuous  V‐D‐J  coding block  through  the  recombination  activating  genes,  RAG1  and  RAG  2 (Talvensaari,  et  al.,  2002)  (Zhang,  et  al.,  1999)  and  the  terminal deoxynucleotidyl transferase enzyme (TdT)  (Landau, et al., 1987). The TCR gene segments are flanked by recombination signal sequences (RSS), which are the sites for the VDJ recombinase and mark the points where the somatic recombination occurs.  b)  Nucleotide  insertion  and  deletion  at  junctional  sites:  incorporation  of template dependent palindromic “P” nucleotides and template  independent “N”  nucleotides  at  the  junctional  sites  increases  the  diversity  of  the  TCR  (Lewis, 1994)  (Nadel & Feeney, 1997)  (Alt & Baltimore, 1982)  (Gilfillan, et al.,  1993).  The  junctional  region  (V(D)J)  encodes  the  hypervariable  CDR3  (Jones, et al., 2003). The CDRs (CDR1, CDR2 within the V genes and CDR at the V(D)J junction) are the regions of greatest variability and are the binding sites  for  antigen,  the  CDR3  is  positioned  at  the  centre  and  it  is  the  one  in direct contact with the MCH/peptide complex).  c)  Combinatorial  recombination:  the  different  combinations  between individual  TCRA  and  TCRB  chains  or  TCRG  and  TCRD  also  increase  the diversity of the TCR repertoire. The estimated repertoire of unique TCR has been calculated at around 1015  (Davis & Bjorkman, 1988).  

















































T cell subsets 
The advent of the monoclonal antibodies and flow cytometry made possible the analysis of  functional T  cell  subpopulations. The most  representative T cell subsets are CD4+ and CD8+ T cells, better known by their  functionality, thus  CD4+  T  cells  or  helper  T  cells  and  CD8+  T  cells  or  cytotoxic  cells. However, CD4+ and CD8+ T  cells  can also be  identified by  their maturation stage using another set of surface markers such as: CD45RO/CD45RA, CD27, CD28 and CCR7. The first studies conducted analysing the CD3+/CD4+/CD8+ T  cell  subsets  recovery  after  transplantation  showed  similar  results where substantial impairment of the CD4+ subpopulation was found independently of other clinical factors while a fast recovery to normal values was found in the CD8+ subpopulation  (Atkinson, et al., 1982) (Janossy, et al., 1986). Even more,  some  groups  demonstrated  that  the  recovery  of  the  CD8+  T  cell subsets was mainly due to a clonal proliferation of mature T cells present in the graft, as was shown in patients positive for CMV infection (Peggs, et al., 2003). Eventually, other markers such as CD45RA, CD45RO and CD27 together with CD4  and  CD8  were  shown  to  be  better  markers  to  define  the  maturation status  of  T  cells.    The  CD45  molecules  are  known  to  appear  in  various isoforms generated by alternative splicing of variable exons 4, 5 and 6 of the extracellular  domain  in  various  thymocyte  subsets  and  changes  in  CD45 isoform  expression  has  been  correlated  with  positive  selection  and thymocyte  development    (Fukuhara,  et  al.,  2002).  The  expression  of  the CD45RA  isoform  represents  naïve,  recent  thymic  emigrant  T  cells;  they represent  the 95‐99% of  the  lymphocytes at birth while an  increase of  the 




cells  expressing  the  CD45RO  isoform  is  observed  during  the  first  two decades of  life, and this conversion on  the phenotype  is associated with an increase in memory cells  (Cossarizza, et al., 1996). Therefore, the analysis of the CD45RA/RO expression might be helpful to define the origin of the new cells  after  transplantation  and  the  reconstitution  pathway  followed  after transplantation. However,  it has become clear that this alone is insufficient, since CD45RO+ cells can re‐express CD45RA as they mature further.  Phenotypic analysis using CD45RA/RO monoclonal antibodies performed in post‐transplanted  patients  showed  a  disparity  between  the  phenotype  of neonatal and post‐transplantation reconstitution. As mention previously,  in neonates the phenotype of CD4+ T cell is associated principally with CD45RA expression,  which  is  associated  with  naïve  T  cells  and  the  naïve  T  cell phenotype  is  inversely  correlated  with  age.  While  in  post‐transplanted patients  there  is  an  inversion  and  CD4+  T  cells  are  associated  with  the expression of CD45RO, which  represents a memory marker    (Storek, et  al., 1995).  Indicating that T cells expressing the CD45RA marker are generated through  the  thymic  dependent  pathway  and  are  better  know  as  recent thymic  emigrant  (RTEs),  while  cells  expressing  the  CD45RO  marker  are generated  through  peripheral  expansion.  However,  a  regression  of  the CD45RO+  phenotype  to  the  CD45RA+  has  been  recently  observed,  which complicate  the  analysis  of  the  recent  thymic  emigrant  through  the expression of their surface markers, making evident the need for better ways to define the recently formed T cells (Haynes, et al., 2000).  Using  other  surface  markers  the  naïve  T  cells  are  defined  as CD45RA+/CD27+/CCR7+/CD28+,  the  central  memory  cell  are  defined  as 




CD45RA‐/CD27+/CCR7+/CD28+ and finally the effector memory T cells are defined as CD45RA‐/CD27+/CCR7‐/CD28+  (Okada, et al., 2008). However, apart of the CD4 and CD8 functional and maturation stage analysis through the analysis of their surface markers, different CD 4 subsets can be analysed  through  their  cytokine  production  profile.  Therefore,  CD4+  cells have  two major  functional  subsets:  Th1  and  Th2.  However,  recently  other CD4 subsets have been described: Th17 and regulatory cells. The CD4+ Th1 T cells are characterised by the production of INF‐γ and IL‐12 cytokines, while the Th2 T cells subsets  is characterised by  the production of  IL‐4,  IL‐5 and IL‐13. The Th17 subset has been recently described, which produces IL‐17, and have been implicated in autoimmune disease  (Harrington, et al., 2005) (Park, et al., 2005).  
Figure 1.7. T cell subsets.  Phenotype definition  of  naïve, memory,  effector  and  terminal  effector  cells depending on the expression of CD45RO and CD27 and phenotype definition of  naïve,  central memory,  peripheral memory  and  effector  cells  depending on the expression of CD45RA and CCR7.  
 
 




Table 1.1. Definition of T cell subsets by the expression of different 
markers  
  CD45 RA  CD27  CCR7  CD28 
Naïve   +  +  +  + 
Central Memory   ‐  +  +  + 
Effector  ‐  +  ‐  + 
Terminal effector  ‐  ‐  ‐  ‐ 
  
T cell subsets with regulatory function  Another important subset of T cells that have been correlated with the HSCT outcome  are  the  regulatory  T  cells.  Different  regulatory  T  cells  have  been defined  up  to  now:  a)  Naturally  occurring  CD4+CD25hi  T  cells  (Tregs);  b) Regulatory T cells 1(Tr1); and finally c) Regulatory T cells TGF‐β producers (Th3).   
Definition of naturally occurring CD4+CD25hi T cells: Tregs  Tregs are naturally occurring T cells and represent a distinct and functional T cell  subset developed  in  the  thymus expressing  the surface markers CD4 and CD25. They represent the 5‐10% of peripheral CD4+ T cells. They exert suppressive functions over other T cells and over other non T‐cells such as 




B‐cells, NK cells and dendritic cells, in a cell‐cell contact dependent manner. They play a central role  in controlling autoimmunity, and contribute  to  the maintenance of self‐tolerance, also an  important role  in controlling  tumour immunity  and  transplantation  tolerance  has  been  observed    (Sakaguchi,  et al.,  2001)  (Shevach,  2002).  The  forkhead  transcription  factor  FOXP3  is preferentially expressed by Tregs and it has been used as specific marker to identify them.   
Regulatory T cells 1 (Tr1) Another type of T cell that exhibits an immunomodulatory function through the secretion of high levels of IL‐10 are known as Tr1. These are generated through  chronic  activation  in  the  presence  of  interleukin‐10  (IL‐10).  Tr1 cells  can  suppress  antigen‐specific  responses  of  naïve  and memory  T  cells through the release of IL‐10 and by inhibiting the secretion of TNFα and INFγ  (Sundstedt, et al., 1997) (Groux, et al., 1997) (Roncarolo, et al., 2001). 
 
Th3 cells Th3 T  cells  are  another  subset with  regulatory/suppressive  functions over Th1  and  Th2  cells.  Their  suppression  activity  is  exerted  through  the production  of  Transforming  Growth  Factor  beta  (TGFβ)    (Weiner,  2001). Recently  it has been demonstrated  that TGFβ  can  induce  the expression of the  transcription  factor  FOXP3  in  the  periphery,  which  induces  the generation of new Tregs  in the periphery. The peripheral Tregs seem to be different  from  the  thymic  derived  Tregs,  however,  a  close  interaction 




between  the  different  types  of  suppressive  cells  has  been  documented (Carrier, et al., 2007) (Carrier, et al., 2007). The  role  of  the  various  T  cell  subsets  present  in  patients  prior  to transplantation  in  determining  the  outcome  of  the  transplant  forms  the subject of this thesis.  





Material and Methods   
 Isolation and cryopreservation of peripheral blood cells  
Reagents used for isolation and cryopreservation Heparin Lympholyte RPMI 1640 Trypan blue FCS DMSO   
Isolation of peripheral blood mononuclear cells (PBMC’s)  Peripheral  blood  samples  of  a  volume  of  40ml  were  transferred  to  50ml Falcon tubes containing 50 IU Heparin (CP Pharmaceuticals, Wrexham, UK). Peripheral  blood  mononuclear  cells  (PBMC’s)  were  separated  from  whole blood  by  density‐gradient  centrifugation  as  follows:  10ml  of  Lympholyte (Cedarlane Laboratories Limited, USA) was added to a 20ml Universal tube. The  Ficoll  contained  in  Lympholyte  is  a  neutral  high  mass  hydrophilic polysaccharide.      10ml  of whole  blood was  layered  carefully  on  top  of  the Lympholyte solution allowing  formation of a defined  interface between the blood and Lympholyte. The samples were then spun at 2200 rpm for 20 min in  a  Heraeus  2.0  centrifuge  (Heraeus,  Brentwood,  UK)  with  no  braking  to allow  the  formation of  the buffy  coat  layer.  Centrifugation of  samples with this  reagent  results  in  the  separation  of  different  layers  containing  the plasma  on  the  top,  then  the  PBMC’s  followed  by  Ficoll  and  finally  on  the 




bottom  the  erythrocytes  and  granulocytes.  Using  a  plastic  sterile  Pasteur pipette,  the  buffy  coat  layer  containing  PBMC’s  was  removed  from  the Lympholyte/plasma  interface  and  transferred  to  a  50ml  Falcon  tube.  The Falcon  tubes  were  then  filled  to  the  top  with  RPMI  1640  (Biowhittaker, Wokingham, UK) and samples were centrifuged at 1800 rpm for 10 min. The supernatant was then decanted, the cell pellet resuspended in a further 50ml of RMPI 1640 and the samples spun at 1600 rpm for 10 min. Before freezing the PBMC’s cell were counted.   
Cell Counting and Viability  The cell pellet was resuspended in 10ml of RPMI 1640 and cells counted by the dye exclusion method. 10µl of  the resuspended cells were stained with an  equal  amount  of  sterile  filtered  PBS  solution  containing  0.4%  (w/v) Trypan  blue  (BDH)  and  counted  using  an  haemocytometer  (Neubaur Chamber, Weber). Following the isolation and counting of PBMC’s, cells were cryopreserved in liquid nitrogen until further use.   
Storage and Cryopreservation  PBMC’s were  isolated as described previously. The cells were  then spun at 1600 rpm for 5 min and the cell pellet resuspended at a concentration of 5‐10x106  cell/ml  in  freeze  mix  (heat  inactivated  foetal  calf  serum,  FCS  and 




10%  dimethyl  sulphoxide  (DMSO)  (BDH)).  The  cell  suspension  was  then transferred to freezing vials (Nunc, Nalgene, USA) in 1ml aliquots containing a maximum of 1x1010 cells. The freezing vials were placed inside polystyrene boxes, and the boxes were stored at ‐70oC and after a minimum of 24 hours cells were transferred to liquid nitrogen until use. Cryopreserved samples were put back in culture by rapid warming at 37°C, followed by at least two washing steps in 50 ml RPMI 1640 (Bio Whittaker) using centrifugation at 1600 rpm for 10 minutes and incubation in complete medium for 12 to 24 hours prior to further use to allow for recovery of cell surface molecules and cellular function.   
Extraction of nucleic acids 
 
RNA Extractions and cDNA synthesis  Total RNA was extracted from 5x105 PBMC’s with RNeasy Mini Kit (QIAgen Inc, Valencia, California) according to manufacturer’s protocol. Samples were  lysed and homogenised using guanidine‐isothiocyanate  lysis. 75µl  of  buffer RLT  (guanidine  thiocyanate  containing buffer provided with the kit)  containing 1% (v/v) β‐mercaptoethanol  (Invitrogen) was added  to the  cell  pellet,  and  the  sample was mixed  by  vortexing  for  1 minute.  After addition of  5µl  of  a  4  ng/µl  poly‐A RNA  solution  as  a  carrier  to  the  lysate, homogenisation was performed by resuspension using a fine pipette tip. This 




resulted  in  disruption  of  plasma  membranes,  release  of  RNA,  shearing  of high molecular weight  genomic  DNA  and  reduction  of  viscosity  of  the  cell lysate. 75µl of 70% sterile, American Chemical Society (ACS) grade ethanol (Sigma  Aldrich)  was  added  to  provide  ideal  binding  conditions.  The  well‐mixed lysate was then loaded onto a column in a collection tube resulting in binding  of  RNA  to  the  silica‐gel‐membrane  in  the  column.  This  procedure isolates  RNA molecules  longer  than  200  nucleotides  thereby  enriching  for mRNA. Tubes were spun at 13,000 rpm for 15 seconds and the flow‐through discarded. Samples were washed by addition of 350µl buffer RW1 (supplied with  the  kit),  spun  at  13,000  rpm  for  15  seconds  and  the  flow‐through discarded.  Traces  of  DNA  that  may  co‐purify  were  removed  by deoxyribonuclease  (DNase)  treatment  on  the  column  using  digestion  with RNase‐free  DNase.  Therefore  DNase  I  (2.72  units/µl)  was  diluted  1:8  in buffer RDD (supplied with the kit) and 80µl were pipetted directly onto the membrane  for  incubation  at  room  temperature  for 15 minutes. DNase  and contaminants  were  the  washed  off  by  addition  of  350µl  buffer  RLT  and centrifugation  at  13,000  rpm  for  15  seconds.  The  flow  through  was discarded and the column transferred to a new collection tube for a further wash with 500µl buffer RPE (supplied with the kit). After centrifugation and discarding  of  the  collection  tube,  500µl  of  80%  sterile,  ACS  grade  ethanol (Sigma  Aldrich) were  added  and  the membrane  dried  by  centrifugation  at 13,000 rpm for 2 minutes. The spin was repeated in a new collection tube at 13,000  rpm  for  a  further  5 minutes.  Purified  RNA was  captured  in  a  new collection tube by elution with 40µl RNase‐free water and centrifugation at 13,000 rpm  for 1 minute  resulting  in a  final volume of approximately 35µl 




RNA. It was either used for RT‐PCR immediately or stored at –70˚C. Reverse  transcription  of  the RNA extracted was performed using 1µg RNA solution  in  a  volume  of  10  µl  with  1  µl  of  500  ng/µl  random  primers (Promega)  and  1  µl  of  10 mM  dNTPs  (Bioline)  for  5 minutes  at  65°C  and subsequent  chilling  on  ice.  The  resulting  12  µl  template  was  reverse transcribed in a 20 µl total reaction volume with 400 units Moloney Murine Leukaemia Virus (M‐MLV) reverse transcriptase (Promega), 10 mM DDT and 80 units RNasin RNase inhibitor (Promega)  in M‐MLV RT buffer (Promega) by  incubation  for  50  minutes  at  37°C.  Afterwards,  the  reaction  was terminated by incubation at 70°C for 15 minutes and the resulting cDNA was stored at ‐20°C.  The quality of  the cDNA was confirmed by β‐actin amplification as  follows: 0.5µl  cDNA  was  amplified  in  a  25µl  reaction  volume  using  0.5  units  Taq (Bioline), 2 mM MgCl2 (Bioline), 0.4 mM dNTPs (Bioline), 0.4 mM 5’ β‐actin primer (5’‐TCA TGA AGT GTG ACG TTG ACA TCC GT‐3’) (Promega) and 0.4 mM  3’  β‐actin  primer  (5’‐CTT  AGA  AGC  ATT  TGC  GGT  GCA  CGA‐3’) (Promega)  in PCR buffer (Bioline). PCR conditions were 94˚C for 2 minutes followed by 94˚C  for 30 seconds, 65˚C  for 1 minute and 68˚C  for 2 minutes for  40  cycles  and  final  polymerisation  at  68˚C  for  7  minutes.  5µl  of  PCR products were  subjected  to  gel  electrophoresis  in  a 2% agarose  gel  to  test amplification of the constitutive gene b‐actin (amplicon of 285pb).      




Preparation of cell lysates 
Reagents 
 
• Proteinase K 100mg/ml  Amplification of TREC molecules was carried out directly from a cell lysates. Cell lysates were prepared from PBMC’s. Cells were counted and transferred (5x105)  to  a  conical  1.5ml  microfuge  tubes  (Eppendorf,  Germany).  The samples  were  centrifuged  at  13000  rpm  for  1 min  in  a  Heraeus  Sepatech Biofuge  15  (Heraeus  Brentwood,  UK).  The  supernatant  were  aspirated  by vacuum suction and the cell pellet  lysed immediately. For every 1x105 cells in  the  cell  pellet,  10ml  of  100mg/ml  proteinase  K  solution  (Sigma,  Saint Louis, MO, USA) was  layered on the  top of  the cell pellet  taking care of not touch the cell pellet. The sample was then vortexed to detach the cell pellet from the bottom of the tube and the sample flicked, letting the pellet and the proteinase  K  solution  be  together  at  the  bottom  of  the  tube.  The  samples were then incubated for 2 hours at 56oC in a heating block. After 2 hours the samples  were  vortexed  and  spun  down  briefly  (10  sec)  in  a  Heraeus Sepatech Biofuge 15 and then incubated at 95oC for 15 min to inactivate the proteinase K. Finally samples were vortexed and spun down at 13000 rpm for 1 min in a Heraeus Sepatech Biofuge 15, and stored at ‐70oC until use. For the amplification 5µl of the cell lysate were added to each PCR reaction.   














Immunofluorescence staining   Many  immunologically  important  cells  can  be  defined  based  on  what molecules  are  present  on  their  surface.  Numbered  human  clusters  of differentiation (CD) are used to classify many epitopes on the cell surface of leukocytes.  A  combination  of  several  surface  markers  is  often  used  to associate cells with certain immune functions or properties.  Antibodies  directed  against  different  CDs  were  purchased  from  different companies.  These  had  fluorochromes  FITC,  PE,  PerCP  or  APC  directly conjugated and were used as described above. PBMC’s were washed in 1% Phosphate buffered saline (PBS) (BioWhittaker, Walkersville,  MD,  USA)  and  2.5%  Foetal  Calf  Serum  (FCS)  (BioWhittaker, Walkersville, MD, USA), the solution of PBS and FCS will be called from here, FACS  buffer.  A  total  of  300,000  PBMC’s were  incubated  for  25 min  at  4oC with a series of fluorescent labelled mono‐clonal Antibodies (mAbs) specific for: CD3, CD4 CD8, CD27, CD45RO, CCR7, CD45RA and CD25 conjugated  to fluorescein, phycoerythrin, PerCP or APC (BD Bioscience, San Jose, California, USA). Antibodies were used at 1:100 dilution and cells were washed twice in 




FACS  buffer  followed  by  fixation  with  1%  paraformaldehyde  until acquisition.  Immunophenotypic  analysis  of  the  stained  and  fixed  cells was performed  using  FACSCalibur  flow  cytometer  and  CellQuest  software  (BD Bioscience, San Jose, California, USA). The frequency of each cell subset was calculated  as  a  percentage  of  positive  cells  in  the  total  lymphocyte  gate. Figure 2.1 shows the phenotypic analysis of CD4 T cell subsets.  
 
 
Table 2.1. Antibody dilutions used for flow cytometry staining 
   Antibody  Label  Company  Dilution  Clone CD3  APC  BD Bioscience   1:125  HIT3a CD4  PerCP  BD Bioscience   1:25  SK3 CD8  PerCP  BD Bioscience   1:25  SK1 CD27  FITC  BD Bioscience   1:20  M‐T271 CD45RO  PE  BD Bioscience   1:20  UCHL1 CCR7  PE  R&D   1:10  150503 CD45RA  FITC  BD Bioscience   1:20  L48 CD25  PE  eBioscience  1:25  2A3 FOXP3  FITC  eBioscience  1:25  PCH101 CTLA‐4  PE  eBioscience  1:20  eBio20A (20A, A3) 
                   




Figure 2.1. Phenotypic analysis of CD4+ T cells (CD3+CD4+).              The left panel of the figure shows the gating of lymphocytes to define the  CD3+CD4+  population;  on  the  right  side  of  the  figure  are  shown  the different  T  cell  maturation  stages,  naïve  (CD27+CD45RO‐),  memory (CD27+CD45RO+),  effector  (CD27‐CD45RO+)  and  terminal  effector  (CD27‐CD45RO‐) as defined by flow cytometry.   
   
Intracellular staining  For FOXP3 intracellular staining a kit for fixations and permeabilization from eBioscience,  Inc (San Diego, California, USA) was used. 100ml of previously prepared cells were used per sample, staining normally for surface markers for  CD3,  CD4  and  CD25  (BD  Bioscience),  after  washing,  cells  were 




resuspended  by  vortex  and  1ml  of  freshly  prepared Fixation/Permeabilization  solution  was  added  and  vortex  again,  and incubated  for  1  hour  at  4oC.  After  incubation  samples  were  washed  two times  by  adding  2ml  of  1x  Permeabilization  buffer  and  centrifuged  and supernatant was decanted. 5ml anti‐human FOXP3 antibody was added per sample with  45ml  of  Permeabilization  buffer,  incubated  for  30 minutes  at 4oC in the dark. After incubation cells were washed again two times followed by  fixation  with  1%  paraformaldehyde  until  acquisition.  Intracellular staining with FOXP3 is presented in Figure 2.2.   






















































































Flow Cytometry  Cells stained with fluorochrome‐conjugated antibodies were visualised using flow  cytometry  using  FACSCalibur  flow  cytometer  and  CellQuest  software (BD Bioscience, San Jose, California, USA) as it was presented on Figures 2.1 and  2.2.  This  technique  is  based  on  the  principle  that  a  beam  of  a  single wavelength light is directed onto a stream of fluid. Detectors are aimed at the point where the stream passes through the light beam. The FACSCalibur has one detector positioned in line with the light beam, called Forwards scatter (FSC),  and  five  detectors  positioned  perpendicular  to  it.  The  latter  are  the Side  Scatter  (SSC)  and  four  fluorescent  detectors.  These  detect  green  FITC emission  (maximum 530  nm),  orange  PE  emission  (maximum 585  nm)  or red  PerCP  emission  (maximum  650  nm),  all  excited  by  a  blue  argon  laser (488 nm); or  long  red‐blue APC emission  (maximum 670 nm) excited by a red  diode  laser  (635  nm).  Each  cell within  the  acquired  liquid  that  passes through  the  beam  scatters  light.  Light  scattered  in  forward  direction  is directly  proportional  to  the  size  of  the  cell  (FSC)  whereas  light  scatter  at larger  angles  to  the  side  (SSC)  is  caused  by  granularity  and  structural complexity inside the cell. In addition fluorochromes on that cell are excited into  emitting  light.  Light  scattered  to  the  sides  is  focused  through  a  lens system  and  is  collected  by  the  SSC  detector  located  at  around  90  degrees from  the  laser’s  path.  Fluorescent  light  travels  along  the  same  path  as  the side scatter signal and is detected through a series of filters and mirrors so that  particular  wavelengths  information  is  delivered  to  the  appropriate detectors. The combination of scattered and fluorescent  light  that  is picked 




up by the detectors is eventually converted to electronic signals.  Filters  are  used  in  order  to  separate  fluorescence  emission  from  the excitation  light  source  and  to  resolve  different  colour.  Detection  channels (FL)  therefore  pass  light  in  a  specified  range  of  wavelength  (band‐pass). Fluorochromes, however, emit light over a range of wavelengths and a signal from one fluorochrome may therefore overlap in a detector used for another fluorochrome.  The  spectral  overlap  was  manually  compensated  using control  samples  stained  with  each  single  colour,  and  the  portion  of  one detector’s  signal  was  subtracted  from  the  other,  leaving  only  the  desired signal.   
Selection of CD4 and CD8 subsets from PBMC’s 
 Isolation  of  CD4+  and  CD8+  T‐cells was  carried  out  using  EasySep  positive magnetic separation (Stem Cell Technologies, Vancouver, Canada) according to the manufacturer’s  instructions and positive selection MS+/RS+ columns with a maximum capacity of 1x107 labelled cells.  
Molecular Biology  










• Primers and probes Real‐Time  PCR  was  carried  out  using  an  ABI/PRISM  7500  sequence detection system (TaqmanR) and SDS software (Applied Biosystems, Foster City, CA)  to quantify TRECs  in  cell  lysates  from donor and patient  samples and  to  quantify  FOXP3  and  CD71  in  diluted  complementary  DNA  (cDNA) from each patient sample.  The  PCR  reactions were  set  up  in  96‐well  optical  reaction  plates  (Applied Biosystems,  Foster  City,  CA,  USA);  sealed  using  Optical  Adhesive  Covers (Applied Biosystems, Foster City, CA, USA) and transferred to the ABI/PRISM 7500 Sequence Detector for analysis. The PCR was carried out using Platinum Taq (Invitrogen Ltd., USA) and ROX dye  (Invitrogen Ltd, USA) was  employed  in  each  reaction  as  a  background reference. Each 25µl reaction contained 5µl of cell lysates or 5µl of cDNA and 5µl of the specific  standard  (TREC,  FOXP3  or  CD71  standard),  and  the  final concentration  of  1U  Platinum  Taq  (Invitrogen  Ltd.,  USA),  3.5mM  MgCl2, 0.25mM  dNTPs,  12.5mM  of  each  primer  (Table  2.2),  3.75mM  fluorescent labelled probe (Table 2.2), 2.5µl Platinum buffer (Invitrogen Ltd., USA) and 0.5µl  of  ROX  reference  dye.  One  cycle  of  denaturation  (95o  for  5 minutes) was performed, followed by 40 cycles of amplification (95oC for 30 sec, 60oC for 1 minute).   
Cloning and Sequencing of TREC and FOXP3 
Amplification of TREC junctional sequences and FOXP3 was performed using 




the  primers  from  Table  2.1  in  50µl  reactions  using  2.5U  High  Fidelity Platinum Taq (Invitrogen) to circumvent the occurrence of mutations. Other reagents  included  0.2  mM  deoxyribonucleotide  triphosphates  (dNTPs) (Bioline),  2 mM MgSO4  (Invitrogen)  and 0.2µM of  both primers  in 1x High Fidelity buffer (Invitrogen). The PCR amplification programme involved 95˚C for  5 minutes  followed  by  40  cycles  of  30  seconds  at  95˚C,  60  seconds  at 60˚C. PCR products were subjected to electrophoresis on a 2.0% TBE gel. Bands corresponding to a size of 100 bp were recovered from the gel using GFX gel band purification kit (GE Healthcare) and ligated into pCR2.1 vector using  the  pCR2.1  TOPO‐TA  cloning  kit  (Invitrogen)  as  it  is  presented  in Figure 2.3. The pCR2.1 TOPO‐TA vector contains single 3’‐thymidine (T) overhangs for TA cloning and the enzyme Topoisomerase I covalently bound to its DNA via 3’ phosphate. Taq polymerase has a nontemplate‐dependent terminal  transferase activity that  adds  single  deoxyadenosine  (A)  to  the  3’  ends  of  PCR  products.  The overhanging  T  residues  of  the  vector  allow  for  efficient  ligation  of  PCR inserts  into  the  vector.  High  Fidelity  Platinum  Taq  (Invitrogen)  likely resulted in  less efficient cloning due to partial removing of A’ overhang but was used as its advantages of proofreading may outweigh this disadvantage. The enzyme topoisomerase I from Vaccinia virus specifically recognises the pentameric  sequence  (C/T)CCTT and cleaves  the phosphodiester backbone of  duplex DNA after  that  sequence  in  one  strand  (Shuman,  1991)  enabling the DNA to unwind. The energy resulting from this cleavage is conserved by 




formation of a covalent bond between the 3’ phosphate of the cleaved strand and a tyrosyl residue (Tyr‐275) of the enzyme. This bond can subsequently be attacked by the 5’ hydroxyl of the original cleaved strand, thus reversing the  reaction  and  releasing  the  enzyme    (Shuman,  1994).  Therefore topoisomerase  I  functions  both  as  a  restriction  enzyme  and  ligase,  can therefore  cleave  and  re‐join  DNA  during  replication  and  enables  faster ligation of PCR products than conventional methods. Finally a stop solution prevents free topoisomerase from re‐binding and nicking the plasmid.  Briefly,  1µl  or  4  µl  of  PCR product  diluted  in  sterile water were  incubated with  1µl  vector  solution  and  1  µl  salt  solution  in  a  total  volume  of  5  µl  at room temperature each  for either 5 or 25 minutes before storage at  ‐20°C. No difference was observed between the four experimental variations.  TOP10F’ cells (Invitrogen) were transformed with pCR2.1 containing either TREC  or  FOXP3  by  calcium  chloride  (CaCl2)  membrane  permeabilisation. Therefore cells were chilled at 4°C for 30 minutes in the presence of plasmid DNA  and  divalent  Calcium  cations  (present  in  the  cell  suspension)  that prepare  the  cell  walls  to  become  permeable  and  were  then  briefly  heat shocked  (at  42°C  for  3  minutes)  causing  the  DNA  to  enter  the  cells. Transformed  cells  were  grown  overnight  on  LB  plates  (10g  Tryptone,  5g Yeast  Extract  and  10g  NaCl  per  L,  pH  7)  containing  Isopropyl  β‐D‐1‐thiogalactopyranoside  (IPTG)  (Alexis  Biochemicals),  5‐Bromo‐4‐Chloro‐3‐indolyl‐β‐D‐galactoside  (X‐gal)  (Sigma)  and  80µg/ml  Kanamycin.  Single white colonies were selected and grown overnight or 16 hours in LB medium containing 50 µg/ml Kanamycin.  Plasmid DNA was extracted by midiprep and  tested  for  the existence of an 






into pCR2.1 vector.  The  figure  shows  the  site  of  ligation  of  the  Nco  I/BamH  I modified HLA‐A24  PCR  product  into  pCR2.1  vector  (modified  from  a  pCR2.1  TOPO map  provided  at  http://www.invitrogen.com).  EcoRI  restriction  sites  and sites  for  sequencing  with  M13  primers  that  were  used  in  further experiments are highlighted in circles. 
 
 




Plasmid DNA midiprep 
 This  method  was  modified  from  the  originally  alkaline  lysis  described  by Birnboim  and  Doly  in  1979  (Birnboim  &  Doly  1979).  50  ml  overnight cultures were spun at 3000 rpm for 20 minutes and cell pellets resuspended in 1 ml of a solution containing 25 mM trishydroxymethylaminomethane (2‐amino‐2‐hydroxymethyl‐1,  3‐propanediol;  abbreviated:  Tris)  and  10  mM ethylenediaminetetraacetic  acid  (EDTA)  at  pH  8.  Then  2  ml  of  freshly prepared  solution  containing  200  mM  sodium  hydroxide  (NaOH)  and  1% (v/v) sodium dodecyl sulphate (SDS) was added and incubated on ice for 5 minutes.  The  lysis  of  bacteria  under  alkaline  conditions  results  in precipitation of DNA and proteins. 3 M sodium acetate (acetic acid) at pH 4.8 was  added  and  incubated  on  ice  for  45  minutes.  The  acetate‐containing buffer neutralizes NaOH in the previous lysis step. It results in large and less supercoiled  chromosomal  DNA  (and  proteins)  forming  an  insoluble white, rubbery  precipitate  with  SDS  while  small  bacterial  DNA  plasmids  can renature  and  stay  in  solution.  After  centrifugation  at  4000  rpm  for  20 minutes,  supernatant  was  added  to  tubes  containing  8  ml  of  absolute ethanol,  gently  mixed  by  inversion  and  spun  at  4000  rpm  at  4°C  for  10 minutes. 400µl of solution containing 10 mM Tris and 1 mM EDTA at pH 8 was  added  to  DNA  pellets  for  incubation  at  65°C  for  10  minutes.  After addition of 500µl Lithium chloride (LiCl) the resulting solution was cooled to ‐20°C  for at  least 10 minutes.  It was then spun at 10000 rpm at 4°C  for 10 minutes  and  1  ml  of  absolute  ethanol  was  subsequently  added  to supernatant  resulting  in  precipitation  of  DNA.  Further  centrifugation  at 




10000  rpm  at  4°C  for  10  minutes  was  performed  to  enable  aspiration  of supernatant. The resulting DNA pellet was dried in a 37°C incubator for 10 to 20  minutes  before  resuspension  in  50µl  water  and  incubation  in  a  water bath at 65°C for 10 minutes.   
 Plasmid DNA miniprep  The midiprep method described above was the preferred method of plasmid DNA  isolation because of high DNA yields with  good purity. Occasionally  a miniprep method was used when a short processing time was prioritised to high DNA yields. Therefore  DNA  was  extracted  by  StrataPrep  plasmid  miniprep  kit (Stratagene)  according  to  the  manufacturer.  This  method  employs  a modification of the alkaline method of cell lysis (Birnboim & Doly, 1979) and binding of DNA on a silica‐based fibre matrix.  Briefly  1.5 ml  of  a  10 ml  overnight  culture were  spun  at  13,000  rpm or  1 minute and the supernatant discarded. The pellet was resuspended in 100µl of  a  ribonuclease‐containing  solution  [50  mM  Tris  HCl  (pH  7.5),  10  mM EDTA, 50 µg/ml RNase A] and gently mixed with 100µl of a cell lysis solution [0.2  M  NaOH,  1%  (w/v)  SDS],  and  125µl  of  a  DNA‐binding  salt  solution (containing an undisclosed chaotropic salt). As described above the  lysis of bacteria  under  alkaline  conditions  resulted  in  precipitation  of  DNA  and proteins.  A  salt  neutralising  buffer  results  in  large  and  less  supercoiled chromosomal DNA forming an insoluble white, rubbery precipitate with SDS 




while  small  bacterial DNA plasmids  can  renature  and  stay  in  solution.  The sample  was  then  spun  at  13,000  rpm  for  5  minutes.  The  DNA  containing supernatant was  then  transferred  to  a  cup with  fibre matrix,  to which  the DNA binds. The  cup was  seated  inside  a  receptacle  tube and  contaminants were  subsequently  washed  from  the  cup  with  wash  buffer.  Therefore  the tube was spun at 13,000 rpm for 30 seconds. After removal of liquid from the tube, 750µl of wash buffer [5 mM Tris HCl (pH 7.5), 50 mM NaCl, 1.25 mM EDTA  and  50%  (v/v)  ethanol] were  added  to  the  cup  and  spun  inside  the tube at 13,000 rpm for a further 30 seconds. After removal of filtered liquid, the  tube  was  spun  for  an  additional  30  seconds  and  the  cup  was  then transferred to a new tube. 50µl sterile deionised water was placed on top of the fibre matrix and incubated at room temperature for 5 minutes for elution of  the  purified  plasmid  DNA,  which  was  captured  in  the  tube  by centrifugation at 13,000 rpm for 30 seconds.   
Absorbance measurement of DNA and RNA 
 DNA  and RNA  absorb  ultraviolet  light with  an  absorption  peak  at  260  nm wavelength.  The  amount  of  light  absorbed  can  be  related  to  the concentration  of  the  absorbing  molecule.  At  a  wavelength  of  260  nm,  the extinction  coefficient  for  double‐stranded  DNA  is  20  (mg/ml)‐1  cm‐1;  for single‐stranded  DNA  and  RNA  it  is  25  (mg/ml)‐1  cm‐1.  Thus,  an  optical density  (OD)  of  1  corresponds  to  50  µg/ml  for  double‐stranded  DNA,  40 μg/ml for single‐stranded DNA and RNA.  




Nucleic  acid  concentration  was  measured  at  260  nm  and  protein contamination was assessed by the ratio of absorbance at 260 nm: 280 nm (which corresponds to 2 in pure nucleic acid solutions) using a Fenway 6405 spectrophotometer.    
Control plasmid quantification  
The concentration of the plasmid DNA was quantified by spectrophotometry and  the  result  expressed  as  ng/µl.  The  calculation  of  the  number  of molecules was then carried out as follows: 
• The average molecular weight of a nucleotide is 330 Daltons. 
• A  base  pair  is  formed  of  two  nucleotides;  the  average molecular weight of a base pair is 660 Daltons. 
• The  3.9Kb  plasmid  used  plus  the  fragment  size  inserted,  has 3965  base  pairs  and  thus  weighs  (3965  x  660)  =  2616900 gram/mole 
• One mole has 6x1023 molecules. Therefore 1 molecule weights 2616900/6x1023 = 4.36 x 10‐18gm 
• If  the  stock plasmid has  an OD  reading  at  260 of  0.872,  then the DNA concentration is 0.872x50ng/µl= 43.6ng/µl 
• 43.6ng = 43.6x10‐9gm, so 
• (43.6x10‐9gm)/ (4.36x10‐18gm) = 1.0x1010 molecules/µl The  number  of  molecules  was  calculated  per  µl  of  plasmid  solution.  The standard  plasmid  was  then  diluted  in  dH2O  to  give  a  solution  with  a calculated  concentration  of  1x108 molecules.  Following  this,  a  series  of  10 




fold  dilutions  was  set  up  to  give  a  set  of  standards  with  a  calculated concentration of 107, 106, 105, 104, 103, 102 molecules and stored frozen at ‐20oC until use.  
Detection and Quantification of TREC  To  quantify  TREC  a  series  of  standard  dilutions  of  plasmid  containing  the signal‐joint breakpoint was used following Douek and cols protocol (Douek, 2000).  Each  sample was  run  in  triplicate  along with  the  dilution  series  of TREC plasmid and not  template  control  (NTC). Data was normalised based on the percentage of CD3+ T cells in total PBMCs and calculated as number of TREC per 1.5x105 CD3+ cells. TREC amplification is shown in Figure 2.4.  
Quantification of FOXP3  Total  RNA  was  purified  from  PBMC’s  with  RNeasy  Mini  Kit  following manufacturer’s  protocol  (QIAgen  Inc,  Valencia,  California).  Complementary DNA  (cDNA)  was  synthesised  using  M‐MLV  Reverse  Transcriptase  and Random  Hexamers  (Promega  Corporation,  Madison  Wisconsin,  USA) according  to manufacture’s  instructions  as  described  in  section  2.2.1.  1:10 dilution of cDNA was used to perform quantitative PCR.  To  allow  quantification  of  FOXP3  molecules  by  Real‐Time  PCR,  it  was essential to prepare different set of standards, as described previously. PCR was performed using FOXP3 primers and TaqMan probes designed by Emanuel Zorn (verbal communication), the sequences of which are shown in 




table  2.6.  For  internal  control, Human TfR  (CD71)  assays‐on‐demand  from TaqMan (Applied Biosystems, USA) was used.  To quantify the expression of FOXP3 and CD71 series of standard dilutions of plasmid  containing  FOXP3  and  CD71  were  used.  Each  sample  was  run  in triplicate  along  with  the  dilution  series  of  the  plasmids  and  not  template control (NTC).  Normalisation  of  FOXP3  expression  was  made  by  dividing  the  total expression  of  FOXP3  by  the  total  expression  of  CD71  and  the multiply  by 100.     Normalisation of FOXP3 = (Total expression of FOXP3) X 100 Total expression of CD71      


















Blue/white colony selection  The  PCR2.1  vector  (Invitrogen)  enables  screening  of  successful  cloning reactions  through  the  colour  of  the  bacterial  colonies.  The  molecular mechanism for blue white screening is based on the Lac operon and is briefly explained here. PCR2.1 contains the β‐galactosidase gene (Lac Z) within the multiple  cloning  site  (MCS).  Cloning  in  pCR2.1  was  performed  with isopropyl‐β‐D‐thiogalactoside  (IPTG)  present  in  the  medium,  which functions  as  the  inducer  of  the  Lac  operon  in  the  absence  of  lactose.  If  no cloned  insert was present  in  the pCR2.1 vector (which would  interrupt  the Lac Z gene) IPTG triggered expression of β‐galactosidase by induction from the T7 promoter. The enzyme then processed 5‐bromo‐4‐chloro‐3‐indolyl‐β‐galactoside (X‐gal) within the medium (a colourless modified galactose sugar that is metabolized by β‐galactosidase). The hydrolysis of colourless X‐gal by the β‐galactosidase caused the characteristic blue colour indicating that the colonies  contained  unligated  vector.  White  colonies  indicated  insertion  of HLA  sequence  and  loss  of  the  cells'  ability  to  hydrolyse  the  marker.  An example of colonies grown under conditions for blue/white screening. 
 
Blue/white colony screening  Bacterial  colonies  with  no  vector  would  appear  blue.  This  is  because  β‐galactosidase is a homo‐tetramer with each monomer made up of one lac Z‐α and one lac Z‐ω protein. If only one of the requisite proteins is expressed in the resulting cell, no functional enzyme will be formed. Thus, if a strain of E. 




coli  without  lac  Z‐α  in  its  genome  was  transformed  with  a  plasmid containing  the  missing  gene  fragment,  transformed  cells  did  produce  β‐galactosidase while untransformed cells did not because they were only able to  produce  the  omega  half  of  the  monomer.  In  addition  growth  of untransformed  cells was  suppressed  by  the  presence  of  Kanamycin  in  the growth  medium.  A  Kanamycin  resistance  gene  on  pCR2.1  allowed successfully  transformed  bacteria  to  survive  despite  the  presence  of  the antibiotic.   
Glycerol stocks  Glycerol stocks were prepared from bacterial hosts carrying engineered DNA vectors.  Therefore  single  colonies were  picked  from  plates,  on which  they had  been  grown  on  selective  medium  overnight  and  were  subsequently grown with the appropriate selective liquid medium overnight. 0.5 ml of the overnight  culture  was  then  mixed  with  the  same  volume  of  glycerol  in  a screw cap microcentrifuge tube for storage at ‐80°C.  
Polymerase chain reaction (PCR)  
Conventional PCR was performed on a PTC‐200 Peltier Thermal Cycler  for TCR Vβ  amplifications (primers are shown  in Table 2.3 using  the  following conditions: 94oC for 2 minutes, 35 cycles of 94oC for 30 seconds, 57oC for 30 seconds and 72oC  for 30 seconds with a  final extension step at 72oC  for 10 minutes.  Therefore  agarose  gels  or  denaturing  sequencing  gels electrophoresis  were  used  for  detection  of  PCR  product  sizes  at  the  final 




phase of the PCR reaction. Quantitative PCR was used  for measuring  the kinetics of PCR amplification during  the  early  exponential  phase  of  the  reaction when  (assuming  100% reaction  efficiency)  doubling  PCR  products  accumulate  at  every  reaction cycle. It was performed on 96 well optical reaction plates (ABI Prism) using the spectrofluorometric thermal cycler ABI 7300 Real Time PCR instrument (Applied Biosystems) as described below for calculation of the quantitatively related  amount  of  starting  material  and  sensitive  detection  of  variability between samples.  Therefore either an intercalating dye (SYBR Green I) or fluorescent Taqman probes  were  used.  SYBR  Green  dye  bound  to  the minor  groove  of  double stranded DNA (increasing its fluorescence over a hundred fold upon binding) and  as  more  amplicons  were  produced  during  the  PCR  reaction,  the fluorescent signal increased.  Whereas SYBR Green bound to any double stranded DNA molecule, the use of  fluorescent  probes  allowed  specific  detection  of  amplification  of  pre‐determined  targets.  TaqMan  probes  were  designed  to  anneal  to  a  specific sequence of the template between the forward and reverse primers used for amplification  of  the  target  (primers  and  probes  used  for  TREC  and  FOXP3 amplification  are  shown  in  Table  2.2.  They  contained  a  high‐energy  dye (reporter) at the 5’ end and a low‐energy molecule (quencher) at the 3’ end. Excitation of the intact probe resulted in the reporters dye’s emission being suppressed  by  the  quencher  dye  in  close  proximity  due  to  fluorescence resonance energy transfer (FRET). During PCR, DNA Taq polymerase cleaved the probe that sits in the path of the enzyme that has 5 exonuclease activity. 




This stopped the transfer of energy  from the reporter  to  the quencher  that were  no  longer  in  proximity  thereby  decreasing  the  quencher  signal  and increasing  the  reporter  signal  with  the  latter  captured  by  the  sequence detection  instrument.  Using  fluorescent  probes,  an  increase  in  the  product targeted  by  the  reporter  probe  at  each  PCR  cycle  causes  a  proportional increase  in  fluorescence due  to  the breakdown of  the probe and  release of the reporter   
Gel electrophoresis 
 Gel  electrophoresis  is  used  for  the  separation  of  deoxyribonucleic  acid  or ribonucleic  acid  using  an  electric  current  applied  to  a  gel  matrix.  Nucleic acids  migrate  from  negative  to  positive  electrodes  due  to  the  naturally occurring negative charge carried by their sugar‐phosphate backbone. Gels  were  prepared  by  heating  100  ml  of  0.5x  Tris‐Borate‐EDTA  (TBE) (Cambrex  Bio  Sciences)  buffer  containing  2  g  (unless  stated  otherwise)  of electrophoresis  grade  agarose  (Gibco  BRL)  in  a  microwave  oven  for  2 minutes or until the agarose solution had began to boil. The mix was cooled down  to  approximately  50˚C  before  adding  10  µl  of  10  mg/ml  ethidium bromide  solution.  The  agarose  solution  was  immediately  poured  into  a sealed tray (Bio Rad) with a comb placed to form wells and allowed to set at room  temperature.  The  comb  was  then  removed.  5µl  DNA  solution  of interest  were  mixed  with  3  µl  Bromophenol  Blue  loading  dye  [containing 0.25% (w/v) xylene cyanol, 0.25% (w/v) bromophenol blue and 50% (v/v) 




glycerol]  before  loading  into  gel  wells  and  run with  1x  TBE  buffer  at  100 Volts  direct  current  in  a  SUB  DNA  cell  (Bio  Rad)  for  45  minutes. Bromophenol blue carries a slight negative charge at moderate pH, therefore migrating in the same direction as DNA in the gel (at 2% agarose at the same rate  as  approximately  500  bp  DNA  fragments).  Xylene  cyanol  is  similarly used  to  indicate  the progress of DNA separation during electrophoresis  (at 2%  agarose  migrating  at  the  same  rate  as  approximately  4000  bp  DNA fragments). DNA separation was visualised and documented using a Gel Doc 1000 single wavelength  (312  nm  UV‐B)  mini‐transilluminator  (Bio‐Rad  Laboratories Ltd.) and a Charged Coupled Device (CCD) camera using a Wratten 2a filter and 2x magnification lens.              










TCRβ  CDR3 size spectratyping 
 The size distribution of the T‐Cell Receptor β‐chain (TCR β) Complementary Determination  Region  3  (CDR3)  was  determined  by  Reverse  Transcript Polymerase  Chain  Reaction  (RT‐PCR).  RNA  was  extracted  from  CD4+  and CD8+ sorted cells. Complementary DNA was prepared following the protocol described previously.  Each TCR Vβ  segment was  amplified with one of  the Vβsubfamily  specific  primer  and  Cβ  primer  recognizing  both  Cβ1  and  Cβ2 regions. PCR was carried out in a final volume of 12.5ml containing 10X PCR buffer,  50X MgCl2,  sterile water,  1U  of  Red  Hot  DNA  polymerase  (ABgene, UK)  10mM  dNTPs  (Bioline,  UK)  and  10pmol  of  1  to  26  different  TCR  Vβ primers  combined with Cβ    primer  conjugated with  to  the  fluorescent  dye Cy5. The sequences of the TCR Vβ primers are described in Table 2.3.  The  amplification was  carried  out  in  a  PTC‐200  Peltier  Thermalcycler  (MJ Research,  Watertown,  Massachusetts,  USA).  The  PCR  conditions  were denaturation  for  95oC  for  1 min,  followed  by  30  cycles  of  denaturation  at 95oC  for  30  sec,  annealing  at  58oC  for  30  sec,  extension  at  72oC  for  1 min, with a final extension step at 72oC for 10 min.  The PCR products were checked first on an 2% agarose gel stained with 5ml of 10mg/ml Ethidium Bromide,  loading 5ml of  the product with 1ml of 5X loading buffer (15% Ficoll, 0.25% Xylene Cyanol, 0.25% Bromophenol blue in  distilled  water).  The  gels  were  run  at  120  volts  for  40  minutes  and visualised  by  ultra  violet  light  using  a  transilluminator,  the  size  of  the product  was  inferred  using  a  molecular  weight  marker,  Hyperladder  IV (Bioline,  UK),  which  has  products  ranging  between  100  to  1000  bp,  each 




product separated by 100bp.  The  size  distribution  of  each  fluorescent  PCR  product  was  determined  by electrophoresis  on  an  automated  DNA  sequencer  ALF‐Express  (Amersham Pharmacia biotech, UK).  The PCR fragments were then denaturalised at 95oC for at least 3 min in the presence of formamide loading dye and then run for 8  hours.  Data  was  collected  and  analysed  by  Allelocator  Software (Amersham  Pharmacia  Biotech,  UK).  The  normal  TCRβ  CDR3  size distribution, representing polyclonal TCR distribution is characterised for a Gaussian distribution,  containing 8  to 10 peaks  for  each Vβ  subfamily. The appearance  of  dominant  peaks  suggests  oligoclonal  or  clonal  distribution. The  absence  of  peaks  suggests  that  there  are  not  T‐cells  expressing  the specific Vβ subfamily. 
 
 
Spectratype complexity scoring  The complexity of Vβ subfamilies was determined by counting distinct peaks per  subfamily.  These were  graded  on  a  score  of  0‐8. Normal  complexity  is characterised  by  a  Gaussian  distribution  that  reflect  the  presence  of polyclonal cDNA. A score of 0 was given if no subfamilies were present and 1 for a  single peak, etc. The overall  spectratype complexity  score per  sample was calculated by  the  total number of  subfamilies. The complexity score  in normal  individuals  range  from 121  to 185  (Fallen,  et  al.,  2003)  (Wu,  et  al., 2000).      





Table 2.3. Primers used for Vβ spectratyping.  The BCint primer was labelled with Cy5 dye.   Vβ  TM (oC)  5´ to 3´ 1  59  GCACAACAGTTCCCTGACTTGCAC 2  57  TCATCAACCATGCAAGCCTGACCT 3  59  GTCTCTAGAGAGAAGAAGGAGCGC 4  50  ACATATGAGAGTGGATTTGTCATT 5.1  54  ATACTTCAGTGAGACACAGAGAAAC 5.2‐5.3  56  TTCCCTAACTATAGCTCTGAGCTG 6  58  AGGCCTGAGGGATCCGTCTC 7  58  CCTGAATGCCCCAACAGCTCTC 8  62  CCATCATGCGGGGACTGGAGTTGC 9  50  CCTAAATCTCCAGACAAAGCT 11  56  TCAACAGTCTCCAGAATAAGGACG 12  57  AAAGGAGAAGTCTCAGAT 13.1  48  CAAGGAGAAGTCCCCAAT 13.2  53  GGTGAGGGTACAACTGCC 14  54  GTCTCTCGAAAAGAGAAGAGGAAT 15  56  AGTGTCTCTCGACAGGCACAG 16  49  AAAGAGTCTAAACAGGATGAGT 17  46  CAGATAGTAAATGACTTTCAG 18  56  GATGAGTCAGGAATGCCAAAGGAA 20  56  ACGTCTGAGGTGCCCCAGAAT 21  53  ATTCACAGTTCGGTAAGGATCGA 22  57  GGGCAGAAACTCGAGTTTCTGGTT 23  50  TTTATGAAAAGATGCAGAGCGAT 24  57  AAGTCAAGTCAGGCCCCAAAGCT BC int  67  CACCCACGAGCTAGCTCCACGTGGTC   




Luminex technology for cytokine quantification 
The  LabMAP  technology  (Luminex)  combines  the  principle  of  a  sandwich immunoassay with  the  florescent‐bead‐base  technology allowing  individual and multiplex analysis for up to 100 different analytes in a single microtiter well (Vignali, 2000).  Cytokine quantification of IL‐1, IL‐2, IL‐4, IL‐10, IL‐12p70, IL‐15, TNF‐α and INF‐γ  A  human  cytokine  quantification  by  multiplex  Luminex  kit  assay  (8‐plex Linco‐plex cytokine kit by Linco Research Inc, St. Charles, MO, USA) was used according  to manufacturer’s  instruction,  as  templates  serum  samples were used. The  Luminex  serum  assay  was  done  in  a  96‐well  microplate  format.  A standard  curve  ranging  from  3.2pg/ml  to  10,000pg/ml  was  generated  by serial  dilution  of  reconstituted  standard  provided  with  the  kit.  The  filter plate  was  blocked  by  adding  200µl  of  assay  buffer  into  each  well  and incubated  on  a  shaker  at  room  temperature.  After  10  minutes  the  assay buffer was  discarded  by  vacuum  aspiration  and  25µl  of  assay  diluent was added  to  the  wells  designated  for  the  samples,  standards  and  quality controls  also provided with  the kit.  Standards, quality  controls  and patient sera were pipetted at 25µl per well in duplicate to the appropriate wells and mixed with 25µl of  antibody coated  fluorescent beads. The microplate was incubated  for  2  hours  at  room  temperature  on  a  shaker. Wells  were  then washed  twice  with  washing  buffer  using  a  vacuum  manifold.  25µl  of 




Biotinylated  secondary  antibody  (Detection  antibody)  was  added  to  the appropriate wells and incubated for 1 hour at room temperature in the dark with  constant  shaking.  25µl  of  Streptavidin‐Phycoerythrin  (PE)  labelled antibodies were added to the plate and after 30 minutes incubation at room temperature  wells  were  washed  twice.  Finally  100µl  of  sheath  fluid  was added  to  the  wells  and  the  plate  read  immediately  on  the  Bio‐Plex  array reader at high and low RP1 targets. Analysis of experimental data was done using parametric curve fitting. 
  
TGFβ1 cytokine quantification  TGF‐β  quantification  was  done  using  the  human  TGFβ‐1  LINCOplex  kit (Linco Research Inc, St. Charles, MO, USA). Quantification of TGFβ1 requires sample pre‐treatment. Thus, quantification of TGFβ1 cannot be multiplexed with other analytes. Serum  samples  were  collected  by  centrifugation  and  frozen  at  ‐20oC  until use. Before  the  assay  the  samples  were  treated  following  manufacturer’s instruction. The samples were diluted with Sample diluent provided with the kit  adding  1  part  of  sample  to  4  parts  of  Sample  Diluent  for  1:5  dilution followed  by  adding  1.0µl  of  1.0N  HCL  to  each  25ul  of  the  diluted  sample, samples need  to be mixed by shaking at  room temperature  for 15 minutes and then incubated for 1 hour at room temperature. Finally the acid‐treated samples  need  to  be  neutralised  by  adding  1.0N NaOH  prior  to  addition  to 








 Comparisons  between  patient  and  control  groups  were  done  using  the  U Mann‐Whitney and the Kaleidagraph software (Synergy Software) 
 
Analysis of Transplant Outcome 
 Statistical  analysis  of  transplant  outcomes  and  various  parameters  was carried  out  using  the  Kaleidagraph  (Synergy  Software),  R  (Free  Software Foundation) and SPSS (SPSS Inc) software packages 
 





 Overall survival (OS) was defined as the probability of survival, independent of state of the disease, at any point in time; patients alive at their last follow‐up were censored, while only death was considered as an event. Disease free survival  (DFS) was defined as  the probability of being alive, disease‐free at any  time point; death,  relapse, and graft  failure were considered as events, while  patients  alive  and  disease  free  with  donor  engraftment  at  their  last follow‐up  were  censored.  Both  these  probabilities  were  analysed  by  the Kaplan‐Meier  method,  and  comparisons  between  probabilities  in  different patient groups were performed using the log‐rank test. 
 
Relapse 
 Relapse  was  defined  as  the  probability  of  having  a  relapse  before  time  t; death without experiencing a relapse was considered a competing event. On the  contrary,  transplantation‐related  mortality  (TRM)  was  defined  as  the probability of dying without previous occurrence of a relapse, which was the competing  event.  Both  these  probabilities  were  estimated  as  cumulative incidence curves.  
Graft versus Host Disease (GvHD)     Also,  the  probability  of  chronic  GVHD  was  estimated  as  cumulative incidence. For chronic GvHD, only patients surviving  in remission and with 




donor engraftment for at least 100 days were evaluated. In this case, relapse or death was  considered  competing  events,  data being  censored at  time of last follow‐up for patients who did not experience chronic GVHD.  All  results  were  expressed  as  5‐year  probability  or  5‐year  cumulative incidence (%) and 95% confidence interval (95% CI).  A univariate analysis of DFS, Relapse, and TRM was performed for the whole study population considering the following variables: patient and donor age; stem  cell  source;  recipient  and  donor  HCMV  serology;  type  of  disease; disease status.  





Analysis of the T cell receptor repertoire and TCR 




T cell repertoire  In  normal  individuals  the  TCR  repertoire  is  relatively  stable,  diverse  and polyclonal, creating the ability to respond to a wide variety of antigens. The stability  of  the  repertoire,  given  the  tendency  of  the  body  to  maintain homeostasis  is  not  static  and  immobile,  on  the  contrary,  it  is  a  dynamic process with a fluctuation in the numbers, diversity and functions within the T cell compartment during immune responses  (Jameson, 2002) (Mahajan, et al.,  2005).  The  shape  of  the  TCR  repertoire  in  the  peripheral  pool  is influenced  by  intrinsic  and  extrinsic  factors  that  together  can  affect  the representation  of  some  TCR  families.  The  intrinsic  factors  that  have  been associated  with  TCR  expression  are:    the  germline  preference  of  usage  of particular Vβ genes; the HLA antigens that contribute to the negative and the positive  selection  of  T‐cells;  TCR  gene  polymorphisms  also  have  been implicated as influencing the TCR repertoire  (Melenhorst, et al., 2008). The  extrinsic  factors  associated  with  modulation  of  functional  TCR repertoire are: infections, the overall antigenic experience and the presence of superantigens (viral or bacterial proteins that bind to and expand T cells 




carrying specific Vβ chains). Both intrinsic and extrinsic factors contribute to establish the TCR repertoire. Clonal or oligoclonal expansions of T cells may occur in different situations, including malignant and non‐malignant diseases and also during the immune reconstitution  after  an  HSCT.  Thus  the  analysis  of  TCR  repertoire  and  the clonality  (or  otherwise)  of  responses  is  an  area  of  great  interest  in immunology, and different methods have been developed to accomplish this task. 
 
 








Methods to analyse the TCR repertoire  
Southern blot Southern  blotting  has  been  considered  as  the  gold  standard  method  to establish T cell clonality in different situations including T cell leukaemia and in  lymphomas    (Droese,  et  al.,  2004)  (Yang,  et  al.,  2005)  (Langerak,  et  al., 2001)  (Langerak,  et  al.,  1999).  It  is  highly  reliable  and  in  principle  it  can detect every clonal TCR rearrangement by using optimally positioned probes and  appropriate  restriction  enzymes.  Therefore,  it  is  the  method  used  to validate other methods for clonal detection. Despite that, the use of Southern blot  in  routine  laboratories  is  limited  due  to  its  many  disadvantages. Southern  blotting  is  a  laborious,  expensive  and  time‐consuming  technique that requires large amounts of good quality DNA to get reliable results.   
Phenotype: flow cytometric analysis Flow cytometric analysis  is a method  that has may advantages over others for  the analysis of  the TCR  repertoire;  it  is  fast,  relatively  easy  to perform, very  reproducible  between  different  laboratories,  fairly  inexpensive  in comparison  with  other methods,  allows  the  quantification  of  the  different TCRVβ receptors and allows the analysis of the TCR repertoire within T cell subsets. The analysis  is based on TCR  recognition by a panel of  antibodies and can be done using multi‐colour flow cytometry and fluorescent labelled monoclonal antibodies. (Pannetier, et al., 1993) (Hodges, et al., 2003)  Up to now monoclonal  antibodies  cover more  than  the 80% of  the whole TCRVβ 




repertoire.  However,  only  a  few  antibodies  have  been  developed  that recognise the TCRVΑ gene products, therefore, the information given by flow cytometry indicates only the usage of each Vβ family. Also, each Vβ has many possibilities  of  V,  D  and  J  recombination  such  complexity  cannot  be effectively  analysed  by  flow  cytometry.  The  advantage  of  this  technique  is the direct visualization of the protein of interest on the cell surface allowing a direct  determination of  the percentages of Vβ‐expressing  cells  in  a  given population  (Lang, et al., 1997) (van den Beemd, et al., 2000).  However,  due  to  the  lack  of  more  complex  repertoire  of  monoclonal antibodies, a confirmation of clonal expansions or the clonality of a response is  required using other molecular methods. Nevertheless,  the method  is an alternative approach for initial screening of clonality and once confirmed, it can be used for monitoring  (Langerak, et al., 2001).    
PCR methods  The development of  the polymerase  chain  reaction  (PCR) has  replaced  the use  of  the  Southern  blot,  due  to  its many  advantages,  in  particular  that  is faster and does not necessarily require high quality DNA. PCR analysis can be done from either DNA or RNA as a starting point. The most widely method used  for  the  analysis  of  the  expressed TCR  repertoire utilises TCRβ mRNA and  requires  a  coupled  reverse  transcription  PCR  (RT‐PCR)  involving  the amplification  of  all  Vβ  segments  using  primers  complementary  to  all TCRVβ genes  and  a  constant  region  primer  (Cβ).  The  disadvantage  of  this 




method  is  that  it  only  provides  a  semi‐quantitative  profile  of  the  TCRVβ usage  (Langerak, et al., 2001) (Pannetier, et al., 1995). This method has been used  successfully  to  assess  clonality  of  the  TCR  repertoire.  Other  PCR methods using DNA and consensus primers can suffer from false negativity as  result  of  improper  annealing  of  the  primers with  gene  segments.  Other approaches  have  tried  to  use  nested  PCR,  but  have  been  proved  to experience contamination.   TCR  PCR  fragments  can  be  detected  in  different  ways  in  order  to discriminate  between  clonal  and polyclonal  expansions.  The methods used for  discrimination  include:  fluorescent  gene  scanning (Immunoscope/Spectratyping);  heteroduplex  analysis;  single  strand conformation polymorphism (SSCP); denaturing gradient gel electrophoresis (DGGE); cloning and sequencing.   
Fluorescent gene scanning  Fluorescent gene scanning consists in the amplification of specific TCR genes using fluorescently labelled primers the resulting PCR products are run on a gene sequencer and analysed through suitable software, in which the yield of transcripts  with  different  CDR3  lengths  can  be  estimated  (GeneScan software,  Applied  Biosystems  or  Alleleloc  software  by  ALF‐Express, Amersham  Pharmacia).  The  technique  involves  the  amplification  of  cDNA using  C  and  V  specific  primers  or  genomic  DNA  between  V  and  J  specific 




primers,  providing  an  estimation  of  specific  expansion,  complexity  and stability  of  a  particular  V  gene  family  relative  to  others  as  well  as  the different TCR clones based on their CDR3 length. The study of CDR3 length or CDR3 spectratyping has been proven  to be a powerful  tool  to analyse T cell  repertoire under normal or pathological conditions, providing a profile of the T cell repertoire and detecting oligoclonal expansion of T cell bearing a particular  TCR  phenotype.  Polyclonal  populations  show  a  normal  bell‐shaped Gaussian distribution that can be seen as a series of peaks (between 8  to  10  peaks  per  family).  Oligoclonal  expansion  can  be  seen  as  distinct peaks, and monoclonal distribution is observed as a single peak in the family being analysed as can be observed in Figure 3.1.  (Assaf, et al., 2000) (Even, et al., 1995) (Gorski, et al., 1994) (Maślanka, et al., 1995). However, because the information given by fluorescent gene scanning (spectratyping) is semi‐quantitative its utility is limited. 
 
Figure 3.1. TCR diversity analysis by CDR3 length Vβ spectratyping.    Panel  A  shows  a  normal  bell‐shaped  Gaussian  distribution representing  polyclonal  profile  of  the  T  cell  repertoire.  Panel  B  shows  an example  of  an  oligoclonal  profile.  Finally  panel  C  shows  a  monoclonal expansion of a TCRVβ family. 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Heteroduplex analysis This method  also  requires  PCR  amplification  and  relies  on  conformational changes  in  DNA  heteroduplexes  rates  caused  by  denaturation  and renaturation of mixtures of products that contain mismatches. In the case of TCRβ  chains,  these  mismatches  between  members  of  the  same  Vβ  family occur at the VDJ junctional regions.  The conformational differences between heteroduplexes can be read out as differential migration of renaturated PCR products after by separation under non‐denaturating conditions. True clonal expansion results  in the predominant  formation of homoduplexes, whereas polyclonal  distributions  result  in  the  formation  of  heteroduplexes.  The homoduplex  represents  PCR  products  with  identical  sequences  with  a uniform  conformation  that  migrates  rapidly  through  the  gel,  whilst heteroduplexes formed by the random association of different products with mis‐matches run more slowly than the homoduplex. The heteroduplexes are detected as a smear of bands on a gel, while the homoduplex can be detected as  a  unique,  clear  band    (Marguerie,  et  al.,  1992)  (Martinelli,  et  al.,  1997) (Langerak, et al., 1997) (Sottini, et al., 1996). The advantages of heteroduplex analysis are; that it is not restricted to the CDR3 length as spectratyping, but also by the conformation and differential migration time that can distinguish differences in CDR3 region sequences that are hidden within a single peak in spectratyping.  In  an  heteroduplex  analysis,  clones  could  be  separated  into different bands using a gel with higher resolution. However,  in comparison with other  techniques  this  is  laborious and  time consuming    (Connelley,  et al., 2008).  




Single Stranded Conformation Polymorphism (SSCP)  The  single  strand  conformation  polymorphism  (SSCP) method  is  based  on non‐denaturing  gel  electrophoresis  and  relies  on  mobility  shifts  of  single stranded DNA, which reflects the different conformations adopted by strands differing in their nucleotide sequence  (Orita, et al., 1989) (Offermans, et al., 1996) (Yamamoto, et al., 1996).   
Denaturing gradient gel electrophoresis (DGGE)  This method  analyses  single  base  changes  at  the  CDR3  region  base  on  the migration of double stranded DNA through a polyacrylamide gel containing linearly  increasing  concentrations of  a denaturing  agent  and  it  is  based on sequence dependent melting behaviour    (Fodde & Losekoot, 1994)  (Myers, et al., 1987) (Offermans, et al., 1996) (Wood, et al., 1994).   
Quantitative Real Time PCR for Vβ   The quantification of the Vβ‐families can also been achieved by quantitative real‐time PCR (qRT‐PCR), and it has been prove to be able to detect a higher number  of  families  with  higher  sensitivity  and  reproducibility.  As  for spectratyping,  24  primers  for  the  Vβ  regions  were  used  together  with  a reverse  primer  for  the  constant  region.  However,  here  an  internal fluorogenic  oligonucleotide  probe  (that  is  labelled with  both  a  fluorescent 




reporter  dye  and  a  quencher  dye)  is  also  used  to  anneal  to  the  conserved region  of  Cβ1  and  Cβ2  close  to  the  Cβ  reverse  primer.  During  PCR amplification  the  internal oligonucleotide probe  is  cleaved by  the Taq DNA polymerase.  After  cleavage,  the  quenching  of  the  reporter  dye  is  lost  and fluorescence can be detected and measured  (Lim, et al., 2002) (Lang, et al., 1997). The main limitations of the technique are the establishment of an adequate standard curve to permit quantification    (Brewer & Ericson, 2005) (Lim, et al.,  2002),  and  that  it  provides  infromation  on  the  Vβ  family  or  subfamily only, rather than  at the level of individual clones. Thus it is a technique best used in conjunction with, for example, one of the PCR‐based methods which can distinguish clonal heterogeneity but not relative quantity.   
Cloning and sequencing  In  principle,  cloning  and  sequencing  provides  the  best  method  to  assess clonality  of  the  T  cell  receptor,  allowing  a  detailed  analysis  of  the  CDR3 region, including the analysis of the individual V, D and J gene segments, and allowing the  identification of non‐template nucleotides. Therefore, not only the diversity but also the exact molecular composition of the TCR repertoire can be evaluated. Nevertheless, this technique has the disadvantages of being time‐consuming and expensive  (Naumov, et al., 1998) (Wilson, et al., 1993)  (Packer & Muraro, 2007) (O'keefe, et al., 2004).  




TCRβ-based oligonucleotide microarray This  method  uses  27  TCRVβ  probes  and  13Jβ  probes  to  analyse  TCR repertoire diversity after a single PCR. Microarray hybridisation and analysis by  appropriate  software  provides  sequence‐specific  information  to differentiate  between  monoclonal  and  polyclonal  expansion  and  it  offers both  qualitative  and  quantitative  data.  This  recently  developed  method seems to be both sensitive and fast, however more work needs to be done in order to validate its potential  (Chen, et al., 2007).   
Kinetics of immune reconstitution  In previous studies, it has been shown that Natural Killer cells (NK cells) are the  first  lymphoid  cells  to  appear  (Storek,  et  al.,  2008).  They  recover  to normal levels within 3 months after transplant followed by CD8+ T‐cells that recover 2  to 3 months post‐transplant. The  last  cells  to  reconstitute are B‐cells, which that take 3 to 5 months to recover and finally CD4+ T‐cells which start to recover 6 months post‐transplant  (Muraro, et al., 2005). During the first  6 months,  the peripheral T‐cell  pool  is  re‐populated basically  through peripheral  expansion  of  cells  expressing  a  memory  phenotype    (Dumont‐Girard, et al., 1998). Therefore, initially most of the cells have a memory and effector phenotypes and  they recover quite quickly,  reaching normal  levels within  6  months.  This  increase  of  memory  and  effector  cells  is  more pronounced in the CD8+ compartment  (Fallen, et al., 2003) while naïve CD8+ T‐cells  recovery  is  achieved between 6  to 12 months post‐transplant.    The CD4+ compartment regenerates very slowly reaching normal levels between 




6  to  10  months  post‐transplant    (Koehl,  et  al.,  2007)  (Kook,  et  al.,  1996)  (Kalwak, et al., 2002)  (de Vries, et al., 2000)  (Kim, et al., 2004). During  the first  6  months  there  is  a  reduction  of  the  naïve  CD4+  T  cells (CD45RA+/CD45RO‐/CD27+),  while  memory  and  effector  cells  reconstitute faster  as  a  result  of  homeostatic  proliferation    (Jameson,  2002)  (Murali‐Krishna  &  Ahmed,  2000).  The  levels  of  memory  and  effector  CD4+  T  cells start  to  decline  after  naïve  CD4+  T  cells  start  to  increase  6  months  after transplant  through  a  thymic  pathway.  TREC  levels  used  as  an  indicator  of recent  thymic  emigrants  (RTE);  TREC  are  detected  soon  after  transplant, however, they do not rise to normal levels until 6 months post‐transplant.  The  slow  recovery  of  naïve  T  cells  post‐transplant  particularly  affects  the CD4+ T‐cell compartment. It has also been shown that naïve T‐cell recovery is faster in younger patients than in older patients, as the thymus involutes with  age,  indicating  the  importance  of  the  thymic  function  for  a  full  T‐cell recovery  (Mackall,  et  al.,  1995).  Furthermore,  thymic  output  might  be compromised by damage to the thymus due to chemo‐ or radio‐therapy and graft  versus  host  disease  (GvHD)  thus  decreasing  the  output  of  newly generated naive T‐cells, and affecting the rates of T‐cell reconstitution after transplant.   




T cell receptor (TCR) reconstitution after HSCT  Recovery of immune competence is a key process for the success of an HSCT. However,  following HSCT a profound period of  immune deficiency appears to comprise this. The recovery of  immune competency not only  implies the recovery of normal numbers of immunological cells, especially of T cells, but also  the  recovery  of  their  diversity,  and  the  capacity  to  respond  to  a wide range  of  antigens.  Immune  reconstitution  after  HSCT  depends  on  several factors  including  age  of  the  recipient,  type  of  disease,  whether  or  not  the graft was T  cell  depleted,  type  of  conditioning  and  the  occurrence  of  post‐transplant  complications  such  as  GvHD  and  infectious  complications. However, the reconstitution of a wider TCR repertoire is not only dependent on  the  clinical  factors  or  the  type  of  conditioning,  it  requires  a  functional thymus. 
 
 
Ageing and thymic involution  The  thymus  involutes  with  age,  and  this  process  become  even  more pronounced in puberty. At the age of 25, the thymus has decreased by 50% of  its  size  at  birth,  the  involution process  continues,  finding  the  thymus  at 10%  of  its  original  size  by  the  age  of  50.  Consequently  a  decrease  of  the thymic  derived  naïve  T  cells  is  observed.  A  homeostatic  process,  which consists of expansion of peripheral T cells, maintains the overall T cell pool. However, an increase in the ratio of memory to naïve T cells occurs resulting 




in  a  higher  susceptibility  to  new  infections  and  a  more  limited  TCR repertoire, with a reduced capacity to recognise novel antigens.  Some factors have been associated with the involution of the thymus: a) Reduction in growth hormone  b) Reduction in insulin‐like growth factor 1 (IGF‐1) c) Increased oncostatin M d) Increased Stem Cell Factor e) Increased interleukin 6 (IL‐6) f) Increased Leukaemia Inhibitory Factor g) Increased TGF‐β production 
 Enhancing T cell reconstitution after HSCT 
 The pronounced  immunodeficiency  after HSCT,  resulting  from  the delay  in immune reconstitution, especially the delay  in the recovery of CD4+ T cells, has  lead  to an  intense effort  in  recent years,  to enhance post‐transplant T‐cell  reconstitution, with  the  goal  of  improving  overall  survival  after  HSCT. Some strategies have proven to  improve immune reconstitution and with a better  reconstitution has  come an  increase  in  the overall  survival.  Some of the  strategies  that  have  been  used  successfully will  be  analysed  here.  The possible  strategies  to  improve  T‐cell  recovery  include  agents  that  protect thymus  stroma  and  those  approaches  that  stimulate  proliferation  and differentiation of T‐cells  (Wils & Cornelissen, 2005). The therapies that have been used  to  improve  thymopoiesis until now  include keratinocyte growth factor (KGF), growth hormone (GH), LHRH agonists, interleukin 7 (IL‐7) and interleukin 15 (IL‐15). 





Growth hormone Growth  hormone  (GH)  is  produced  by  the  pituitary  gland  but  it  has  been demonstrated  that  it  is  also  produced  in  the  thymus  by  thymocytes  and thymic  epithelial  cells  (TEC)  and  acts  indirectly  on  both  thymocytes  and TECs to stimulate proliferation (Savino, et al., 2003). In the bone marrow, it drives expansion of T and B progenitors (Knyszynski, et al., 1992) (Tian, et al.,  1998)  (Sumita,  et  al.,  2005).  An  association  between  a  decreased secretion  of  GH  or  its  mediator  Insulin‐like  growth  factor  1  (IGF1)  and thymic involution has been found  (Taub & Longo, 2005). Administration of GH or IGF‐1 has been associated with recovery of thymic function and with improved immune reconstitution after HSCT  (Chen, et al., 2003) (Jardieu, et al., 1994). GH production decreases with age and it may play a role in thymic involution  since  treatment  with  GH  reverses  age‐associated  thymic involution in mice models.   
Keratinocyte growth factor  Keratinocyte growth factor (KGF) is a member of the fibroblast growth factor family  and  was  discovered  as  a  stimulator  of  epithelial  proliferation  and differentiation;  it  has  been  implicated  in  thymic  development    (Min,  et  al., 2002).  In normal healthy  thymus, KGF seems  to have no effect, however,  a key role as a cytoprotector has been  found  in situations of  thymic damage. KGF  is  produced  by mesenchymal  cells  (fibroblast)  as  an  essential  growth factor for TEC development, but is also produced by thymocytes. It has been 




proposed  that  KGF  protects  epithelial  cells  from  damage  by  chemo‐  and radiotherapy  and  from  GvHD.  The  administration  of  KGF  prior  to transplantation has been shown to enhance thymopoiesis and peripheral T‐cell reconstitution of naïve CD4 and CD8 T‐cells with a broad TCR repertoire  (Min, et al., 2002) (Alpdogan, et al., 2006) (Kelly, et al., 2008). However the mechanism of KGF protection is not fully understood.   
 
Hormones  
Sex steroid blockade  Thymic  atrophy  has  been  correlated  with  the  onset  of  puberty  and  more directly  when  an  augmentation  of  sex  steroid  hormones  begins,  with  a negative effect on thymopoiesis, In animal models it has been demonstrated that  sex  steroid  ablation  by  castration,  either  via  surgical  castration  by removal  of  gonads  or  chemically  castration  by  using  luteinising  hormone‐releasing hormone analogue (LHRH‐A),  reverses  the  thymic atrophy with a full recovery on its function  (Mackall & Gress, 1997) (Utsuyama & Hirokawa, 1989) (Flores, et al., 1999) (Bertho, et al., 1997) (Steinmann, et al., 1985). In clinical studies,  it has been demonstrated that sex steroid ablation restores thymic  function  inducing  effective  thymopoiesis,  promoting  immune reconstitution  with  an  increase  in  the  production  of  B  and  T  cell  in autologous   (Goldberg, et al., 2005) and allogeneic transplant   (Goldberg, et al.,  2007)  (Sutherland,  et  al.,  2005)  (Roden,  et  al.,  2004).  Also  it  has  been 








Interleukin 7  Interleukin  7  (IL‐7)  is  a  cytokine  produce  by  stromal  cells  of  the  bone marrow  and  thymus.  It  is  an  essential  cytokine  involved  in  T  and  B  cell differentiation  and  proliferation.  Pre‐clinical  studies  have  shown  that  the administration  of  IL‐7  after  HSCT  can  enhance  immune  reconstitution  by increasing  thymopoiesis,  increasing  the  peripheral  proliferation  of  recent thymic emigrants (RTEs) and by decreasing apoptosis of peripheral T cells, suggesting a potential for clinical use. In clinical studies the administration of recombinant human IL‐7 (rhIL‐7) enhances T cell reconstitution by different mechanisms: increasing the proliferation of de novo generated T cells and by decreasing T cell apoptosis in the periphery, inducing a sustained increase in peripheral CD4+ and CD8+ T cells causing a wide T cell  repertoire diversity  




(Parkman  &  Weinberg,  1997)  (Alpdogan,  et  al.,  2001)  (Alpdogan,  et  al., 2003) (Sportès, et al., 2008).  
Interleukin 15 Interleukin  15  (IL‐15)  is  a  member  of  the  IL‐2  family  of  cytokines.  It stimulates  the  proliferation  of  previously  activated  T  cells.  In  pre‐clinical studies  IL‐15 has shown an  increase  in  the peripheral expansion of CD8+ T cells, NK cells and NKT cells  (Alpdogan, et al., 2005) (Katsanis, et al., 1996).  In my studies, I have chosen to focus on the effect of sex steroid blockade on thymic function and the output of new naïve T cells.   The  beneficial  effect  on  the  immune  system  of  sex  steroid  blockade  by luteinizing  hormone‐releasing  hormone  analogues  (LHRH‐A)  was demonstrated  in patients  treated  for  prostate  cancer by  an  increase  in  the number of naïve CD4+ and CD8+ T cells  in peripheral blood  (Sutherland, et al., 2005). However, its effect on patients treated prior to HSC transplant has not previously been shown. A study was therefore carried out to evaluate the TCR  repertoire  reconstitution  by  spectratyping  in  patients  treated  with LHRH‐A  prior  to  transplantation  in  comparison  to  patients  who  weren’t treated, the clinical details presented in Table 3.1.   




Materials and Methods 
  This  study  was  carried  out  in  collaboration  with  the  Department  of Immunology  of  Monash  University  in  Melbourne,  Australia.  However,  all work  presented  here  was  carried  out  by  myself  at  the  Anthony  Nolan Research Institute in London, UK. The complete study has been published in the Clinical Cancer Research journal  (Sutherland, et al., 2008).   
Patients, disease and treatment regimen 
Patient age, sex, disease and pre‐transplant regimen are presented in Table 3.1. The  study consisted of  a nonrandomised pilot  study  involving patients undergoing an HSCT at the Alfred Hospital and the Peter MacCallum Cancer Institute  in  Melbourne,  Australia  from  2001  to  2005.  For  patients  who consented  to  treatment with  the LHRH‐A goserelin  (Zoladex, AstraZeneca), an initial dose of 10.8mg for men and 3.6mg for women was administered 21 days prior to transplantation. For men, an additional 1‐month dose (3.6mg) was  given  at  day  63  post‐transplant  and  women  were  given  monthly injections of 3.6mg with a final dose at day 63 post‐transplant. In all treated patients, castrate levels of sex steroids were obtained within the first month of administration. Castrate levels of estradiol were maintained for 6 months post‐transplant, whereas testosterone castrate levels were not achieved until 4 months post‐transplant and were  subsequently maintained  for 6 months 




post‐HSCT. The  levels  returned  to normal after 12 months post‐transplant. Patients  were  analysed  pre‐treatment  and  at  3,  6,  9  and  12 months  post‐transplant.  Ethical  approval  was  obtained  from  the  Alfred  Committee  of Ethical Research on Humans (trial no. 01/006).   The  types  of  transplants  performed  were  both  autologous  and  allogeneic transplants,  and  a  total  of  four  patient  groups  analysed.  The  autologous control group without LHRH‐A treatment consisted of a total of 16 patients and  the  autologous  LHRH‐A  group  consisted  of  7  patients.  The  Allogeneic control group consisted of 8 patients and the Allogeneic LHRH‐A group of a total of 13 patients. Clinical details of the patient cohorts are shown in Table 3.1.               





Table 3.1. Patient demographics 
 
 Table 3.1                                                     Patient Group          Allogeneic control  Allogeneic LHRH‐A  Autologous control  Autologous LHRH‐A Patient No.  8  13  16  7 Gender (Male/Female)  4M/4F  10M/3F  9M/7F  4M/3F Age, years (Median±SE)  40.24±3.55  43±3.02  56.44±2.10  54.5±2.31 Diagnosis                Acute Leukaemia  4  10  1  0       Chronic Leukaemia  1  2  0  0       Lymphoma  0  1  5  4       Multiple Myeloma  0  0  10  3       Aplastic anemia  3  0  0  0 Conditioning                Cyclophosphamide/ATG  2  0  0  0       Cyclophosphamide/TBI  0  0  1  0       Cyclophosphamide/TBI/ATG  5  8  0  0       Fludarabine/Melphalan  0  3  0  0       Fludarabine/Melphalan/ATG  1  0  0  0       Melphalan  0  0  9  4       LACE  0  0  4  3       Missing  0  2  2  0 Remission Status at transplant                Complete Response  1  3  6  2       Partial Response  3  3  8  2       Progressive Disease  2  7  0  1       Stable Disease  2  0  2  2       Relapse refractory  0  0  0  0       Relapse untested  0  0  0  0 Stem Cell Source                Peripheral blood  8  13  16  7       Bone marrow  0  0  0  0 Donor                HLA identical related  5  8  NA  NA       HLA identical unrelated  3  5  NA  NA ATG: antithymocyte globulin; TBI: total body irradiation; LACE: Lomustine, etoposide, cytarabine and  cyclophosphamide 
    




Preparation of peripheral blood mononuclear cells  PBMC’s were isolated as described previously in Material and Methods they were stored in liquid nitrogen until required.  
Spectratyping  Spectratyping  analysis  was  done  on  both  CD4+  and  CD8+  T  cells  pre‐transplant, 6, 9 and 12 months post‐transplant. The protocol is presented in chapter 2. Briefly,  PBMC’s  were  separated  into  CD4+  and  CD8+  T  cell  populations  by EasySep  magnetic  separation  with  95%  purity.  RNA  was  extracted  from sorted cells and converted into cDNA. The cDNA obtained was used for PCR amplification  and  the  PCR  products  run  in  a  sequencing  gel  as mentioned previously.  The  complexity  of  the  TCR  repertoire  was  determined  by counting  distinct  peaks  per  Vβ  family  on  a  score  of  0  to  8.  The  overall complexity of TCRβ subfamilies was calculated as the spectratype complexity score  (SCS)  as  described  by  Wu,  et  al.  The  complexity  score  in  normal individual  ranges  from  121  to  185  peaks  (Fallen,  et  al.  2000)  (Wu,  et  al., 2000)  
Statistical analysis  The spectratyping scores were compared between the healthy control group and  the  four  patient  groups  at  the  different  time  points  using  the  Mann‐Whitney U test with KaleidaGraph 4.03 software (Synergy Software). 





Vβ  Spectratyping prior to transplantation 
 In  samples  prior  to  transplantation Vβ  spectratyping was  performed  in  all groups  and  compared with  normal  values;  in  20  healthy  controls  (median age  27±3  years)  the  normal  median±SD  of  the  CD4+  T  cell  subset  was 170±19.82 peaks (normal range 129 to 185 peaks), while the normal range of  the  CD8+  T  cell  subset  was  121  to  180  peaks  (median±SD  143±19.71 peaks).  In the autologous control group the median value of the Vβ diversity in the CD4+ T cell subset was 90±45.16 (range 28‐149 peaks) while the median of the CD8+ T cell subset was even lower 48±34.58 peaks (range 13‐136 peaks). Both  groups  had  statistically  significant  lower  number  of  peaks  compared with  healthy  controls,  p=0.0003  and p<0.0001  respectively,  representing  a very  restricted  T  cell  repertoire  in  both  CD4  and  CD8  compartments  pre‐transplantation,  may  be  due  to  the  type  of  disease  or  the  previous treatments.   The median  of  the  autologous  LHRH‐A  treated  patients was  impossible  to determine  because  only  one  patient  sample  was  available  to  perform  the analysis.  Therefore,  a  meaningful  comparison  with  healthy  controls  could not be performed. However, in an analysis with all pre‐transplant samples of 




the autologous cohort  (either  treated or control group), both CD4 and CD8 compartments  were  significantly  less  diverse  than  in  healthy  controls (p=0.0004  for CD4 and p<0.0001  for CD8), as presented  in Figures 3.2 and 3.3.  The  median±SD  value  for  the  CD4+  T  cell  subset  in  the  allogeneic  control group was 90.5±63.58 peaks (range 0‐162 peaks). No significant difference was  observed  between  the  autologous  and  allogeneic  control  groups. However,  a  statistically  significance  was  observed  compared  with  the healthy control group, p=0.002.  The median  of  the  CD8+  T  cell  subset  in  the  allogeneic  control  group was 25±49.52  (range  0‐152).  Again,  no  difference  was  observed  between  the autologous  and  allogeneic  control  groups,  while  a  statistically  significant difference was observe between the allogeneic control group and the healthy controls, p=0.001.  In  the  LHRH‐A  treated  allogeneic  group,  the median±SD of  the CD4+ T  cell subsets was 76±38.67 peaks (range 11‐124 peaks). While the median value of  the  CD8+  T  cell  subset  was  54±21.68  peaks  (range  13‐87  peaks).  The diversity  of  both  the  CD4+  and  CD8+  T  cell  subsets  were  statistically significantly  lower  than  the  healthy  controls,  p=0.0002  for  each  subset. When  pre‐transplant  samples  from  patients  for  both  allogeneic  groups (control and LHRH‐A treated) were put together and analysed the number of 




peaks was statistically lower (less diverse) than healthy controls (p<0.0001 and p<0.0001, respectively), data presented in figures 3.2 and 3.3. As for the autologous groups, the T cell repertoire in patients seemed to be limited  in  the  allogeneic  setting.  Although  both  groups  show  very  low diversity in both CD4 and CD8 compartments, it is clear by the data showed in  Figure  3.3  that  the  skewed  repertoire  is  more  pronounce  in  the  CD8 compartment in the allogeneic group.   
Figure 3.2. Comparisons of CD4+ T cell Vβ repertoires between autologous and allogeneic 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Reconstitution pattern of the autologous transplant group at 6, 9 
and 12 months post-transplant  The  median±SD  values  of  the  TCRVβ  repertoires  of  the  CD4+  T  cell compartment  of  the  autologous  control  group  at  6 months  post‐transplant were  of  95±38.06  peaks,  at  9 months  post‐transplant  of  114±58.44  peaks and at 12 months post‐transplant of 143±50.36 peaks, as presented in Table 3.4.  Although  this  shows  an  increasing  trend,  it  was  not  statistically significant.  The median values of the CD8+ T cell compartment for this control group at 6 months  were  of  66±35.74  peaks,  showing  statistically  significant improvement  in comparison with  the pre‐transplant values  (p=0.009), at 9 months of 87±32.06 peaks (it was not statistically different to the previous observation) and at 12 months of 82±57.12 peaks (no statistically significant difference) (Table 3.5). The  median  values  of  the  CD4+  T  cell  compartment  in  LHRH‐A  treated autologous  transplant  group  were  at  6  months  of  127±40.50  peaks,  at  9 months  of  133±56.06  peaks  and  at  12  months  of  130±28.49  peaks,  not showing  a  statistically  significant  improvement  in  the  pattern  of reconstitution.  While  the  median  values  of  the  CD8+  T  cell  compartment were at 6 months of 99±29 peaks, at 9 months of 93.5±3.69 peaks and at 12 months  of  102±38.19  peaks,  not  statistically  significant,  data  presented  in Table 3.4. 





Table 3.2. Comparison of the reconstitution pattern of CD4+ and CD8+ T 





T cell reconstitution in the autologous setting    Controls vs LHRH‐A treated group            CD4+ T cell subset  CD8+ T cell  Subset      (p value)     (p value) Pre‐transplant  p=NS    p=NS    6 Months    p=NS    p=NS    9 Months    p=NS    p=NS    12 Months  p=NS     p=NS    





Reconstitution pattern in the CD4+ T cell compartment between control group 
(solid black circles) and LHRH-A treated group (solid red squares) in an 
autologous setting. The two groups showed very similar pattern of 
reconstitution, and only few patients reach normal TCR repertoires 12 months 
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Reconstitution pattern in the allogeneic transplant groups  The  allogeneic  transplant  control  group  showed  the  following  pattern  of TCRVβ  reconstitution  in  the  CD4+  T  cell  compartment  after  HSCT;  at  6 months the median number±SD of peaks was 76.5±19.05 peaks, at 9 months 128±39.73  peaks,  (a  significant  improvement,  p=0.05)  and  at  12  months 89±31.61 peaks as shown in Table 3.4.  The CD8+ T cell compartment reconstituted as follow, at 6 months a median ±SD  of  71.5±21.03  peaks,  at  9  months  60±16.38  peaks  and  at  12  months 71±15.15 peaks, as presented in Table 3.5.  The  median  values  of  the  CD4+  repertoires  by  Vβ  spectratyping  of  the allogeneic LHRH‐A treated group reconstituted as follows (data presented in Table 3.4), at 6 months 120±26.95 peaks, showing a significant improvement (p=0.009)  in  comparison  to  the  pre‐transplant  repertoire,  at  9  months  of 130±38.98  peaks  (an  increase  from  6  months  post‐transplant,  but  not statistically significant) and at 12 months of 179±22.38 peaks (a statistically significant increase from the previous time‐point, p=0.04).  The CD8+ T cell compartment median repertoire values at 6 months was of 83±17.66 peaks (a statistically significant improvement in comparison to the pre‐transplant  repertoire,  p=0.002),  at  9  months  98.5±27.07  peaks  (not statistically  significant)  and  at  12  months  of  113.5±56.34  peaks  (no statistical significance) (Table 3.5). 




In the allogeneic transplant setting, the reconstitution pattern showed great differences between the treated and control groups, in particular in the CD4+ T  cell  compartment.  The  LHRH‐A  treated  group  recovered  diversity  in  the CD4 compartment more rapidly, as presented in Table 3.3 and in Figure 3.6. On the other hand, while the CD8 compartment also showed a trend towards faster  recovery  of  diversity  in  the  LHRH‐A  treated  patients,  this  was  not statistically significant, as presented in Table 3.3 and Figure 3.7. A larger study may be required to demonstrate significant effects within the CD8+  compartment,  or  it may  be  that  peripheral  expansion  plays  a  role  in early  CD8  T  cell  reconstitution  and  the  effects  of  thymic  reactivation  are masked.               

























T cell reconstitution in the allogeneic setting       Controls vs LHRH‐A treated group            CD4+ T cell subset  CD8+ T cell subset      (p value)     (p value) Pre‐transplant  p=NS    P=NS    6 Months    p=0.0022**  P=0.03* 9 Months    p=NS    P=0.09    12 Months  p=0.008**  P=0.07 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p=NS                 p=0.002                   p=NS                 p=0.008
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p=NS                  p=0.03                   p=0.09                   p=0.07




Table 3.4. Median±SD values of the total CD4+ T cell repertoires  Median±SD  values  of  the  total  CD4+  T  cell  repertoires  of  all  groups, and  comparisons  of  improvements  on  the  reconstitution  between  the different  time‐points.  The  greater  improvement was  seen  in  the  allogeneic LHRH‐A  treated  group  from  the  pre‐transplant  period  to  6  months  post‐transplant.   
Spectratyping of CD4+ T cell compartment (median values)             Group  Pre‐transplant  6months  p value  9months  p value  12months  p value                    
Allogeneic  Control  90.5±63.58  76.5±19.05  p=NS  128±39.73  p=0.056  89±31.61  P=NS    LHRH‐A  76±38.67  120±26.95  p=0.009  130±38.98  p=NS  179±22.38  P=0.04 





Table 3.5. Median±SD values of the total CD8+ T cell repertoires  Median±SD  values  of  the  total  CD8+  T  cell  repertoires  of  all  control and LHRH‐A treated groups in an allogeneic and an autologous settings, and comparisons  of  improvements  on  the  reconstitution  between  the  different time‐points.  The  greater  improvement was  seen  in  the  allogeneic  LHRH‐A treated group from the pre‐transplant period to 6 months post‐transplant. 
 
 
Spectratyping of CD8+ T cell compartment (median values)             Group  Pre‐transplant  6months  p value  9months  p value  12months  p value                    
Allogeneic  Control  25±49.52  71.5±21.03  p=0.04  60±16.38  p=NS  71±15.15  p=NS    LHRH‐A  54±21.68  83±17.66  p=0.02  98.5±27.07  p=NS  113.5±56.34  p=NS 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Discussion The ability to regenerate the peripheral T cell pool, in particular the CD4+ T cell pool, after an HSCT is a key element for the success of the transplant. It has  been  reported  previously  that  adults  can  take  up  to  two  years  to regenerate normal numbers of naïve CD4 T cells, mainly due to the atrophy of  the  thymus    (Dumont‐Girard,  et  al.,  1998)  (Fallen,  et  al.,  2003).  Several strategies have been used to try to  improve reconstitution after  transplant, and some of these have shown a beneficial effect and have improved survival after HSCT  by  decreasing  the  incidence  of  infectious  complications  and  by improving  anti‐tumour  responses.  In  this  study  the  effect  of  LHRH‐A treatment  on  the  reconstitution  of  T  cell  diversity  was  analysed  in  both autologous  and  allogeneic  transplant  settings.  This  study  was  part  of  a prospective  trial  aimed  to  assess  the  impact  on  immune  reconstitution  of LHRH‐A administration before and after an HSCT; my role in this study was to carry out the measurement of TCR Vβ diversity, other measurements were carried out by other members of the collaborative group. As  previously  reported  for  this  cohort  (Sutherland,  et  al.,  2008),  LHRH‐A treated  patients  showed  a  faster  engraftment  in  both  autologous  and allogeneic  settings.  Moreover,  a  very  striking  finding  was  a  significant increase  of  TREC  in  the  CD4+  T  cell  compartment  together  with  a  faster reconstitution  of  the  CD4+  naïve  T  cell  subset  in  both  autologous  and allogeneic  groups. However,  it was particularly  important  in  the allogeneic group, in which I have shown that the reconstitution of the TCRVβ diversity in the CD4 compartment was also improved.  




An  interesting  finding  was  that  a  restricted  diversity  was  found  in  all patients  pre‐transplantation  in  comparison  to  healthy  controls.  The restricted  repertoire may  be  due  to  the  nature  of  the  disease  or  the  prior treatments received by the patients. However, T cell reconstitution shows a significant  increase  in  the  diversity  as  early  as  6  months  post‐transplant. Moreover, the LHRH‐A treated patients in particular in the allogeneic setting show a completely normal T cell repertoire 12 months post transplant. This is  most  striking  in  the  CD4+  compartment  in  contrast  with  previous publications,  where  a  slow  recovery  of  the  CD4  compartment  has  been observed. After transplantation, the reconstitution of a broad T cell repertoire requires a thymic‐dependent pathway. After 6 months post‐transplant the autologous LHRH‐A treated group showed a good reconstitution in both CD4+ and CD8+ T cells, however, it was not statistically significant when compared with the control  group.  At  9  and  12  months  the  LHRH‐A  groups  showed  also  an improvement in the reconstitution of the diversity of CD4 and CD8 T cells, as the  control  group  continued  to  show  restricted  repertoires.  However, statistical differences were not found in the reconstitution pattern between the two groups. At 12 months both groups showed almost normal pattern of T cell receptor diversity. In  contrast,  in  the  allogeneic  group,  the  T  cell  diversity  of  the  CD4 compartment  reached  almost  normal  level  within  6  months,  while  the control  group  remained  restricted.  The  reconstitution  followed  the  same pattern,  and  at  12  months  all  the  patients  studied  to  whom  LHRH‐A  was administered  had  normal  TCR  repertoires.  The  repertoire  of  the  control 




groups  continued  with  improvements  but  they  remained  lower  than  the LHRH‐A treated group.  The CD8 compartment also showed a trend towards better reconstitution in the  LHRH‐A  treated  group  at  the  different  time  points,  but  the  differences with the control group were not statistically significant.  The mechanisms of  thymic  recovery after LHRH‐A administration have not yet been elucidated due to the complex mechanisms involved in both thymic atrophy and thymic regeneration. However, many studies have been carried out by different groups in order to understand this process. One mechanism suggests  that  sex  steroid  ablation  affects  the  reorganization  of  the  thymic stromal  cell  microenvironment,  increasing  the  proliferation  of  thymic epithelial cells and inducing the production of  IL‐7 and GH by stromal cells that also contribute  to  thymic expansion (Ann Chidgey, Monash University, unpublished  observations).  It  is  important  to  considerate  that  a  critical requirement  for  thymic  regeneration  is  to  have  some  remnant  thymic function,  because  it  has  been  demonstrated  that  young  castrated  mice regenerate  larger  thymuses  that  older  mice  (Sutherland,  et  al.,  2005).  In considering the mechanism of sex steroid ablation it has been observed that many  thymic  cells,  including  thymic epithelial  cells  (TEC),  thymic dendritic cells,  CD31+  thymic  endothelial  cells  and  thymocytes  all  have  androgen receptors (AR).  Unfortunately, this broad expression of AR makes it difficult to  confine  the  mechanism  of  regeneration  to  only  one  cell  type  or  one mechanism.  However,  AR  deficient  mice  show  thymic  enlargement  in comparison to non‐deficient mice. The depletion of sex steroids may result in changes  in proliferation of both  thymocytes and TEC, or a  reduction  in  the 




release  of  pro‐apoptotic  molecules  after  stimulation  of  the  androgen receptors. Also  it has been observed that steroids kill  thymocytes, and that blockading  sex  steroid  production may  allow more  thymocytes  to  survive and become T cells. It is important to mention that the steroid ablation effect in mice is only temporary and wears off after a year (Fletcher, et al., 2009). However, even a transient increase in thymic output would be of benefit to the patient.  Studies on immune reconstitution in younger patients show that normal levels of naïve CD4 and CD8 T cells are obtained some 12‐15 months after transplant (Fallen, et al., 2003) (Paul Travers, unpublished data).   Other  candidates  for  mediating  thymic  regeneration  after  sex  steroid ablation treatment are: growth hormone (GH) and Insulin‐like growth factor 1  (IGF‐1)  through  the stimulation of TEC‐produced growth  factor  thymulin (Taub    &  Longo,  2005);  antiapoptotic  molecules  such  as  IL‐7  and keratinocyte  growth  factor  (KGF)  which  have  shown  to  induce  thymic regeneration  in  mice  (Min,  et  al.,  2002)  (Pido‐Lopez,  et  al.,  2002);  or reduction in proapoptotic molecules such as TGF‐β. Due to the complex and largely  unknown  mechanisms  that  underlie  thymic  atrophy  and regeneration,  one  can  only  speculate  on  the  molecular  mechanism  that drives thymic regeneration after treatment with LHRH‐A.  It  is  possible  then  that  a  steroid  ablation  effect  persisting  for  only  1  year would allow the patients to establish normal  levels of T cells; a subsequent decrease  in  the  thymic  output would  simply  return  the  immune  system  to the state it would normally be in individuals of that age.  




Chapter 4  
Prognostic analysis of pre-transplant peripheral T cell 
levels and TRECs in patients receiving an allo-HSCT   
Introduction  Haematopoietic stem cell transplantation is a potentially curative treatment for  many  haematological,  hereditary  and  immunological  disorders.  Even though  more  than  30,000  transplants  are  performed  every  year,  the  full range of factors that determine the successful outcome of the transplant are yet to be elucidated. The major factor implicated in the success of an HSCT is to find a fully compatible HLA‐match donor. However, even in a 10/10 HLA‐matched  setting,  complications  have  not  been  avoided  completely  and patients  transplanted  with  fully  matched  donors  still  die  after  transplant. This suggests  that  there must be other  factors affecting  the outcome of  the transplant.  Many groups (Gaziev, et al., 2002) (Savage, et al., 1997) (Enright, et al., 1996) have  suggested  different  prognostic  factors  that  may  be  correlated  with transplant success, such as:  










• the relapse of the primary tumour.  However,  all  the  previous  elements  are  not  independent  factors  but represent  a  combination  of  pre‐transplant  and  post‐transplant  variables, which could complicate  the selection of  the best possible  factors  to predict the transplant outcome. Therefore, I have focused on parameters that could be  measured  prior  to  the  transplant  to  ask  whether  any  of  these  are predictive  factors  for  the  outcome  of  the  HSCT.  The  identification  of  such pre‐transplant  prognostic  factors may  help  to  identify  patients who  are  at higher risks of transplant complications and poorer transplant outcome and who  are  more  likely  to  benefit  from  alternative  or  intensified  therapeutic approaches.   
Graft characteristics and transplant outcome 
 The composition of the stem cell graft has been associated with the clinical outcome  after  transplantation,  and  some  cells  are  in  particular  associated with the development of GvHD.  Vela‐Ojeada et al.  showed  that  the  transfer of over 6x106 CD34+ cells/kg  is associated with the onset of acute GvHD (Vela‐Ojeda, et al., 2006). It was also shown by Vela‐Ojeda et al.  that better overall  survival was associated with the infusion of fewer than 8x106 CD34+ cells/kg, along with fewer than 3x107 NK cells/kg and fewer than 1.5x107 NKT cells/kg. Likewise, Przepiorka and 




cols  found  that  a  high  dose  of  CD34+  cells  was  an  independent  predictive factor  for  the  onset  of  aGvHD  (Przepioka,  et  al.,  1999). On  the  other  hand, Gorin et al.  found better outcome in patients with acute myeloid leukaemia who  received higher doses of mononuclear  cells  (greater  than 2.7x108/kg)  (Gorin, et al., 2003).   
Pre transplant immune status of the patient 




 As mentioned in previous chapters, thymic function plays an essential role in immune  reconstitution. After  transplantation  there  are  two main  routes  to repopulate the immune system: a thymic independent pathway, which relies on  the  expansion  of  transplanted mature  donor  T  cells, which  is  therefore only capable of generating a limited TCR repertoire, and a thymic dependent pathway,  which  involves  the  generation  of  new  T  cells  from  engrafted progenitor  cells  (haematopoietic  stem  cells  and  any  committed  lymphoid 




progenitor cells present in the graft) and recapitulates T cell ontogeny in the thymus.  This  second  pathway  can  therefore  generate  the  broad  TCR repertoire required for adequate immune responses.  The thymic dependent pathway  clearly  requires  a  functional  thymus,  suggesting  that  pre‐transplantation thymic activity may be analysed to predict engraftment and reconstitution,  independently  of  the  age  of  the  recipient    (Mackall,  et  al., 1993).  Thymic function and the thymic dependent pathway of reconstitution can be assessed  by  the  analysis  by  flow  cytometry  of  recent  thymic  emigrants (RTE), initially identified as naïve T cells that express the CD45RA+ marker. However,  some  disadvantages  to  this method  have  been  reported.  On  one hand, it has been showed that some CD45RO+ memory T cells can re‐express the CD45RA isoform, but remain as functional memory cells (Haynes, et al., 2000); and on the other hand, some CD45RA+ T cells can undergo extensive division while  retaining  the  expression  of  CD45RA    (Kimmig,  et  al.,  2002), thus complicating the use of CD45RA for analysis of thymic function.   Thymic function can also be evaluated throughout the quantification of T cell receptor excision circles  (TRECs) by quantitative real  time PCR (qRT‐PCR). As mentioned in the introductory chapter, TRECs are episomal circles of DNA that  are  formed  from  the  deletion  of  the  TCRδ  region  during  the rearrangement of the TCRα locus. TRECs are not replicated during each cell division  but  on  the  contrary  they  become  diluted  out  as  T  cells  divide  (Douek, et al., 1998).  It has been suggested by several groups that assessment of the status of the thymus  prior  to  transplant  can  be  used  as  a  good  indicator  of  recovery  of 




immune  competency  after  the  transplant  and  therefore  could  be  used  as predictor of the transplant outcome  (Talvensaari, et al., 2002) (Clave, et al., 2005).  Chen et al.  (Chen, et al., 2007) showed that in paediatric patients, the quality of  the  thymic  function  before  HSCT was  correlated with  the  rate  of  T  cell reconstitution.  Those  patients  with  a  higher  thymic  output  pre‐transplant reconstituted  their  immune  system  faster  than  the  patients  with  low  pre‐transplant thymic output. Also, they proposed that the rate of reconstitution influenced the outcome of the transplant, suggesting that the assessment of TREC levels as a marker of thymus function prior to transplant could be used as  a  good  predictor  for  post‐transplant  reconstitution  and  consequently  of transplant outcome. Others have shown a direct impact of the pre‐transplant levels of TRECs on transplant outcome. Talvensaari et al. showed that low levels of TRECs pre‐transplant correlated with higher incidence of both acute and chronic GvHD post‐transplant in an allogeneic transplant setting  (Talvensaari, et al., 2001). Also,  Svaldi  et  al.  showed  a  correlation  of  high  levels  of  TRECs  pre‐transplantation  with  better  overall  survival  (OS)  and  better  disease  free survival  (DFS)  in  patients  with  multiple  myeloma  (MM)  who  received  an autologous  transplant    (Svaldi,  et  al.,  2003).    Interestingly,  Clave  et  al.  also showed a correlation between high TREC levels prior to transplantation with better  overall  survival  (OS)  and  fewer  infectious  complications, which was confirmed  in  a  multivariate  analysis  of  the  outcome  after  allogeneic transplant  from  HLA‐identical  sibling  donors    (Clave,  et  al.,  2005)  (Clave, 2006). 




In conclusion, all previous work suggested that the assessment of the thymic function  of  the  recipient  prior  to  transplantation  could  be  used  as  a predictive  prognostic  factor  of  HSCT  outcome  and  also  could  be  used  to identify those patients requiring a closer monitoring.  I  therefore  undertook  to  assess  the  contribution  of  other  pre‐transplant immune  parameters  to  the  overall  outcome  of  unrelated  donor transplantation.  
 
T cell subsets Pre‐transplant T cell status is an important component of the immunological status  of  the  patient  that  can  be  assessed  to  evaluate  its  correlation  with transplant outcome.  Parameters  of  immune  status  that  can  be  evaluated  are,  for  example,  the distributions of different T cell subsets, such as: CD4 (helper) T cells in their different stages of differentiation (naïve, memory and effector), and of CD8 (cytotoxic) T cells also in their different stages of differentiation.  In addition other important immune cell subsets can be defined and evaluated, including dendritic cells (DC), natural killer cells (NK) and natural killer T cells (NKT).  The identification of these different  immune cell subsets can be carried out by  the  expression  of  different  cell  surface  markers,  analysed  by  flow cytometry.  T cells can be identified by the expression of the CD3 marker. Two functional subsets  of  CD3+  T  cells  have  been  identified,  the  helper  subset,  which 




expresses the CD4 marker on the cell surface and the cytotoxic subset, which expresses  the  CD8  surface  marker,  as  mentioned  previously  in  the description of T cell ontogeny in Chapter 1 (T cell ontogeny). Moreover, the stage of  differentiation of  either CD4+ or CD8+ T  cells  is  important  in  their function  and  has  been  categorised  into  naïve,  central  memory,  effector memory and terminal effector stages (Sallusto, et al., 1999). Cells at each of these stages express different homing and cell surface receptors, which can help to identify their phenotype.  In  the  introduction  it was mentioned  that many  studies  have  analysed  the cellular  composition  of  the  haematopoietic  stem  cell  graft  and  have investigated  its  impact  on  transplant  outcome.  However,  just  a  few  have analysed  the  impact  of  the  immune  cell  status  of  the  recipients  and  its correlation with transplant outcome. Rosinksi et al. evaluated the impact of different T cell subsets on transplant outcome  in  patients  receiving  an  autologous  HSCT,  showing  the  following findings: 1. All patients evaluated that were undergoing an HSCT had CD4+ T cell levels  below  those  observed  in  healthy  controls,  showing  a immunodeficiency within the population of patients studied. 2. Higher  pre‐transplant  levels  of  CD4+  T  cells  correlated  with  better disease free survival (DFS) and better overall survival. 3. Higher pre‐transplant  levels of memory CD4+ T cells correlated with better DFS, which was confirmed by a multivariate analysis. 




Arpinati  et  al.  also  analysed  the  levels  of  other  immune  cells,  in  particular antigen‐presenting cells (APCs) such as dendritic cells (DCs), and monocytes and their correlation with the onset of GvHD  (Arpinati, et al., 2007). Dendritic  cells  are  the  most  potent  antigen‐presenting  cells.  Different subtypes of DC have been described  (Shortman & Liu, 2002), with a major division  into  two  functional  subsets: DC1 or myeloid  (mDC) expressing  the CD11c marker, which reside in the peripheral lymphoid organs, and DC2 or plasmacytoid  (pDC)  subsets  expressing  the  CD123  marker,  which  are present  in  secondary  lymphoid  organs  while  their  numbers  in  peripheral blood remain low.  Another  important  cell  type  are  monocytes,  which  express  the  surface marker CD14 and can differentiate either into DC or macrophages depending on the cytokine environment (Geissman, et al., 2010). In both cases, they will function as antigen presenting cells (APC). The development of acute GvHD is initiated through the activation of donor derived  mature  T  cells  by  host  APC,  through  either  direct  or  indirect presentation of alloantigens. Thus these cells play a pivotal role in the onset of acute GvHD; the assessment of APC in the patient prior to transplant may be an important determinant of transplant outcomes.  The  role of dendritic  cells  in HSCT has been evaluated recently,  and  it was observed that low DC levels after transplantation are found in patients with severe aGvHD  (Vakkila, et al., 2005). Moreover, Reddy et al. showed that low DC levels after HSCT could predict the onset of GvHD, and could even predict relapse and death  (Reddy, et al., 2004).  These results appear contradictory, 




since GvHD is usually considered to contribute to the graft‐versus‐leukaemia response.  The resolution of the contradiction may be that DC are susceptible to  allo‐killing,  and will  be  eliminated  early  in  the  course of GvHD, perhaps before  the onset of other  symptoms, hence  low DC  levels  can be not  really predictive but an early warning that GVHD taking place.  The paradox is that GvHD would normally be associated with less relapse, but here it may be that low  levels  of DC  –  in  this  case  probably  of  donor DC  –  fail  to  stimulate  an effective anti‐tumour response through a failure in crosspresentation (Rock & Shen, 2005)  An evaluation of the pre‐transplant status of APC, which included mDC, pDC and  monocytes  was  done  by  Arpinti,  and  a  correlation  between  pre‐transplant  levels  and  transplant  outcomes  was  investigated,  in  particular with  respect  to  the  onset  of  GvHD.  However,  no  correlation  was  found between  the  levels of  either mDC or pDC and  the development of  acute or chronic GvHD. Surprisingly,  the  levels of monocytes did  influence the onset of  GvHD  and  high  levels  of monocytes  correlated with  higher  incidence  of acute  GvHD  in  allogeneic  HSCT  from  related  donors.  However,  that observation  was  not  reproducible  in  HSCT  from  unrelated  donors,  which may be due to the different conditioning therapies received.  All these observations suggest that there is a relationship between the pre‐transplant immune status of the recipient and the transplant outcome. This may be due to an impact on GvHD, on early infection control, or on immune mediated tumour control after HSCT. Therefore, in this study the aim was to analyse  further  the  pre‐transplant  immune  status  of  the  recipients, 




specifically by evaluating T  cell  subset  levels  and  the  level of TREC,  and  to correlate these with transplant outcomes. Clearly there are other subsets of T cells ‐ NKT cells and γδ T cells ‐ as well as NK  cells  themselves  that might  also  play  a  role  in  the  transplant  outcome.  Analysis  of  the  reconstitution  and  role  of  these  cells  was  the  subject  of  a separate PhD project  (Andrea Knight, UCL PhD Thesis, 2010).    In  the work presented  here  the  focus  is  on  the  role  of  CD4  and  CD8  T  cells  and  the association  that  different  T  cell  subsets  might  have  with  the  outcome  of transplantation.  




Materials and Methods 
Patients and controls The study group consisted of 113 recipients who had received an HSCT from an unrelated donor identified through the Anthony Nolan Trust (ANT) donor registry. 64 donors from the registry with the same age range as the patients were analysed as a control group. Both recipients and donors were required to have 4‐digit  allele  typing  results  at  six HLA  loci  (HLA‐A,  ‐B,  ‐C,  ‐DRB1,  ‐DQB1,  ‐DPB1).  Because  the  study  was  registry  based,  blood  samples  and clinical data were provided by the  individual transplantation centres (TCs). Clinical  data were  collected  on  standard  forms, which were  collected  from data managers at the individual TCs.  The  transplants  in  the  cohort  took  place  between  September  1996  and January  2003.  A‐broad  ranges  of  diseases  were  indications  for transplantation  and  the  patient  and  donor  pre‐transplantation demographics can be seen in Table 4.1. The majority of the transplantation protocols  included  T‐cell  depletion  (86.7%),  in  most  cases  using Alemtuzumab  (Campath  1H)  in  vivo  (81.4%).  A  roughly  equal  number  of patients  received  transplants  for  each  of  the  main  diagnoses:  29  patients with AML, 25 patients with ALL, 26 patients with chronic myeloid leukaemia (CML), 28 patients with other malignant diseases  and only 5 patients with non‐malignant diseases (Table 4.1). Early disease stage was defined as first complete remission (CR1) in acute leukaemia and first chronic phase (1CP) in CML. Untreated patients (e.g., with MDS) were included in this definition. All patients with a disease beyond  this were grouped as  late‐stage disease. The median age of  the patients was 32.31±16.41 years with a broad range, 




including  infants.  The  donors  had  a  median  age  of  34.24±6.29  years,  also with a relatively broad range.  
Table 4.1 Patient demographics 
 
          Patients  Donors    n=113 (%)  n=68 (%) 
Age, years (Median±SD)  32.14±16.41  34.24±6.29        
Gender     46 (67.6) M/22 (32.4)F      Sex Matched  67 (59.3)         Male patient/Female donor  11 (9.7)         Female patient/M donor  35 (31.0)           
CMV           Low risk  71 (62.8)         High risk  37 (32.8)         Missing  4 (4.4)           
Diagnosis           Chronic myeloid leukaemia (CML)  26 (23.0)         Acute myeloid leukaemia (AML)  29 (25.7)         Acute lymphoblastic leukaemia (ALL)  25 (22.1)         Other malignant  28 (24.8)         Non‐malignant  5 (4.4)                  
Stage of the disease            Early  60 (53.1)         Late  46 (40.7)         Missing  7 (6.2)           
Conditioning Regimen           Myeloablative  78 (69.0)         RIC  30 (26.5)         Missing  5 (4.4)           
Stem cell source           Bone Marrow (BM)  95 (84.1)         PBSC  18 (15.9)           
T cell depletion            Campath in vivo   92 (81.4)         No T cell depletion  9 (8.0)         Missing   12 (10.6)            Abbreviations: CMV: cytomegalovirus; PBSC: Peripheral blood stem cells; RIC: Reduce intensity conditioning   




Isolation of peripheral blood mononuclear cells (PBMC) PBMC  were  isolated  from  peripheral  blood  samples  by  standard  Ficoll density  gradient  centrifugation.  Briefly,  whole  blood  was  diluted  with  an equal volume of RPMI164 medium and overlaid on 25 ml of Ficoll  (density 1.077, Sigma, UK) in a 50ml Falcon Tube. Tubes were centrifuged at 4°C for 30 min at 700g, decelerating without brake. The white interphase containing nucleated cells  (between  the plasma and  the Ficoll  fractions) was removed with  a  pipette  and  transferred  into  a  fresh  tube,  then  washed  twice  with RPMI1640.    At  this  point  the  number  of  cells  in  the  sample  was  counted using a haemocytometer. Aliquots of 1 × 106 PBMC were resuspended in freezing medium, consisting of 90% heat inactivated foetal calf serum and 10% DMSO, before storage at ‐196°C  in  liquid  nitrogen  vapour  phase.  For  flow  cytometric  analysis,  cells were thawed, washed and counted. Cell viability was analysed using Trypan blue exclusion.  
Flow Cytometry Blood was taken at the pre‐conditioning period by venepuncture. Peripheral mononuclear  cells  (PBMC´s)  were  isolated  as  described  in  Materials  and Methods  and  T‐cell  subsets  were  analysed  phenotypically  by  4‐color  flow cytometry  using  a  titrated  panel  of  directly  conjugated  antibodies  to  CD3, CD4, CD8, CD27, CD45RO, CCR7 and CD45RA. All the antibody dilutions were titrated to give equivalent levels of staining and the working concentrations are  shown  in  Table  4.2  (BD  BioScience,  San  Jose,  California,  USA). Fluorescein  isothiocyanate  (FITC),  phycoerythrin  (PE)  and  PerCP  and 




allophycocyanin  (APC)  were  used  as  fluorochromes.  The  acquisition  was performed using a FACSCalibur flow cytometer and CellQuest software (BD Bioscience).  Acquired  data  was  analysed  with  Flow  Jo  software  (TreeStar Inc,  USA).  The  frequency  of  each  subset was  calculated  as  a  percentage  of positive cells relative to the total lymphocyte gate.    




Table 4.2. Antibody dilutions for staining PBMC populations   Antibody  Manufacturer  Label  Final dilution CD3  BD  APC  1:10 CD4   BD  PerCP  1:10 CD8  BD  PerCP  1:10 CD45RO  BD  PE  1:25 CD27  BD  FITC  1:10 CCR7  BD  PE  1:25 CD45RA  BD  FITC  1:25   
T cell subset analysis The  combinations of  antibodies used  to define naïve, memory  and  effector CD4+ and CD8+ T‐cells are shown in Tables 4.3 and 4.4 respectively.  
 
Table 4.3. Immunophenotypic analysis of CD4+ T cells Immunophenotypic definitions of naïve, memory and effector CD4+ T cells 
      
  CD4+ T cells         Naïve  Memory  Effector  Terminal Effector CD45RA   +  ‐  ‐  + CD45RO  ‐  +  +  ‐ CD27  +  +  ‐  ‐ CCR7  +  +  ‐  ‐ 




Table 4.4 Immunophenotypic analysis of CD8+ T cells 




Quantitative Real Time-PCR Real‐Time  PCR  was  carried  out  using  an  ABI/PRISM  7500  sequence detection system (Taqman®) and SDS software (Applied Biosystems, Foster City,  CA)  to  quantify  TREC  in  cell  lysates  from  donor  and  patient  samples DNA.  The  PCR  reactions were  set  up  in  96‐well  optical  reaction  plates  (Applied Biosystems,  Foster  City,  CA,  USA);  sealed  using  Optical  Adhesive  Covers (Applied Biosystems, Foster City, CA, USA) and transferred to the ABI/PRISM 7500 Sequence Detector for analysis. 




The  PCR  was  carried  out  using  Platinum  Taq  (Invitrogen)  and  ROX  dye (Invitrogen)  was  employed  in  each  reaction  as  a  background  reference  to control  for  sample  to  sample  variation  in  pipetting  or  in  fluorescence detection. Each 25µl reaction contained 5µl of cell lysates or 5µl of cDNA or 5µl of the specific  standard  (TREC  standard),  and  the  final  concentration  of  1U Platinum Taq  (Invitrogen),  3.5mM MgCl2,  0.25mM dNTPs,  12.5mM of  each primer  (Table  2.6),  3.75mM  fluorescent  labelled  probe  (Table  4.5),  2.5µl Platinum  buffer  (Invitrogen)  and  0.5µl  of  ROX  reference  dye.  One  cycle  of denaturation  (95o  for  5 minutes) was  performed,  followed  by  40  cycles  of amplification (95oC for 30 sec, 60oC).   
 
Table 4.5. Primers and probes used for TREC quantification   Gene 5’ primer  3’ primer  Probe TREC  cacatccctttcaaccatgct  gccagctgcagggtttagg  FAM‐acacctctggtttttgtaaaggtgcccact‐TAMRA   
Detection and quantification of TREC by Real-Time PCR To quantify TREC a  standard consisting of  a  series of dilutions of  a known quantity of plasmid containing the signal‐joint  junction was used. Each test sample  was  run  in  triplicate  and  each  run  included  the  dilution  standard series  of  TREC  plasmid  and  a  no‐template  control  (NTC).  Data  was normalised  based  on  the  percentage  of  CD3+  T  cells  in  total  PBMCs  and calculated as number of TREC per 1.5x105 CD3+ cells. 





 Comparison of the levels of each T‐cell subset between patients and healthy controls  were  made  by  Student  T  test  or  Mann‐Whitney  U  test  using Kaleidagraph (Synergy Software version 4.03). Associations  between  the  pre‐transplant  counts  for  the  naïve  and memory lymphocyte  subset  with  TREC  level  were  assessed  by  the  Spearman correlation test. All p values were two‐tailed. Disease  free  survival  (DFS) was  defined  as  the  time  from  study  entry  to  a documented progression or death without progression. Overall survival (OS) was  defined  as  the  time  from  study  entry  to  death  from  any  cause.  Both survival  times  were  analysed  using  the  Kaplan‐Meier  method  using  SSPS Software. Univariate analysis of  the different  immunologic counts with DFS and  OS  were  made  using  the  two‐sided  log‐rank  test.  Patients  were segregated  into  two  groups  based  on  the mean  count  of  each  lymphocyte subset.          





TREC values pre-transplantation  The  number  of  TREC  copies  per  150,000  CD3+  cells  was  measured  by quantitative  real‐time  PCR  in  preconditioning  samples  from  113  patients who underwent an HSCT from unrelated donors (UD) and  in a group of 68 healthy donors.  A statistical analysis was performed as shown in figure 4.1, and a  significant  correlation between TREC values prior  to  transplantation and  age  was  found  in  the  patient  group  (r=‐0.416,  p<0.001),  despite  the great  variability  in  TREC  values.  However,  in  the  control  group  the  same effect could not be demonstrated (r=‐0.185, p=0.129), although a slope can be  clearly  observed,  the  lack  of  correlation  could  be  due  the  difference  in donor and patient ages, where in the patients’ group we can observe a wider age range, the donor group was more restricted in age, between 20 and 50.          
 


















































































The mean and standard error of the TREC values for the 62 healthy controls was  498.10±51.37  TREC  per  150,000  CD3+  cells  (range  59‐2391), statistically significantly higher (p=0.001) than the mean TREC per 150,000 CD3+ cells of 313.13±67.87 (range 0‐2613) in the patient group, as presented in  Table  4.6.  Patients with malignant  diseases  have  statistically  significant lower  values  of  TREC  per  150,000  CD3+  cells  (p=0.03)  than  patients  with non‐malignant diseases. However, only 5 patients out of  the 113 have non‐malignant disease, and the majority of them were children, so it is difficult to draw significant conclusions about the impact of malignancy per se.   It could be thought that the effect of malignancy may simply be that the presence of malignant  cells  in  the  blood  sample  reduces  the  effective  concentration  of TREC, leading to the lower levels being measured.  However, the TREC levels are normalised to a cell count of 150,000 CD3+ cells, and so the presence of variable  numbers  of  malignant  cells  between  samples  should  not  be  a significant factor in the interpretation of the results. 




Figure 4.2. Comparison of TREC levels pre­transplant between patients and healthy controls.  TREC levels were measured by quantitative Real‐Time PCR. Patients pre‐transplant  have  significantly  lower  levels  of  TRECs  per  150,000  CD3+ cells compared with healthy donors. 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observations;  the  reasons why  the  results  reported  here  differ  from  those reported earlier by others will be discussed in a later section. Furthermore, the values of TREC did not show an association with the onset of either acute or  chronic  GvHD.  However,  the  incidence  of  extensive  cGvHD was  slightly higher in patients with lower values of TREC (p=0.048).    An  analysis  between  the  TREC  values  pre‐transplant  and  the  incidence  of infections was also performed, but again no association was found.    
T cell subsets pre-transplantation  The  distribution  of  separate  CD3+,  CD4+  and  CD8+  T  cell  subsets,  and  of functional  T  cell  subsets  (naïve,  memory  and  effector  phenotypes)  were analysed  by  flow  cytometry  in  a  group  of  113  patients  and  in  66  healthy controls,  the  results  of  statistical  analyses  are  given  in  Table  4.6.  Patients were undergoing an HSCT and samples were taken prior to the start of the conditioning  regimen  to  evaluate  their  T  cell  status.    The  samples  were collected as part of a  long  term project  to  identify  immunogenetic markers for  transplant  outcome;  sample  collection began over 10 years  ago  and no absolute quantification of cell numbers in the peripheral blood was done at the  time of  collection,  therefore,  only percentages  can be presented  in  this study. As illustrated in Figure 4.3, which in a dot plot format shows the distribution of values for each sample, it is clear to see that the distribution of CD3+ cells in  the  patients  is  lower  than  in  the  controls.    The mean±SE  percentage  of 




CD3+ cells in the patient group was of 38.11±2.01% (range 0‐89), which was significantly  lower  (p<0.0001)  than  in  the  control  group  (mean±SE  of 62.79±1.71%,  range  26‐86).   Within  the  CD3+  cells,  the  CD4+  T  cell  subset was  also  significantly  lower  in  the  patient  group with  a mean±SE  value  of 30.77±1.78%  (range  0‐60)  compared  with  the  control  group  which  had  a mean±SE  value  of  54.27±1.28%  (range  36‐77)  CD4+  T  cells  (p<0.0001).  In contrast,  the  CD8+  subset  was  not  different  between  the  patient  and  the donor  groups.  The patients  showed  a mean±SE of  CD8+ T  cells  33.18±2.14 (range  1‐75),  while  the  control  group  showed  a  mean±SE  of  34.39±0.94 (range 21‐52) CD8+ T cells.   This observation argues that the decrease in the CD3+  and  CD4+  T  cell  percentages  are  not  simply  due  to  an  expansion  of another  cell population,  since an expansion of  a CD3‐ population would be expected to drive down the percentages of both CD4+ and CD8+ T cells.  Looking in more detail at the CD4+ T cell subset, as shown in Figure 4.4, the lower  levels  in  this  subset  were  largely  due  to  a  significantly  lower  naïve (CD4+CD45RA+CD27+CD45RO‐) CD4+ T‐cell percentage in the patient group, with a mean±SE of 31.88±2.21% (range 0‐90) compared to the control group mean of 40.76±1.56% (1‐69), (p=0.004). The distribution of values of naïve CD4+ within the patient group does not appear to be unimodal, and while the upper part of the range in patients overlaps the upper range in the controls, the patient group appears to have a discrete population in which low levels of naïve CD4+ T cells are found.  The CD4+ memory (CD4+CD45RO+CD27+) T cell subset was not significantly different between the patients and the donor groups  (mean±SE  of  45.77±1.94%  versus  41.88±1.23%).  However,  the 




effector  (CD4+CD27‐CD45RO+)  CD4+  T  cell  subset  was  significantly  higher (p=0.02)  in  the  patient  group  (mean  17.94±1.46%  versus  14.04±0.73 respectively).   When  analysed  in more  detail,  the  percentages  of  the  naïve,  memory  and effector  CD8  subpopulations  were  not  different  between  patients  and donors, as presented in Figure 4.5.  





Table 4.6. Summary of statistics  Summary of statistics (mean±SE values) and comparison of TREC and T  cells  subsets  between  healthy  donors  and  patients.  Patients  had significantly lower values of TRECs, and lower percentages of CD3+ cells and CD4+ cells.                 Patient (n=113)  Donors (n=68)  p value    (Mean±SE)  (Mean±SE)   T test TREC/150,000CD3+ cells  313.13±67.87  498.10±51.37  p=0.001          CD3+ cells (Percentage of Lymphocytes)  28.11±2.01  62.79±1.71  p<0.0001          CD4+ T cells  (percentage of CD3+ T cells)  30.77±1.78  54.27±1.28  p<0.0001          CD8+ T cells (percentage of CD3+ T cells)  33.18±2.14  34.39±0.94  p=NS          CD4 Subsets        Naïve (percentage of total CD4+ T cells)  31.88±2.21  40.76±1.56  p=0.001 Memory (percentage of total CD4+ T cells)  45.77±1.94  41.88±1.23  p=NS Effector (percentage of total CD4+ T cells)  17.94±1.46  14.04±0.73  p=0.02          CD8 Subsets        Naïve (percentage of total CD8+ T cells)  36.27±2.45  38.29±1.62  p=NS Memory (percentage of total CD8+ T cells)  27.89±2.04  29.07±1.24  p=NS Effector (percentage of total CD8+ T cells)  17.30±1.82  16.51±1.43  p=NS 
      NS: Not significant 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Transplant outcome and T cell subsets  A  correlation  of  the  distribution  of  T  cell  subsets  with  the  transplant outcome was performed. The mean  follow‐up of  the patients  in  the  cohort was  1206  days,  which  is  sufficient  to  allow  the  identification  of  most significant post‐transplant events. Pre‐transplant  levels of CD3+ T cells  in patients did not appear to have any relationship with  the  transplant outcomes. However, CD4+ T  cell  levels did show  a  correlation with  transplant  outcome.  Two  groups  of  patients were formed as before, either above or below the mean level of CD4+ T cells, and an analysis of  the  transplant outcome was performed. Patients with higher proportions  of  CD4+  T  cells  pre‐transplant  showed  a  trend  towards  lower relapse rates (log rank 0.063) than patients with lower proportions of CD4+ T  cells.  Overall  survival,  disease  free  survival  (DFS)  and  the  incidence  of cGvHD were  not  correlated with  the  pre‐transplant  levels  of  CD4+  T  cells. The  same  analysis  was  performed  with  the  different  CD4+  T  cell subpopulations  to  identify  the subset with  the highest association with  the transplant outcome.  Patients  with  higher  proportions  of  naïve  CD4+  T‐cells  showed  a  trend towards  improved DFS  (log  rank  test, 0.096),  conversely patients with  low naïve  CD4+  T‐cells  showed  a  trend  towards  increased  risk  of  relapse  (log rank  test,  0.071);  this  data  is  presented  in  Figure  4.6  However,  overall survival and the onset of cGvHD were not affected by the levels of naïve CD4+ T cells. Neither  the  levels  of  memory  nor  effector  CD4+  cells  appear  to  have  an impact  on  the  transplant  outcome.  An  analysis  of  donor  CD4+  T  cells 










       As for the CD4+ T cell subset, patients were divided into two groups based on the mean level of the CD8+ T cells: patients with percentages of CD8+ T cells pre transplant higher or lower than the mean. In contrast to the results with the CD4+ T cells, the levels of CD8+ T cells were not  correlated  with  the  transplant  outcome.  Although  no  impact  of  the overall  CD8+  T  cells  was  observed,  an  analysis  was  also  made  with  the different  CD8+  subpopulations.  Only  high  levels  of  naïve  CD8+  T‐cells  pre‐transplant  showed  a  correlation,  with  a  trend  towards  improved  overall 












Correlation between TREC values and T-cell subsets  A  positive  correlation  was  found  between  high  TREC  levels  per  150,000 CD3+ cells pre‐transplant and both naïve CD4+ T‐cells and naïve CD8+ T‐cells pre‐transplant (r2= 0.476, p<0.0001 and r2= 0.352, p=0.0003, respectively). Such  a  correlation  is  to  be  expected,  since  the  population  of  naïve  T  cells exiting  from  the  thymus has  the highest  concentration of TREC, which will become  somewhat  diluted  by  homeostatic  proliferation within  the  naïve  T 




cell  compartment  and  more  significantly  diluted  during  T  cell  expansion after activation and thus will be  low in memory and effector T cell subsets. Conversely,  a  negative  correlation  was  found  between  TREC  levels  per 150,000 CD3+ cells and both memory CD4+ and memory CD8+ T‐cells (r2= ‐0.330,  p=0.0006  and  r2=  ‐0.257,  p=0.01).  This  is  to  be  expected  since  only percentages could be analysed and of course a higher percentages of naïve CD4 or CD8 T cells implies a corresponding lower percentage of memory and effector cells.  
 
Donor TREC and T cell subset influence on Transplant Outcome Analysis of the impact of the donor T cell subsets and TRECs and transplant outcome was also performed. However, donor T cell subsets and donor TREC showed  no  significant  associations with  any  outcome measure,  suggesting that  the donor  immune status pre‐transplant does not affect  the success of the  HSCT,  whereas,  the  patients  immune  status  plays  an  important  role regulating the immune responses following an HSCT. 





During the past decades, much effort has been made to improve the outcome of  allogeneic  HSCT.  However,  infections,  relapse  and  graft  versus  host disease are still significant causes of morbidity and mortality in transplanted patients.  New  efforts  to  identify  those  patients  at  greater  risk  of  poor outcome are required in order to determine if further therapeutic strategies, such  as  Donor  Lymphocytes  Infusion  (DLI),  are  necessary.  Recently,  some studies  have  analysed  the  impact  of  various  recipient  and  donor  T‐cell subsets  as well  as  overall  thymic  output  in  allogeneic  HSCT  from  siblings. Those  studies  have  shown  that  the  status  of  the  immune  system  prior  to transplantation could be used as a predictive tool for HSCT outcome. In this study  an  evaluation  of  T‐cell  subsets  and  TREC  levels  as  an  indicator  of thymic  function  pre‐transplant  were  analysed  and  compared  with  healthy individuals.  Percentages  of  CD3+  T‐cells  were  significantly  lower  in  patients  pre‐transplant than in healthy controls; however, it is necessary to bear in mind that here only percentages have been analysed and thus it  is possible these changes may be  a  consequence of  previous  treatments  or  of  the  remission state  of  the  patient.  For  further  studies  absolute  quantification  will  be needed. The low CD3+ percentages in patients were due to a decrease in the CD4+  population  consistent  with  data  that  has  previously  been  published (Rosinski,  et  al.,  2005). Within  the  CD4  T‐cells,  the  naïve  CD4+  subset was significantly  lower  in  patients  pre‐transplant.  Therefore,  the  low  overall CD4+ cells percentages are principally due to a decrease in the naïve subset. 




On  the  other  hand,  the  overall  percentages  of  CD8+  T‐cells  and  the  CD8+ subsets were comparable between donors and patients. Rosinski et al. (Rosinski, et al., 2005) published that pre‐transplant levels of memory  CD4+CD45RA‐CD62L‐  T‐cell  had  a  prognostic  effect  on  transplant outcome in haematological malignancies and breast cancer, independently of other known factors. However, in the study shown here the prognostic effect of  the  CD4+  memory  subset  was  not  demonstrated.  On  the  contrary,  a prognostic effect of the naïve subset of both CD4 and CD8 was found. A trend towards better survival was observed in patients who had higher naïve CD8+ T‐cells pre‐transplant. While higher levels of naive CD4+ cells was associated with  a  decrease  in  the  risk  of  relapse  and with  a  trend  towards  enhanced disease  free  survival without  reaching  statistical  significance.  It  seems  that while there is an influence of the naïve T cells on outcome, the mechanism of this effect is not yet clear. One question to ask is why the levels of naïve CD4+ T cells should be lower in the  patient  cohort  than  in  the  controls,  while  there  was  no  significant difference  in  the  levels  of  naïve  CD8+  T  cells.  One  possibility  is  that,  since survival  of  naïve  T  cells  depends  on  tonic  signalling  through  the  T  cell receptor  (Seddon  &  Zamoyska,  2002),  and  since  the  MHC  class  II+  APC capable  of  such  signalling  to  CD4+  T  cells  are  of  haematopoietic  origin, alterations  in  haematopoiesis  as  a  consequence  of  the  underlying malignancy  or  it’s  treatment may  impact  on  the  numbers  of  APC  and  thus indirectly influence the number of naïve CD4+ T cells. Since the CD8+ T cells receive signals form MHC class I molecules, which are ubiquitous, there may then  be  no  observable  effect  on  the  naïve  CD8+  T  cell  compartment.




Chapter 5  
Regulatory T cells in HSCT  
Introduction    Allogeneic Haematopoietic Stem Cell Transplantation  (allo‐HSCT)  is a well‐established therapy for a variety of malignant and non‐malignant diseases of the haematopoietic system  (Gratwohl, et al., 2002). Although HLA matching has  improved  allo‐HSCT  outcome,  recipients  remain  susceptible  to  life‐threatening  post‐transplant  complications,  including  infections,  disease relapse and the development of Graft versus Host Disease (GvHD)  (Shaw, et al.,  2001).  Donor  T  cells  facilitate  cell  engraftment,  protect  against opportunistic  infections  and  promote  anti‐tumour  activity,  protecting  the patient  from  disease  relapse  (through  the  graft  versus  leukaemia  effect, GvL).  However,  donor  cells  also  attack  host  tissues  producing  graft  versus host  disease,  GvHD    (Ferrara,  2000).  One  of  the  major  challenges  in  allo‐HSCT  has  been  to  find  the  optimal  balance  between  the  beneficial  and harmful  effect  of  T  cells    (Edinger,  et  al.,  2003).  Recently,  advances  in  the understanding  of  regulatory  T  cells  (CD4+CD25hi  T  cells)  has  started  the development  of  new  methodologies  and  new  strategies  to  improve  the outcome  of  HSCT  using  Tregs  as  modulators  of  immune  responses  after transplantation.  The  new  knowledge  has  given  new  insights  about  the immune responses following an HSC transplant.  




Definition of CD4+CD25hi Treg population  Recently,  a  distinct  subset  of  the  CD3+CD4+  compartment  subset  with immune suppressive capacity has been defined as regulatory T cells (Treg). They appear to have an important role in controlling allo‐reactive T cells and maintaining  peripheral  tolerance  to  self‐antigens.  These  regulatory  T  cells constitutively express the α‐chain of the high‐affinity IL‐2 receptor (IL‐2Ra, CD25)  (Sakaguchi, et al., 1996) and they represent 5 to 10% of the normal T cell compartment in mice and humans  (Sakaguchi, et al., 1996) (Zorn, 2006)  (Itot,  et  al.,  1999).  In  a  normal  thymus,  2‐5%  of  CD4+CD8‐  thymocytes express  CD25;  those  cells  are  functionally  competent    (Itot,  et  al.,  1999). They  also  express  the  transcription  factor  FOXP3    (Hori,  et  al.,  2003) (Fontenot,  et  al.,  2003).  Their most  characteristic  feature  is  their  impaired proliferative  response  (anergy)  to  standard  stimuli,  and  their  suppressive activity. Studies  indicate  that  thymus  is  continuously  producing  potentially  self‐reactive CD4+CD25‐ T cells as well as functionally mature CD4+CD25+ Tregs. Consequently,  the  thymus contributes  to  the maintenance of  self‐tolerance, not only by  the central process of negative selection but also by producing CD4+CD25+  Tregs  that  act  in  peripheral  sites  to  control  unwanted  self‐reactivity.  CD4+CD25+  Tregs  are  pluripotent  suppressors  modulating  many  different immune  reactions.  They  inhibit  naïve  CD4+  T  cell  proliferation  and differentiation; prevent cytotoxic activity of CD8+ T cells both in vivo and in vitro    (Piccirillo  &  Shevach,  2001)  (Murakami,  et  al.,  2002)  (Suvas,  et  al., 2003)  (Dittmer,  et  al.,  2004);  suppress  the  activation  and  antibody 




production of B cells  (Sakaguchi, et al., 1995) (Bystry, et al., 2001) and limit the  activity  of  cells  from  the  innate  immune  system,  such  as  NK  cells, neutrophils  and  monocytes    (Maly,  et  al.,  2000).  Moreover,  they  can efficiently limit the stimulatory capacity of antigen‐presenting cells   (APC’s) by down‐regulating cell surface expression of co‐stimulatory molecules such as CD80 and CD86  (Cederbom, et al., 2000).   











































Expression of FOXP3  The  forkhead  box  transcriptional  regulator,  FOXP3,  has  been  shown  to  be expressed  almost  exclusively  in CD4+CD25hi T  cells,  and  to be  essential  for both their generation and function (Hori, et al., 2003) (Khattari, et al., 2003) (Fontenot,  et  al.,  2003).  This  FOXP3  expression  has  been  used  recently  as specific marker that better defines the regulatory subset of CD4+ T cells, and discriminates  them  from  activated  effector  T  cells,  which  temporarily express the high affinity IL‐2 receptor, CD25. In peripheral blood of normal donors, up to 96% of CD4+CD25hi T cells expressed FOXP3, whereas only 22‐47%  of  CD4+CD25int  T  cells  stained  positive  for  FOXP3  by  flow  cytometry  (Roncador,  et  al.,  2005).  Activation  of  CD4+CD25+  T  cells  increases  FOXP3 expression. In contrast, activated effector T cells, which up‐regulate CD25, do not express FOXP3. Retroviral  transfection  of  CD4+CD25‐  T  cells  with  the  FOXP3  transcription factor  induces  Treg‐like  cells  both  phenotypically,  with  the  induction  of expression of CD25, CTLA‐4, GITR and CD103; and functionally, by acquiring a  suppressor  function,  indicating  that  the  transcription  factor  itself  is sufficient to induce Tregs  (Hori, et al., 2003) (Fontenot, et al., 2003) (Khattri, et al., 2003). Over‐expression of FOXP3 induces suppressive activity in both CD4+CD25‐ and CD8+ T cells. Therefore, regulatory T cells can be defined as CD3+CD4+CD25hiFOXP3+ T cells, which have suppressive functions and which control alloreactive and autoreactive immune responses. Moreover, a role of Tregs  in  controlling  and  inhibiting  anti‐tumour  responses  has  been identified  (Dranoff, 2005).   




Expression of other markers in Tregs  Several studies have been carried out  to better characterise and to  identify new  markers  for  regulatory  T  cells.  Those  studies  have  revealed  a  high expression of the negative regulator of T cell activation CTLA‐4 (Cytotoxic T‐Lymphocyte  Antigen  4  or  CD152);  the  glucocorticoid‐induce  tumour necrosis  factor  receptor,  (GITR)    (McHugh,  et  al.,  2002),  and  expression  of membrane‐bound tumour growth factor (TGF‐β1) (Green, et al., 2003). In contrast to the CD28 receptor to which it is evolutionary related, ligation of  cytotoxic  T‐lymphocyte  antigen  (CTLA‐4)  on  the  surface  of  activated  T cells by  its  ligands CD80/86 expressed on APC’s, delivers a negative  signal leading  to  inhibition  of  T  cell  activation    (Chambers,  et  al.,  2001).  GITR function is not completely understood in humans, however, it seem to down‐regulate Treg function  (Bushell & Wood, 2007) (Kanamaru, et al., 2004) (Ko, et al., 2005). The expression of the membrane‐bound tumour growth factor TGF‐β1  has  been  associated  with  the  specific  mechanism  of immunosuppression,  which  in  Tregs  is  dependent  on  cell‐cell  contact  (Nakamura, et al., 2001).    




Mechanisms of suppression of Tregs  The  precise  molecular  mechanisms  of  Treg  suppression  are  currently controversial.  In  vitro  studies  have  shown  that  Tregs  have  to  be  activated through their T cell receptor (TCR), but once they have been activated they can suppress responses to other antigens non‐specifically  (Takahashi, et al., 1998) (Thornton & Shevach, 1998). In vitro Tregs suppress their targets in a cell‐cell contact dependent manner via  the  Fas/FasL  (CD95/CD95L)  signaling  pathway  for  inhibition  of proliferation  with  or  without  inducing  cell  death.  Other  pathways may  be involved since even in vitro Tregs require stimulation via TCR to exert their regulatory function  (Baatar, et al., 2007) (McIver, et al., 2008). However, in vivo  regulation  seems  to  be  more  complicated  and  several  suppressive cytokines have been implicated in Treg suppressor function (Asseman, et al., 1999) (Annacker, et al., 2001).  So  far,  it  is  not  completely  understood whether  CD4+CD25hi  Tregs  can  use different  suppressor  mechanisms  or  whether  individual  specialised regulatory subsets exist that exert suppression just via one mechanism.  Although the mechanism of Treg suppression remains unclear, the following conclusions have been accepted: 
• Tregs  require  T‐cell  receptor  (TCR)  ligation  to  antigen‐specific  or polyclonal stimuli for activation (Takashi, et al., 1998) (Thornton and Shevach 1998). 
• Once activated, Tregs are able to suppress without regard to antigen specificity  (Takahashi, et al., 1998) (Thornton & Shevach, 1998). 





Clinical impact of regulatory T cells in transplantation  Tregs are actively involved in immune mediated mechanisms after allogeneic stem  cell  transplantation  and  a  potential  clinical  benefit  of  Tregs  in controlling  GvHD  and  reducing  the  complications  of  allogeneic  HSCT  has been  suggested.  However,  a  role  of  Tregs  in  suppressing  anti‐tumour immune responses has also been proposed contributing to increase relapse. Thus,  their  role  in  the  overall  transplant  outcome  remains  controversial  (Meignin, et al., 2005) (Zorn, et al., 2005). The  majority  of  the  published  work  to  date  has  focused  on  the  post‐transplant period, analysing the impact of donor derived Tregs on transplant outcome, as mentioned in chapter 1. Tregs have been associated with lower incidence  of  GvHD,  though,  data  obtained  until  now,  have  not  been conclusive    (Cohen,  et  al.,  2002)  (Clark,  et  al.,  2004)  (Sanchez,  et  al.,  2004)  (Zorn, et al., 2005). Recent data have shown that Tregs can survive and can even expand after aggressive conditioning and after T cell depletion before an HSCT  (Bloom, et al., 2008) (Bayer, et al., 2009), indicating that they may be capable of playing an important role  in the early post‐transplant events. Therefore,  in  this  study we aimed  to  examine  the  impact of pre‐transplant Treg  levels  in  patients  undergoing  HSC  transplantation  from  an  unrelated donor  and  analyse  their  association  with  overall  survival  (OS),  disease relapse, disease free survival (DFS) and GvHD.  




Patients, Materials and Methods 
 
Patients and controls    The  study  included  two  separate,  independent  cohorts:  an  initial  cohort  (n=90)  of  patients  receiving  an  HSCT  from  unrelated  donors  through  the Anthony Nolan Trust (ANT) in the UK; and a second cohort (n=24) from an independent  centre  (The  Alfred  Hospital  in  Australia)  receiving  either autologous or allogeneic transplants.  For  the  first group, both recipient and donor were required to have 4‐digit allele  typing  results  at  six  HLA  loci  (HLA‐A,  ‐B,  ‐C,  ‐DRB1,  ‐DQB1,  ‐DPB1). Because  the  study was  registry  based,  the  blood  samples  and  clinical  data were provided by the individual transplantation centres (TCs). Clinical data were collected on standard forms, which were sent to data managers at the individual TCs.  The transplantations took place between September 1996 and January 2003. A  broad  ranges  of  diseases  were  indications  for  transplantation,  and  the patient and donor pre‐transplantation factors can be seen in Table 5.1. The majority of the transplantation protocols included T‐cell depletion (85%), in most  cases  using  Alemtuzumab  (Campath  1‐H)  in  vivo  (80%).  A  roughly equal  number  of  patients  received  transplants  for  each  of  the  diagnoses: AML, ALL, chronic myeloid leukaemia (CML), and other malignant diseases. A  small  number  received  transplant  for  non‐malignant  diseases,  patient information is presented in table 5.1. Early disease stage was defined as first complete remission (CR1) in acute leukaemia and first chronic phase (1CP) 




in CML. Untreated patients (e.g., with MDS) were included in this definition. All patients with disease beyond this were grouped as late‐stage disease. The median  age  of  the  patients  was  30  years  with  a  broad  range,  including infants. The donors had a median age of 34 years, although once again with a relatively broad range.  The  second  study  group  comprised  patients  from  The  Alfred Hospital  and the  Peter  MacCallum  Cancer  Institute  in  Melbourne  Australia.  All  patients gave  written  informed  consent  to  treatment  with  LHRH‐A.  Pre‐treatment samples were taken from 2001 to 2005 from patients undergoing an HSCT. Transplant type included both allogeneic and autologous. For the allogeneic transplants,  both  recipient  and donor were  required  to  have 4‐digit  allele‐level typing results at six HLA loci (HLA‐A, ‐B, ‐C, ‐DRB1, ‐DQB1, ‐DPB1), and be fully matched at HLA‐A, ‐B, ‐C, ‐DRB1, and ‐DQB1 (10/10 match). 1  patient  with  chronic  myeloid  leukaemia  (CML),  8  patients  with  acute myeloid leukaemia, 2 patients with acute lymphoblastic leukaemia (ALL), 13 with  other  malignancies  (including  Hodgkin  and  non‐Hodgkin  lymphoma, multiple myeloma and aplastic anemia) were analysed. Early disease  stage was defined as  first  complete  remission  (CR1)  in  acute leukaemia  and  first  chronic  phase  (1CP)  in  CML.  Untreated  patients  (e.g., with MDS) were included in this definition. All patients with disease beyond this were grouped as late‐stage disease. The median age of the patients was 51.5 years, ranging between 2 to 59. Patient demographics are summarised in Table 5.1. 





Table 5.1 Patient 
demographics        Anthony Nolan Trust  The Alfred Hospital    UK group  Australian group    n= 90 (%)  n= 24 (%)        Age, years  29.39±1.77  51.5±1.98        Gender           Male  49 (54.4)  17 (70.8)      Female  41 (45.6)  7 (29.2)        Diagnosis           CML  22 (24.4)  1 (4.2)      AML  22 (24.4)  8 (33.3)      ALL  19 (21.1)  2 (8.3)      Other malignant  23 (25.6)  13 (54.2)      Non‐malignant  4 (4.4)  0 (0)        Conditioning regimen           Myeloablative  61 (67.8)  13 (54.2)      RIC  24 (26.7)  11 (45.8)      Missing  5 (5.5)  0 (0)        Stem Cell Source           Peripheral blood  15 (16.7)  24 (100)      Bone Marrow  75 (83.3)  0 (0)        Type of Transplant           Autologous  0 (0)  12 (50)      Allogeneic related donor  0(0)  8 (33.3)      Allogeneic UD  90 (100)  4 (16.7)        T cell depletion           Yes  80 (89.9)  0 (0)      No  10 (11.1)  24 (100)        Abbreviations: CML: chronic myeloid leukaema; AML: acute myeloid leukaemia; ALL: acute lymphoblastic leukaemia, RIC: reduce intensity conditioning: UD: unrelated donor 
   




Isolation of peripheral blood mononuclear cells (PBMC)  PBMC  were  isolated  from  peripheral  blood  samples  by  standard  Ficoll density  gradient  centrifugation.  Aliquots  of  1  x  106  PBMC  were  frozen  in liquid  nitrogen  in  freezing media,  consisting  of  90%  foetal  calf  serum  and 10%  DMSO.  For  flow  cytometric  analysis,  cells  were  thawed,  washed  and counted. Cell viability was analysed using trypan blue.   
RNA extraction and cDNA synthesis  RNA isolation was performed using RNeasy mini kit (Qiagen, Valencia, CA). Total  RNA  was  eluted  with  water  and  store  at  ‐70oC.  For  reverse transcription of mRNA and cDNA synthesis, 1mg of total RNA was reversed transcribed  and  stored  at  ‐20oC  until  quantitative  real‐time  polymerase chain reaction (qRT‐PCR) was performed.    
Flow Cytometry  Cell  phenotypes were  analyzed  by  4‐color  flow  cytometry  using  a  titrated panel of directly conjugated antibodies to CD3, CD4 (BD BioScience, San Jose, California,  USA)  and  CD25  (2A3  clone,  eBioSiences).  Fluorescein isothiocyanate  (FITC),  phycoerythrin  (PE)  and  PerCP  were  used  as fluorophores.  The  acquisition  was  performed  using  FACSCalibur  flow cytometer  and  CellQuest  software  (BD  Bioscience).  Acquired  data  was 





Quantitative PCR  FOXP3  gene  expression  was  measured  from  PBMC’s  using  an  ABI  Prism 7500  Sequence  Detection  System  (Applied  Biosystems,  Foster  City,  CA)  as described previously. GAPDH was used as an internal control gene for mRNA expression. Primer and probe sequences for GAPDH were as follows: 5’‐GGA GTC AAC GGA TTT GGT CGT ATT‐3’ (forward) 5’‐GGC AAC AAT ATC CAC TTT ACC AGA GT‐3’  (reverse) FAM‐CTG GTG ACC AGG CGC C‐3’TAMRA (probe). Primer and probe sequences for FOXP3 were as follows: 5’‐GCC TCC TCT TCT TCC  TTG  AA‐3’  (forward),  5’‐GTG  AGG  CTG  ATC  ATG  GCT‐3’  (reverse),  3’‐VIC‐CCA  TCG  CAG  CTG  CAG  CTC  TCA  A‐TAMRA‐5’  (probe).  To  create  a standard curve, GAPDH and FOXP3 cDNA were amplified by PCR using  the same  primers  designed  for  qRT‐PCR  and  cloned  into  a  TOPO  vector (Invitrogen)  following  manufacturer’s  instruction.  Plasmid  DNA  was extracted  and  quantified  by  UV  spectrophotometry.  The  number  of  copies was  calculated  by  using  the molecular weight  of  the  vector  and  each  gene amplicon.  Serial  dilutions  of  the  amplified  genes  at  known  concentrations were  tested  by  qRT‐PCR.  qRT‐PCR  of  cDNA  from  patients,  standards,  and water  as  a  negative  no‐template  control  (NTC) were  carried  out  in  a  total volume  of  25µl with  Platinum Taq  (Invitrogen).  Thermal  cycler  conditions 




were as follows: 5min at 95oC and 50 cycles of 95oC for 30seconds and 60oC for 40 seconds. Standard curve extrapolation of copy number was performed in  both  FOXP3  and  GAPDH.  Sample  data  was  normalised  by  dividing  the number of  copies of  FOXP3  transcripts by  the number of  copies of GAPDH transcripts. All PCR assays were performed in triplicates and reported as the mean. 
 
Statistical analyses  Analysis was performed using either SPSS version 14.0 (SPSS, Chicago, IL) or R  version  2.2.1  (http://www.r‐project.org) with  the  help  and  advice  of  Dr Rafael  Duarte  and  Dr.  Hazael Maldonado  of  the  Anthony Nolan  Trust.  The association between variables was assessed using chi‐squared test or Mann‐Whitney  test.  Correlation  analyses  were  performed  using  Pearson correlation test.  Acute  (a)GVHD was  analysed  as  a  binary  variable  using  logistic  regression models.  The  probabilities  of  Transplant  Related  Mortality  (TRM),  disease relapse  and  chronic  GvHD  (cGvHD)  were  compared  using  Gray’s  test  and analysed using  the Cumulative  Incidence (Cum Inc) method (Gooley, 1999) (Szydlo, 2004) The  probabilities  of  Overall  Survival  (OS)  and Disease  Free  Survival  (DFS) were  analysed by  the Kaplan‐Meier methods  and  compared using  log‐rank statistic (Szydlo, 2004). For time‐dependent variables, multivariate analysis was performed using Cox‐regression analysis. Outcomes were considered to be significant when p<0.05. A trend was identified when 0.05<p<0.1. 





CD4+CD25hi regulatory T cells  
 
Treg levels in patients and controls: gating CD25hi T cells  Precise  definition  of  Tregs  is  not  conclusive  as  yet.  However,  they  are naturally occurring T cells, predominantly confined  to  the CD25hi  subset of CD4+ T cells  (Baecher‐Allan, et al., 2001) (Baecher‐Allan, et al., 2003). They express the transcription factor FOXP3 along with varying levels of cytotoxic T lymphocyte associated antigen 4 (CTLA‐4), glucocorticoid induced tumour necrosis  factor receptor  (GITR), and programmed death 1  (PD‐1)    (Hori, et al., 2003) (Fontenot, et al., 2003). Upon stimulation, they produce regulatory cytokines  such  as  interleukin‐4  (IL‐4),  interleukin‐10  (IL‐10)  and transforming growth factor β (TGF‐β)  (Viguier, et al., 2004) (Liyanage, et al., 2002). They represent 1 to 2% of the peripheral CD4+ T cells.  Our  first  definition  of  Tregs  was  CD4+CD25hi  cells.  We  assessed  the percentage  of  CD4+  lymphocytes  expressing  high  levels  of  CD25  by  flow cytometry, following the gating strategy showed in Figure 5.1.       




In  the  last couple of years  it has been described that CD4+CD25hi Tregs are increased in cancer patients. We compared the frequency of Tregs in patients prior  to  UD/HSCT  (n=90)  and  in  healthy  controls  (n=49).  In  contrast  to previous  publications  but  consistent  with  Clark  et  al  and  Nadal  et  al,  we found  that  the mean  percentage  of  CD4+CD25hi  T  cells  in  patients  prior  to transplantation was slightly but significantly lower (2.23%±0.29%) than that in  healthy  controls  (3.03%±0.19%)  (p=0.03)    as  is  shown  in  Figure  5.2. However, the percentages in both healthy controls and patients were within the normal range. This observation was confirmed in a second independent cohort  from  an  Australian  group,  where  a  mean  of  1.66%±0.17%  of CD4+CD25hi T cells was observed, which was significantly lower than in the healthy  control  group  (p<0.0001),  as  presented  in  Table  5.2  and  in  Figure 5.2.    
Table 5.2. Comparing the expression of Tregs  Comparing the expression of Tregs (CD4+CD25hi T cells)  in a control group  and  two  independent  patient  cohorts.  Both  patient  groups  had statistically significantly lower Tregs when compared with the control group.   Comparison between the patient groups and controls        Group  Mean±SE  p value Control group (n=49)  3.03±0.19%    ANRI group (n=90)  2.23±0.29%  P=0.03 Australian group (n=24)  1.66±0.17%  p<0.0001    












































  ANRI group                      Control group                 Australian group
      (n=90)                                 (n=49)                               (n=24)
p=0.03 p<0.0001




Expression of Tregs in different diseases 
 As mentioned  previously,  CD4+CD25hi  regulatory  T  cells  were  significantly lower in patients with haematological malignancies (n=90) when compared with healthy controls (n=49). However, when we  looked at  the  frequencies of Tregs in the different diseases we found significantly lower Tregs in CML patients  (0.71%  ±  0.17%)  compared  with  AML  patients  (3.68%  ±  0.62%) (p<0.0001)  and  with  healthy  controls  (3.03%  ±  0.19%)  (p<0.0001)  as Nadal’s group have previously described. Low Treg levels equivalent to those seen in CML patients in the case of ALL patients (Nadal, et al, 2007).  It  has  also  been  described  by Wang  et  al    (Wang,  et  al.,  2005),  that  AML patients  have  higher  frequencies  of  Tregs  than  healthy  controls.  However, although  we  found  higher  frequencies  of  Tregs  in  the  AML  patient  group compared  with  healthy  controls  it  did  not  reach  a  statistical  significance (p=0.19).  The analysis couldn’t be performed in the Australian group due to the lower number of patients included in the study group. 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Pre-transplant patient Tregs levels and clinical outcome 
 
Overall Survival and other non-relapse outcomes  Based on the mean value of the CD4+CD25hi T cells (Tregs) the patients were separated  into  two different groups, TregLow group  in which  those patients with Tregs below the mean (less than 2.31%) were included, and the TregHigh group including the patients with Tregs over the mean.   The  median  time  of  follow‐up  of  recipients  in  the  first  cohort  was  three‐years. For the whole population, the estimated three‐year OS and DFS were 47.8%, and 31.8%, respectively. As is shown in Figure 5.4, the outcome was significantly poorer  in  the TregHigh  group  than  in  their TregLow  counterpart (OS,  28% vs.  55.4%;  p=0.030; DFS,  12% vs.  39.7%;  p=0.017,  respectively). We then investigated the reasons for the inferior OS and DFS. There was no association  between  Treg  expression  and  non‐relapse mortality  (all  cases: 32.9%; n/s.).  In  addition,  there was no  association between pre‐transplant Treg levels and the incidence of acute GvHD (all cases: overall 45.6%, grades III‐IV 3%; n/s.)  or  chronic GVHD  (all  cases,  overall  36.1%,  extensive 7.8%; n/s.).  In the second cohort, the median follow up was one year and the estimated one‐year OS and DFS were 87.5% and 54.2% respectively.  In contrast with the  first  cohort  the  overall  survival was not  different  between  the TregHigh group and the TregLow group (100% vs. 75%). However, supporting the data of the first cohort the DFS was significantly lower in the TregHigh group than in  the TregLow group  (16.7% vs. 91.7%, p<0.001), data presented  in Figure 5.5.  




Because the donor graft  is the one that reconstitute the recipient's immune system an analysis of donor Tregs and transplant outcome was carried out; unlike  the  situation  with  patient  Treg  levels,  the  donor  Tregs  showed  no correlation with the overall survival, DFS or the relapse rate in this analysis.   
Figure 5.4. Overall survival (OS) and Disease Free Survival (DFS) in patients from the Anthony 















































Disease Free Survival (DFS) and Relapse  Higher  CD4+CD25hi  Tregs  levels,  however,  did  associate with  an  increased risk  of  disease  relapse  in  both  cohorts.  TregHigh  patients  had  a  significant increase  in  the  incidence  of  disease  relapse  compared  to  TregLow  patients. The  estimated  three‐year  risk  of  relapse  in  the  first  cohort  was  80%  in TregHigh  and  31.7%  in  TregLow  patients  (p<0.0001)  as  presented  in  Figure 5.6;  and  the  estimated  one‐year  risk  in  the  second  group was  75%  in  the TregHigh  group  and  8.3%  in  the TregLow  group  (p=0.001)  as  can  be  seen  in Figure 5.6, suggesting an effect of Tregs on graft versus tumour responses in these populations.  
Figure 5.6. Relapse rate in patients after HSCT. Both groups showed higher incidence of relapse 
associated with high levels of Tregs.  Both  the UK  (panel  A)  and  the Australian  (panel  B)  patient  cohorts were stratified in the same fashion, into groups with Treg levels either above or below the mean for the cohort.  A comparison of relapse rates in the two patient  cohorts  examined  showed  that  in  both  cohorts,  patients with  high levels of Tregs showed higher relapse rates.            A. Group from the ANT, UK (n=90)  B. Group from the Alfred Hospital, Australia (n=24) 




Specific markers for Tregs: FOXP3 expression  While  the  study  had  clearly  shown  an  association  between  high  levels  of CD4+CD25hi  T  cell  subsets,  this  broad phenotypic  definition did  not  clearly discriminate  between  inflammatory  and  regulatory  CD4  T  cells.  Since activated  T  cells  are  also  known  to  express  CD25,  relying  on  CD25  as  a marker  of  CD4+CD25hi  regulatory  T  cells  could  overestimate  the  true number.  To  assess  whether  this  subpopulation  of  T  cells  was  indeed regulatory,  we  also  measured  the  expression  of  the  Treg  specific transcription  factor  FOXP3,  which  is  thought  to  be  a  reliable  marker  for Tregs    (Hori,  et  al.,  2003).  Thus,  we  analysed  the  expression  of  FOXP3  by qRT‐PCR in patients where samples prior to transplantation were available. Patients  prior  to  transplantation  also had  significantly  lower  expression of FOXP3  (27.18  ±  5.28  FOXP3  copies/GAPDH)  in  comparison  with  healthy controls (49.57 ± 4.05 FOXP3 copies/GAPDH) (p=0.012).  We  then  examined  the  correlation  of  the  expression  of  FOXP3  and CD4+CD25hi  populations  in  donors  and  patients.  As  expected,  we  found  a positive  correlation  between  the  proportion  of  CD4+CD25hi  T  cells  and FOXP3  transcripts  in  donor  samples  as  is  shown  in  Figure  5.7  panel  A. However, the correlation between CD4+CD25hi T cells proportion and FOXP3 transcripts  in  patients’  samples  was  not  particularly  strong  (r=0.518) (Figure  5.7  Panel  B).  This  relatively  poor  correlation  was  surprising, especially  in view of the good correlation of CD4+CD25hi T cells with TGF‐β expression (this would be described in more detail  later). One possibility is that  in  the  patient  group,  there  are  cells  that  express  FOXP3  and  are committed to becoming Tregs but which do no yet express the CD25hiTGFβ+ 




phenotype. The  intranuclear  expression  of  FOXP3  by  flow  cytometry  (Figure  5.8) was also  tested  in 11 samples  from the  first cohort and  in  the 24 patients  from the  second  cohort  and  a  correlation  with  the  CD4+CD25hi  expression  was analysed;  a  strong  correlation  was  found  in  both  groups  (r2=0.623  and r2=0.766, respectively). As an indicator of Treg function we also quantified TGF‐β levels in plasma by Luminex  technology. We analysed  the  correlation between CD4+CD25hi  T cell phenotype and FOXP3 expression and as expected, we found a positive correlation  (r2=0.518,  p<0.0001).  We  also  found  a  positive  correlation between CD4+CD25hi T cells and TGF‐β production (r2=0.884, p<0.0001) and between FOXP3 expression and TGF‐β (r2=0.733, p<0.0001). 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The  quantification  of  FOXP3  by  flow  cytometry  was  only  possible  in  the Australian  group  of  patients  (n=24)  and  in  15  healthy  controls.  As  in  the quantification  of  FOXP3  mRNA  and  in  accordance  with  the  results  of CD4+CD25hi  quantification,  patients  also  showed  statistically  significant lower expression of FOXP3 than healthy controls (median 2.36 ± 1.05% vs. 3.25  ±  2.03,  p=0.004)  as  presented  in  Figure  5.10.  In  this  case,  since  the measurements  in  patients  and  controls  are  both  within  the  gated  CD4+ lymphocyte  population,  artefacts  that  arise  from  expansions  of  other  non‐CD4+  cells  can be excluded.    Specifically,  the presence of malignant  cells  in the  patients  cannot  lower  the  percentage  of  FoxP3+CD4+  cells  unless  the malignant  cells  themselves  are  CD4+,  which  in  this  cohort  they  were  not.   While  this  cannot  be  conclusive  proof,  it  is  suggestive  that  the  decreased FoxP3 levels seen in the Anthony Nolan cohort is also a real decline and not an artefactual one. 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Figure 5.11. FOXP3 expression in different diseases. The expression of FOXP3 by quantitative real‐time PCR showed that healthy  controls  (n=26)  had  significantly  greater  FOXP3  expression compared  to  patients  CML  (n=19)  (p<0.0001).  The  mean  expression  of FOXP3 was similar between healthy controls and AML patients (n=9) as was the  level  in  ALL  patients.  However,  the  number  of  AML  and  ALL  patients analysed may be too small to make any meaningful conclusion. 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FOXP3Low  group  of  those  patients  with  FOXP3  below  the  mean  (less  than 27.18  copies  and  less  than  2.36%  respectively)  and  the  FOXP3High  group including the patients with FOXP3 levels over the mean.   As mention  before,  the median  time  of  follow‐up  of  recipients  in  the  ANT cohort was three‐years. For the whole population, the estimated three‐year OS and DFS were 47.8%, and 31.8%, respectively. As is shown in Figure 5.11, and  supporting  the  previous  data  of  Tregs  the  outcome  was  significantly poorer in the FOXP3High group than in their FOXP3Low counterpart (OS, 48.9% vs. 86.7%; p=0.018; DFS, 6.7% vs. 26.8%; p=0.074, respectively). As shown in the analysis of Tregs, an analysis was performed to find the reason for the inferior  OS  and  DFS,  and  again  the  results  failed  to  show  an  association between FOXP3 expression and non‐relapse mortality. In addition, there was no  association  between  pre‐transplant  FOXP3  levels  and  the  incidence  of acute GvHD in the patients. In  the  Australian  cohort  the median  follow  up was  one  year  as  previously presented.  The  estimated  one‐year  OS  and  DFS  were  87.5%  and  54.2% respectively.  As  in  the  previous  analysis,  the  overall  survival  was  not different  between  the  FOXP3High  group  and  the  FOXP3Low  group  (100% vs. 76.9%).  However,  the  DFS  was  significantly  lower  in  the  FOXP3High  group than  in  the FOXP3Low group  (23.1% vs. 90.9%, p=0.001), data presented  in Figure 5.12.      














FOXP3 and Relapse Results with FOXP3 analysis also supported the previous data based on the CD4+CD25hi phenotype; high FOXP3 levels were associated with an increased risk of disease  relapse  in both cohorts. FOXP3High patients had a  significant increase in the incidence of disease relapse compared to FOXP3Low patients. The  estimated  three‐year  risk  of  relapse  in  the  first  cohort  was  80%  in FOXP3High and 48.8% in FOXP3Low patients (p=0.011) as presented in Figure 5.14; and the estimated one‐year risk in the second group was 69.2% in the FOXP3High group and 9.1% in the FOXP3Low group (p=0.002) as can be seen in Figure  5.13,  supporting  the  hypothesis  that  Tregs  might  be  involved  in suppressing anti‐tumour responses.    
































Table 5.3 Multivariate analysis of OS, DFS and Relapse. In a multivariate analysis  including clinical  factors and  level of CD4+CD25hi Tregs was the most significant factor involved in transplant outcome. 
 
 
   Univariate   Multivariate  RR 
95% 
CI    
            lower  Upper 
Overall Survival                Age   <0.001  0.055  1.96  0.99  3.89 Stem cell source  0.011  NS  1.35  0.63  2.89 Conditioning  0.077  NS  1.21  0.61  2.43 Stage  0.002  NS  1.29  0.79  2.1 Treg level  0.024  0.028  2.06  1.08  3.91 
                 
Disease Free Survival                Age   0.002  NS  1.46  0.81  2.65 Stem cell source  0.003  NS  1.51  0.75  3.05 Conditioning  0.053  NS  1.39  0.76  2.56 Stage  <0.001  NS  1.05  0.67  1.65 Treg level  0.017  0.024  1.92  1.09  3.38 
                 
































Table 5.4 The multivariate analysis.  The  results  were  virtually  identical  to  the  multivariate  analysis  using CD4+CD25hi T cell levels, indicating that in fact Treg are playing a pivotal role in transplant outcome 
 
   Univariate   Multivariate  RR 
95% 
CI    
            lower  upper 
Overall Survival                Age   <0.001  NS  1.86  0.81  4.29 Stem cell source  0.011  NS  1.19  0.48  2.96 Conditioning  0.077  NS  0.79  0.32  1.97 Stage  0.002  NS  0.27  0.69  2.33 FOXP3 expression  0.024  0.014  2.68  1.22  5.87 
                 
Disease Free Survival                Age   0.002  NS  1.22  0.61  2.43 Stem cell source  0.003  NS  1.42  0.62  3.25 Conditioning  0.053  NS  1.04  0.47  2.26 Stage  <0.001  NS  1.07  0.62  1.83 FOXP3 expression  0.017  0.027  2.21  1.09  4.45 
                 
Relapse                Age   0.004  NS  0.95  0.41  2.22 Stem cell source  <0.001  0.028  2.96  1.13  7.78 Conditioning  0.03  NS  0.9  0.35  2.33 Stage  <0.001  NS  1.24  0.65  2.36 FOXP3 expression  <0.001  0.003  3.61  1.55  8.42            NS: Not significant           
 
 




Effect of Regulatory T cells by Disease  To  better  understand  the  effect  of  Tregs  on  the  overall  outcome  of  the transplant,  the  group  of  patients  was  divided  into  two  different  groups, patients with acute leukaemias and patients with chronic leukaemias, and an analysis  of  relapse  was  performed,  correlating  this  independently  with CD4+CD25Hi T cells and with the expression of FOXP3. The  results  showed  that  the  estimated  three‐year OS  for  the population of patients with acute  leukaemias (n=42) was 36%.   The outcome was poorer for  the  patients  with  either  high  CD4+CD25Hi  Tregs  or  high  expression  of FOXP3,  at  15.8%  and  14.3%  respectively  overall  survival  at  3  years compared  with  patients  with  low  CD4+CD25Hi  or  low  FOXP3  expression, whose overall  survival was 52.2% and 48.1% respectively.   These data are presented in Figure 5.14. The worse outcome in these patients was due to a high incidence of relapse. The overall relapse rate for the population with acute leukaemias was 45%, with  a  higher  incidence  in  those  patients  with  high  percentages  of CD4+CD25Hi  (65%  relapse)  or  high  expression  of  FOXP3  (58%  relapse)  in comparison with patients with low levels. The  same  analysis  was  done  in  patients  with  chronic  leukaemias, unfortunately  only  one  patient  had  high  levels  of  CD4+CD25Hi  T  cells  and high  expression  of  FOXP3,  therefore,  it  was  not  useful  to  draw  any conclusion. However, this one patient did suffer a relapse and died at 1‐year post transplant.   





Acute Leukaemias. A study for survival and relapse was performed in patients with acute leukaemias  stratified  into  two groups based on  the  levels of CD4+CD25Hi T cells  (Tregs;  in  the  upper  two  panels)  or  the  expression  of  FOXP3  (in  the lower panels). Results are shown separately  for Overall Survival,  in  the  left hand  column,  and  Relapse,  in  the  right  hand  column.    Patients  with  high levels of Tregs had worse OS (log rank, 0.011) and greater relapse rates (log rank, 0.004) than those patients with low levels. Similar results were found when  analysing  the  expression  of  FOXP3,  patients with  high  expression  of FOXP3 had worse outcome (log rank, 0.039) and greater  relapse rates  (log rank, 0.007) than those patients with low expression. 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Discussion Natural  occurring  Tregs  have  been  extensively  studied  in  the  context  of clinical  HSCT mostly  in  the  post‐transplant  period, where  an  imbalance  of donor  derived  Tregs  and  effector  T  cells  has  been  associated  with  the occurrence of GvHD. Those studies have  led  to an  increased  interest  in  the potential use of regulatory T cells to modulate post‐transplant allo‐reactive phenomena.  In  the  context  of  UD‐HSCT,  T  cell  depletion  is  used  to  avoid these  allo‐reactive  phenomena.  However,  the  consequence  of  using  this approach may be also detrimental for the transplant outcome, increasing the rates  of  disease  relapse  and  opportunistic  infections.  Numerous  recent publications  have  identified  donor  derived  Tregs  as  an  important  tool  to decrease  the  incidence  of  GvHD while  preserving  the  GvL  effect.  However, very little work has been done in the context of patient derived Tregs. In this study we aimed  to  analyse  the  effect  of  recipient’s  derived Tregs  levels  on the  post‐transplant  allo‐reactive  phenomena  and  transplant  outcome.  In contrast  to  previous  publications,  our  results  did  not  show  any  impact  on preventing GvHD. However, our results do show that high recipient levels of Tregs  prior  to  transplantation  predict  an  increased  incidence  of  disease relapse,  which  translates  into  poorer  DFS  and  OS  in  the  UD‐HSCT  setting. Some questions have arisen trying to understand the mechanism of this Treg effect. A key question that needs to be addressed is whether or not Tregs can survive patient conditioning and T cell depletion? And if they survive, what is the mechanism of their response that causes an increased relapse rate? Recent  data  has  indicated  that  T  cell  depleting  agents  such  as  Campath  or ATG can spare Tregs from depletion through the induction of anti‐apoptotic signals. However, while they are more resistant to apoptosis they retain their 




suppressive capacity  (Pearl, et al., 2005) (Watanabe, et al., 2006). Along with those  studies,  it  has  also  been  published  that  Tregs  are  preferentially expanded under lymphopenic conditions  (Cox, et al., 2005). Together, these observations  may  explain  why  patient  Tregs  could  be  implicated  in regulating post‐transplant phenomena. In our cohort 90% of the transplants were performed using Campath for T cell depletion, therefore, Tregs may be expanded faster post‐transplant.  The  other  observation  from  our  data  was  that  Tregs  were  not  associated with  the  incidence  of  GvHD,  but  with  the  incidence  of  relapse,  which was confirmed  in a second  independent cohort. This would appear paradoxical, but similar results have been obtained by others (Nadal, et al., 2007), which may suggest difference  in  the capacity of Tregs to regulate  limited antigen‐specific responses versus complex allogeneic responses. There have been interesting data published, demonstrating that tumours can induce or  recruit Tregs  to  inhibit  anti‐tumour  responses  in murine models  (Shimizu, et al., 1999).  In humans, an increased number of Tregs has been found in peripheral blood in many  different  types  of  cancers  (head  and  neck,  hepatocellular,  gastric, breast,  ovarian,  lung, melanoma,  etc.)    (Wolf,  et  al.,  2005)  (Ascierto,  et  al., 2010)  (Deng,  et  al.,  2010)  (Kordasti,  et  al.,  2007)  (Kobayashi,  et  al.,  2007) and the level of Tregs is associated with the progression of the disease. Such observations support the idea that tumours can evade immuno‐surveillance through  the  induction  of  regulatory  T  cells  that  can  suppress  anti‐tumour responses.  Also  very  recently  data  have  been  published  showing  that increased  Tregs  post‐transplant  in  CML  patients  are  associated  with  an 




increase in relapse rate  (Nadal, et al., 2007). Whether this Tregs are patient derived  or  donor  derived  expanded  under  the  lymphopenic  conditions  or tumour induced we still do not know.  Another theory is that tumours can produce cytokines such as TGF‐β or IL‐10 that can induce regulatory T cells to evade tumour‐specific responses. In our cohort, we found a good correlation between the frequency of Tregs  in peripheral  blood  and  the  levels  of  TGF‐β  in  plasma  (r=0.884;  p<0.0001). However,  whether  this  production  of  TGF‐β  is  Treg  derived  or  tumour derived is not know. Altogether  these  findings  suggest  that  an  imbalance  in  favour  of  recipient‐derived  Tregs  prior  to  UD‐HSCT  might  have  an  impact  on  the  outcome through  the  suppression  of  donor‐derived  GvT  responses,  depending  not only on the presence of Tregs but also on the individual microenvironment, such as type of T cell response (Th1 vs. Th2) and cytokine production.  We also  found in our data,  that patients can be stratified  into high and  low risk of disease relapse sub‐groups based on their level of Treg cells prior to transplantation.  Consequently, it is possible that a strategy based on the depletion of patient Tregs prior to transplant may be beneficial to reduce the risk of relapse and improve the outcome of HSCT in such high‐risk patients. Although our  study has  opened new questions  that  need  to  be  resolved,  it has reinforced the little knowledge we have on Tregs and has confirmed the position  of  Tregs  as  a  potential  target  for  therapeutic  intervention  in  the transplantation‐field.





Cytokine profiles and the outcome of haematopoietic 
stem cell transplant (HSCT)  
 




• receptors  such  as  the  killer  immunoglobulin‐like  receptor (KIR), immunoregulatory molecules,  
• regulatory T‐cells. 




As  shown  in  the previous  chapter,  an  analysis  of  the  effect  of  regulatory T cells and its correlation with transplant outcome found that high numbers of regulatory  T‐cells  in  the  pre‐transplant  period  correlated  with  worse transplant  outcome,  poorer disease  free  survival  and  a higher  incidence of relapse. However, the mechanism of this effect was not clear. In this chapter we will  focus  in  analysing  the  effects  of  the  pre‐transplant  cytokine  levels seeking  to  understand  the  possible  effect  of  regulatory  T‐cells  on  cytokine production and the contribution of these cytokines to transplant outcome.    
Effects of cytokine levels, cytokine polymorphisms and HSCT 
outcome  Cytokine polymorphisms affecting  the  level of cytokine expression, and  the dysregulation  of  the  cytokine  network  that  occurs  during  the  transplant procedure, have been associated mainly with the development of acute graft versus  host  disease  (aGvHD),  worse  transplant  outcome  and  greater transplant  related  mortality  (TRM)  (Ferrara,  2000).  Host  cell  damage induced  during  the  conditioning  regimen,  coupled  with  the  release  of endotoxin  and  other  innate  stimuli  as  a  consequence  of  breaching  the integrity of the gut, results in an acute inflammatory stimulus that causes T cell  activation,  the  release  of  pro‐inflammatory  cytokines  and  the upregulation  of  HLA  molecules  on  host  cells.  The  high  level  of  cytokine production that occurs through T‐cell activation is called the cytokine storm  (Cohen,  et  al.,  2000)  (Antin  &  Ferrara,  1992)  (Ferrara,  et  al.,  1993). Proinflammatory  cytokines  produced  during  the  cytokine  storm,  such  as IFN‐γ, TNF‐α and IL‐6, are implicated in the pathogenesis of aGVHD. On the 




other hand anti‐inflammatory and immunomodulatory cytokines such as IL‐10 and TGF‐β are associated with transplant tolerance. Consistent with this, the  production  of  cytokines  such  as  TNF  alpha,  in  the  pre‐transplant  period has  been  implicated  in  the  induction  of  transplant  complications  (Remberger, et al., 1995) (Holler, et al., 1990).  The evidence until now points towards the fact that variation in the level of expression  of  cytokines,  either  drug‐induced  variation  or  innate  variation resulting from polymorphisms in the cytokine genes (and promoters) has an impact on the transplant outcome. Therefore, measurement of  the cytokine levels both in the pre‐transplant period and the post‐transplant period could be an important tool in predicting the overall outcome.  
 
Cytokines and transplant outcome  Pro‐inflammatory  cytokines  such  as  TNF‐α,  IL‐2,  IL‐6  and  IL‐12  are associated with the pathogenesis of GvHD but also with complete remission of  advanced  tumours    (Nair,  et  al.,  2006). There  is  evidence  that  IFN‐γ  has protective  role  in  anti‐tumour  immunity,  exerting  anti‐proliferative,  anti‐angiogenic  and  pro‐apoptotic  effects  in  different  tumour  cells    (Beatty  & Paterson,  2001)  (Ikeda,  et  al.,  2002).  Consequently,  cytokine  therapy  has been applied using the anti‐tumour cytokines mentioned before (IL‐2, IL‐12, TNF‐α  and  IFN‐γ)  in  both  mice  and  human  with  success  in  eliminating established  tumours  through  the  induction  of  enhanced  anti‐tumour 




responses, promoting activation of T‐effector/memory cells and of NK‐cells, and increasing secretion of IFN‐γ  (Egilmez, et al., 2007).  However,  long‐term  efficacy  of  this  treatment  has  not  been  achieved.  The failure of the cytokine therapy is due an augmentation of suppressive activity post‐treatment  that  initiates  the decline of  the anti‐tumour effect  (Egilmez, et al., 2007).  The  relationship between  transplant outcome and cytokine production has been  further  complicated  by  the  suggestion  that  tumours  secrete  anti‐inflammatory cytokines such as IL‐10 and TGF‐β that induce the recruitment of regulatory T cells, including naturally occurring Tregs, Tr1 and Th3 (Nair, et  al,  2006).  Moreover,  some  tumours  have  been  shown  to  express indoleamine‐2,3‐dioxygenase  (IDO),  an  enzyme which  depletes  tryptophan from the local environment and induces the production of regulatory T cells (Curti,  et  al.,  2006).  Regulatory  T  cells  secrete  more  anti‐inflammatory cytokines  that  further  induce  the conversion of CD4 T‐cells  into Tregs. The infiltration of regulatory T cells and the production of an anti‐inflammatory environment  decrease  immune  surveillance  and  neutralise  and  reduce potential anti‐tumour activity inducing relapse or recurrence of the original tumour (Nair, et al, 2006). Regulatory cells also have a key role in regulating cancer progression by  inhibition of CD4+ or CD8+ T cell responses. Another mechanism  of  Treg  suppression  which  requires  TGF‐β   and  IL‐10  (Larmonier,  et  al.,  2007)  is  by  inhibiting  dendritic  cell  function  (DC´s) causing down‐regulation of TNF‐α  and  IL‐12 expression.  In addition,  it has been  demonstrated  that  depletion  of  regulatory  T  cells  enhances  anti‐tumour  responses,  inducing complete  remission.  In  the previous chapter,  a 




correlation of regulatory T cells and transplant outcome was demonstrated. To understand how this might be mediated, and to verify that the increased Treg numbers seen in some patients correlated with increased Treg function, an  analysis  of  cytokine  profiles  in  the  pre‐transplant  serum  samples  was carried  out,  concentrating  on  pro‐inflammatory  cytokines  versus  anti‐inflammatory cytokines. The  range  of  cytokines  that  were  included  in  the  analysis  were:  tumour necrosis  factor alpha  (TNF‐α),  interferon gamma (IFN‐γ),  interleukin 1  (IL‐1),  interleukin  2  (IL‐2),  interleukin  6  (IL‐6),  interleukin  12  (IL‐12), interleukin  17  (IL‐17),  interleukin  10  (IL‐10)  and  transforming  growing factor  beta  (TGB‐β).    These  cytokines were  chosen  to  be  representative  of inflammatory (TNF‐α, IFN‐γ, IL‐1, IL‐6, IL‐12, IL‐17), helper (IL‐4, IL‐10) and regulatory  (TGF‐β,  IL‐10)  immune  responses.    Note  that  not  all  of  these cytokines  are  necessarily  expressed  by  T  cells;  for  example,  IL‐1  can  be produced by  a wide variety of  cells  including endothelial  cells, while  IL‐10 can be produced by monocytes and cytotoxic CD8+ T cells as well as Th2 and Treg cells.    In  the  next  section,  the  known  associations  of  these  cytokines with  HSCT outcome will be outlined. 
 
Pro-inflammatory cytokines 
Tumour Necrosis Factor alpha (TNF-α)  TNF‐α  is  a  pro‐inflammatory  cytokine  implicated  in  the  pathogenesis  of inflammatory  or  autoimmune  diseases;  anti‐TNF‐α  has  been  used  as 




treatment  for  rheumatoid  arthritis    (Bongartz,  et  al.,  2006).      It  is  also implicated  in  tumour  growth  control  and,  furthermore  TNF‐α  has  been associated with  early  stages  of  aGvHD.  High  levels  of  TNF‐α  in  serum  are correlated with the severity of aGvHD and elevated plasma levels during pre‐transplant  conditioning  are  associated  with  the  development  of  aGvHD, worse  transplant  outcome  and  increased  TRM  (Remberger,  et  al.,  1995). Furthermore,  it  has  been  reported  that  neutralization  of  TNF‐α  reduces complications  after HSC  transplantation  (Holler,  et  al.,  1993).    The  relative concentration  of  TNF‐α  has  also  been  correlated with  the  severity  of  both acute and chronic GvHD.  (Holler, et al., 1990) (Hägglund, et al., 1995) (Cavet, et al., 1999) (Takahashi, et al., 2000) (Rocha, et al., 2002) (Ochs, et al., 1996). A  polymorphism  has  been  identified  in  the  TNFA  gene  associated  with  a change  in  TNF‐α secretion;  there  is  a  single  base  polymorphism  (G/A)  in position ‐308 of the promoter region  (Wilson, et al., 1992) and the (A) allele is  correlated  with  increased  production  of  TNF‐α  caused  by  higher transcriptional activation. Thus, genetic factors as well as other factors that cause  increased  production  of  TNF‐α could  be  implicated  in  the development of acute or chronic GvHD, TRM and poorer transplant outcome  (Holler, et al., 1993) (Holler, et al., 1990).  However, as with many immune phenomena, there may be benefits as well as  disadvantages  associated  with  elevated  TNF‐α  production;  there  is evidence that TNF‐α can be used as a therapy to promote tumour regression by induction of effector T‐cells  (Egilmez, et al., 2007).   
 








IL-1 is involved in inflammatory processes. IL-1α, IL-1β and interleukin-1 
receptor α-agonist (IL-1Ra) are well-characterised mediators of immune and 
inflammatory responses (Dinarello, 2009).  




Interleukin-2 (IL-2)  The  importance of  IL‐2  in  the  initiation of GvHD has been demonstrated  in both experimental  and clinical  transplantation  (Theobald,  et  al.,  1992). For example,  IL‐2  secretion  could be used  as  a  predictive  factor  for  the  risk  of aGvHD    (Theobald,  et  al.,  1992).  Soluble  IL‐2  receptor  levels  may  be  a sensitive  indicator  of  impending  GvHD  onset  and  correlate  with  disease severity.    
Interleukin-6 (IL-6)  High serum levels of Interleukin 6 (IL‐6) are associated with both acute and chronic GvHD (Cavet, et al., 2001), and it has been demonstrated that a (C/G) polymorphism in position ‐174 of the IL6 gene associated with high levels of production  of  IL‐6  is  implicated  in  the  development  of  higher  grades  of aGvHD  but  does  not  increase  the  severity  (Cavet,  et  al.,  2001).  Also  IL‐6 polymorphisms have been associated with the onset of cGvHD  (Symington, et  al.,  1992)  (Abdallah,  et  al.,  1997)  (Tanaka,  et  al.,  1995)  (Socié   ,  et  al., 2001). IL‐6 may also play a role in mediating the balance between regulatory and inflammatory responses, diverting CD4 T cells from the Treg pathway to become pro‐inflammatory Th17 cells  (Kitani & Xu, 2008). 
 
 




Interleukin-12 (IL-12)  IL‐12  is  a  potent  pro‐inflammatory  cytokine  and  is  involved  in  the specification of activated naïve CD4 T cells to differentiate into Th1 T cells.  It has been shown to have an anti‐tumour effect  in murine models (Reddy, et al.,  2005). When  this was  tested  in  humans  undergoing HSCT,  Reddy  et  al showed  that  high  levels  of  IL‐12  post‐transplant  were  associated  with  a lower incidence of relapse and improved disease free survival (DSF) without increasing  the  risk  of  GvHD,  in  comparison  with  those  patients  with  low levels  who  showed  higher  relapse  rates    (Reddy,  et  al.,  2005).      This  is consistent  with  a  beneficial  anti‐tumour  effect  of  high  IL‐12  levels.  Moreover,  IL‐12  injections  in  murine  models  have  been  shown  to  induce tumour  regression.  Therefore,  there  is  a  pivotal  role  of  IL‐12  in  inducing anti‐tumour immunity  (Nair, et al., 2006). 
 
 
Interleukin-17 (IL-17)  IL‐17  is  a  cytokine  produced  by  T‐cells  that  stimulates  macrophages  to secrete pro‐inflammatory cytokines such as IL‐1β and TNF‐α and induces T‐cells  to proliferate.  It has been suggested  that  that  IL‐17 may have a major role in inducing allo‐immune reactivity  (Antonysamy, et al., 1999). 
 
 






Interleukin-10 (IL-10)  Interleukin‐10 (IL‐10)  is a highly polymorphic  immunoregulatory cytokine, which suppresses allo‐antigen specific T‐cell responses and is strongly anti‐inflammatory (Hempel, et al., 1997). IL‐10 inhibits the secretion of cytokines such  as  IL‐1,  IL‐6,  IL‐8,  IL‐12  and  also  TNF‐α  (Steven,  et  al.,  2000).  This inhibitory property of the IL‐10 could suggest that it could act as to suppress GvHD  and  it  could  induce  T  cell  tolerance  in  the  HSC  transplant  setting. Several  studies  have  demonstrated  that  increased  IL‐10  production  is associated  with  fewer  transplant  related  complications    (Remberger  & Ringdén,  1997).  Holler  et  al.  (Holler,  et  al.,  2000)  demonstrated  the predictive  value  of  IL‐10,  showing  that  increased  IL‐10  production  was associated with  better  transplant  outcome  in  the  absence  of  GvHD.  Also  it has  been  reported  that  a  high  level  of  IL‐10  at  the  time  of  donor  infusion might induce a state of anergy (Willems, et al., 1994) Exposure  to  IL‐10  also  induces  regulatory  T‐cells  (Tr1  and  Th3)  in  the periphery, which can be  identified by cytokine production  (IL‐10 and TGF‐
β); these cytokines act to suppress undesired immune responses (Roncarolo, et al., 2006). Host Tr1 cells correlated with absence of GvHD and long term tolerance  in HSCT patients    (Bacchetta, et al., 1994) but on  the other hand, both  IL‐10  and  TGF‐β  are  associated  with  inhibition  of  anti‐tumour responses by effector T‐cells and induction of tumour recurrence. 




Transforming Growing Factor beta (TGF-β)  Transforming  growing  factor  beta  (TGF‐β)  polymorphism  has  been associated  with  variation  in  plasma  concentration  of  TGF‐β.    The  picture with respect to TGF‐β and transplant outcome is not clear, and contradictory results have been published. In some studies, neither TGF‐β polymorphisms nor  plasma  levels  of  the  cytokine  were  found  to  be  associated  with transplant  complications  or  transplant  outcome    (Cavet,  et  al.,  2001) (Grainger,  et  al.,  1999). However,  other  groups  have  published  that  a  high expression  phenotype  of  TGF‐β  was  associated  with  severe  and  chronic GvHD  (Leffell, et al., 2001) (Liem, et al., 1998).  As  mentioned  in  the  previous  section,  TGF‐β  also  has  been  involved  in suppressing anti‐tumour immune responses  (Seoane, 2008), and it has been implicated as an important factor for tumour progression  (Medicherla, et al., 2007)  by  inducing  FoxP3  to  promote  differentiation  of  non‐regulatory  T‐cells into regulatory T‐cells (Pyzik & Piccirillo, 2007).   This  study  is  focused on  the measurement,  in  the pre‐transplant period, of the  levels of  the cytokines described above and  the hypothesis  is based on the  study  described  in  the  previous  chapter  of  this  thesis,  where  higher levels  of  pre‐transplant  regulatory  T‐cells  were  observed  to  have  a deleterious  impact on  transplant outcome and  increased relapse rate. Here we suggest the effect of Tregs is part of a wider balance of pro‐inflammatory cytokines  versus  regulatory  cytokines  that  has  an  impact  on  transplant complications such that the overall skewing of the cytokine profile towards immune‐regulation has detrimental effect on relapse rates.  








 The  study  group  consisted  of  62  patients  undergoing  HSCT  from  an unrelated  donor  (UD‐HSCT)  identified  through  the  Anthony  Nolan  Trust (ANT) donor registry.  16 donors from the registry with the same age range as the patients were analysed as a control group. Both recipients and donors were required to have 4‐digit allele typing results at six HLA loci (HLA‐A, ‐B, ‐C,  ‐DRB1,  ‐DQB1,  ‐DPB1).  Because  the  study  was  registry  based,  blood samples  and  clinical  data were  provided  by  the  individual  transplantation centres  (TCs).  Clinical  data were  collected  on  standard  forms, which were collected from data managers at the individual TCs. A basic description of the cohort  including  patient  age,  sex,  disease  and  conditioning  is  presented  in Table  6.1.  Forty  patients  (65%)  received  a  standard  conditioning  regimen; 20 had reduced intensity conditioning (RIC) (32%).  
Analysis of Cytokine levels in plasma samples 
 The  cytometric  bead  array  technology  (Luminex®)  has  been  applied recently  for  the  simultaneous  measurement  of  a  number  of  different biomarkers including cytokines. In a multiplex method, the measurement of 9 cytokines (IL‐1β, IL‐2, IL‐4, IL‐10, IL‐12p70, IL‐15, IL‐17, TNF‐α and IFN‐γ) was quantified simultaneously using  a  Human  cytokine/chemokine  panel‐9  plex  (Lincoplex  kit,  Linco 




Research) in 50µl of undiluted plasma. TGF‐β requires a pre‐treated plasma sample and for that reason TGF‐β was measured separately with a singleplex kit also from Linco Research.  Standards  and  antibodies  were  also  purchased  from  Linco  Research. (Lincoplex kits, Billerica, Ma). Cytokine  quantification  was  done  from  plasma  samples  according  with manufacturers instructions and measurements were carried out in duplicate. Standard curves for each cytokine were created ranging form 3.2 to 10,000 pg/ml. The standard curve for TGF‐β quantification range from 0.064 to 200 ng/ml.                 








N=16 Patient age (years)  32.55±2.03  27±2.01 Donor age (years)  33.75±0.79         Sex Matched  37 (60)   M patient/F donor  3 (4)   F patient/M donor  22 (36)   F/M    9/7       CMV status      Patient +/Donor +  6 (10)   Patient ‐/Donor ‐  39 (63)   Patient +/Donor ‐  8 (13)   Patient ‐/Donor +  7 (11)   Missing  2 (3)         Disease      CML  20 (32)   AML  11 (18)   ALL  10 (16)   Other malignant  18 (29)   Other non‐malignant  3 (5)         Stage at transplant      Early  38 (61)   Late  14 (23)   Relapse  6 (10)   Missing  4 (6)         Conditioning regimen      Standard myeloablative  40 (65)   Reduce intensity (RIC)  20 (32)   Missing  2 (3)         Type of Transplant      Bone Marrow  51 (82)   PBMC´s  11 (18)   



















Cytokine levels in patients and controls  The  levels  of  the panel  of  cytokines were measured  from peripheral  blood samples  of  patients  and  healthy  controls  and  the  values  were  compared between  patients  and  controls  for  significant  differences  in  the  level  of circulating  cytokines.    The  results,  presented  in  Table  6.2,  show  that  only four cytokines, IL‐10, TNF‐α, IFN‐γ and TGF‐β, showed significant differences between patients and controls. The  levels  of  IL‐10  were  statistically  significant  higher  (p=  0.0005)  in  the patients  than  in  healthy  controls  (means  of  109.13pg/ml  and  17.55pg/ml respectively). The  same  pattern  was  observed  when  IFN‐γ  was  analysed.  The  healthy controls have lower levels of IFN‐γ (mean of 0.34pg/ml) than patients (mean of 2.9pg/ml). The difference was also statistically significant (p= 0.009). The mean level of TNF‐α in healthy controls was 1.32 pg/ml (range 0 to 21.1 pg/ml), while the levels in patients were significantly higher, with a mean of 165.16pg/ml  (range  0  to  1485.47).  The  difference  was  statistically significant (p<0.0001, Mann Whitney U test). The mean  levels  of  TGF‐β  in  healthy  controls was  6.62  ng/ml  (range  0  to 31.86  ng/ml)  and  was  statistically  significant  (p<0.0001)  when  it  was compared with patients mean levels (258.09pg/ml, range 0‐2674.76). None of the other cytokines analysed (IL‐1β,  IL‐2, IL‐4, IL‐12p70, IL‐15 and IL‐17) showed significant differences between donors and patients. 































Cytokine  Patients (n= 62)  Controls (n= 16)     
   Mean±SE  Mean±SE  Mann‐Whitney Test (p value) IL‐1β  8.27±2.93pg/ml  2.28±1.40pg/ml  p=NS IL‐2  12.54±6.09pg/ml  7.93±6.17pg/ml  p=NS IL‐4  168.78±53.30pg/ ml  93.59±36.49pg/ml  p=NS IL‐10  109.13±34.09pg/ml  17.55±7.84pg/ml  p=0.0005 IL12p70  41.07±20.06pg/ml  13.33±7.71pg/ml  p=NS IL‐15  313.15±231.10pg/ml  7.81±5.34pg/ml  p=NS IL‐17  21.16±8.22pg/ml  21.20±8.23pg/ml  p=NS TNF‐alpha  165.16±32.93pg/ml  1.32±1.32pg/ml  p<0.0001 IFN‐gamma  2.92±0.49pg/ml  0.34±0.34pg/ml  p=0.009 TGF‐beta  258.09±66.41ng/ml  6.62±1.74ng/ml  p<0.0001 


















































Cytokine levels and HSCT outcome  As  discussed  in  the  introduction,  various  authors  have  suggested correlations between cytokines, their level of expression and the outcome of HSCT.    In  the previous  chapter,  an  association between high  levels of Treg and an increased risk of relapse mortality was identified.  To verify whether this was reflected in the profile of cytokines, particularly those characteristic of  Treg  function,  the  levels  of  various  cytokines  in  the  pre‐transplant samples were measured and, while these showed an  increase  in TGF‐β and IL‐10,  which  would  be  consistent  with  increased  Treg  activity,  they  also showed  an  increase  in  TNF‐α  and  IFN‐γ,  which  are  characteristic  of inflammatory,  type  1  immune  responses.      Based  on  the  results  of  the previous  chapter,  an  analysis  was  therefore  carried  out  to  determine whether there was any correlation between the pre‐transplant levels of anti‐inflammatory  and  pro‐inflammatory  cytokines  and  the  outcome  for  the patients in the cohort.   The  patient  cohort  was  described  in  the  methods  section  above  and  the patient characteristics are shown in Table 6.1. The median follow‐up of the cohort was 1048.73 days and the overall survival (OS) was 40.3%.   A  comparison  was  done  between  the  patients  who  relapsed  and  patients who did not relapse, finding that the group that relapsed had lower levels of TNF‐α than the group that did not relapse (p=0.035, Mann Whitney U test). Subsequently,  patients  were  divided  into  two  groups  according  to  TNF‐α plasma  levels,  the  patients  with  levels  of  TNF‐α  higher  than  the  mean, 165.16pg/ml  formed the high‐TNF‐α group (n=46), while  the patients with 




cytokines  levels  below  that  level  were  considered  the  low‐TNF‐α  group (n=16). Comparing  these  two  groups,  61.5%  of  the  patients  from  the  low‐TNF‐α group  relapsed,  while  only  the  40%  from  the  high‐TNF‐α  group  did  (p= 0.031, log rank test) as presented in Figure 6.2. These findings are consistent with  previously  published  work  of  Remberger  et  al,  who  also  showed  a correlation between TNF‐α levels and relapse  (Remberger, et al., 1995). High levels of TNF‐α showed also a trend towards better survival than those patients with  low  levels  (64.7% vs. 32.6%; p=0.052). High  levels were also correlated with improved DFS (p=0.031).  Accordingly to Holler et al,  increases of TNF‐α  levels before HSCT has been proved to be predictive for development of transplant complications within the  first  year  post‐transplant    (Holler  E.  ,  et  al.,  1990).  However,  although variation  in  TNF‐α  levels  have  been  strongly  associated  with  the  onset  of chronic  and  acute  GvHD  and  with  higher  incidence  of  transplant  related mortality  (TRM),  we  did  not  find  an  association  between  TNF‐α  and  the onset of either acute or chronic GvHD or TRM.          




Figure 6.2 TNF­α and transplant outcome. Survival curves showing the impact of the levels of TNF‐α  in Overall Survival (OS), Disease Free Survival (DFS) and risk of relapse when patients are stratified into a high‐TNF−α group and a low‐TNF‐α group. The high level group has better OS with lower rates of relapse and improved DFS.         a) Association of TNF‐α and OS  b) Association of TNF‐α and DFS               c) Association of TNF‐α and Relapse   The  cohort  was  also  stratified  based  on  their  plasma  levels  of  IL‐10.  The high‐IL‐10  group  (n=47),  when  IL‐10  plasma  levels  were  above  the mean 




(109.13pg/ml)  and  the  low‐IL‐10  group  (n=15),  when  plasma  levels  were below the mean.  The high‐IL‐10 group did not show any association with the onset of either acute or chronic GvHD. In addition, there was no significant association with TRM.  In  contrast  to  published  work  suggesting  that  high  levels  of  IL‐10  pre‐transplant  could  have  a  protective  effect  on  transplant  outcome;  in  this cohort the low‐IL‐10 group had significantly better overall survival than the high‐IL‐10 group (43.2% versus 0%; p<0.001); all patients in the high group died  within  the  first  year  following  transplantation.  Disease  free  survival (DFS) was impaired in the high‐IL‐10 group; all patients on this group have died or have relapsed within the first year post‐transplant. Relapse rate was also higher in the high‐IL‐10 group than in the low‐IL‐10 group, however, the difference  is  not  strong  to  draw  significant  conclusions  (57.1%  versus 51.4%, p=0.010) as is presented in Figure 6.3. The high‐IL‐10 group was also associated with faster engraftment in comparison with the low‐IL‐10 group (16.4 days versus 21.5 days; p=0.002). Engraftment after HSCT  is define as obtaining an absolute neutrophil count of >500/ml.        





Figure 6.3 The impact of IL­10 levels in transplant outcome.  High levels of IL‐10 are associated with worse overall survival due to greater  relapse  rates.  Patients  with  low‐IL‐10  plasma  levels  have significantly  better  overall  survival  (p<0.001,  log  rank  test),  less  DFS (p=0.001,  log  rank  test)  and  lower  relapse  rates  (p=0.010,  log  rank  test). Relapse  occurs  within  the  first  year  post‐transplant.  Low  levels  of  IL‐10 could be associated with better specific allo‐responses that contribute to the graft versus  leukaemia effect (GvL). High  levels of  IL‐10 also contributes to faster engraftment (p=0.002, log rank test).        a) Association of IL‐10 and OS                          b) Association of IL‐10 and DSF            c) Association of IL‐10 and Relapse                         d) Association of IL‐10 and engraftment    




Transforming  growth  factor  beta  (TGF‐β)  is  a  regulatory  cytokine;  it modulates  many  immune  responses,  especially  inflammatory  responses, where  it  antagonises  the  functions  of  TNF‐α  and  other  pro‐inflammatory cytokines. In the context of HSCT, if TNF‐α promotes aGvHD then since TGF‐
β   is a regulatory cytokine,  it should  inhibit  the onset of GvHD; however,  in contradiction to that, TGF‐β has also been implicated in the onset of aGvHD  (Visentainer, et al., 2003). To analyse the association of TGF‐β with transplant outcome, the cohort was stratified  into  a  high  TGF‐β  group  with  concentrations  of  TGF‐β  levels  in plasma greater than 258.09ng/ml (the mean value in the cohort) and a low TGF‐β group with plasma concentration below the mean. Pre‐transplant  TGF‐β   levels  did  not  show  a  correlation with  TRM,  neither did they show a correlation to acute nor chronic GvHD, in contrast with what has been published from other studies (Cavet, et al., 2001) (Grainger, et al., 1999). Low levels of TGF‐β showed a trend towards better survival (44.1% versus 20.0%;  p=0.082).  Low  levels  of  TGF‐β  correlated  significantly  with  better DFS (27.3% versus 10.0%; p=0.026); the data is presented in Figure 6.4.  The worse  overall  and  disease  free  survival  in  the  high  TGF‐β cohort  was correlated  with  higher  rates  of  relapse,  with  a  strikingly  high  correlation between high levels of TGF‐β and higher risk of relapse (90% versus 42.4%; p<0.001), as shown in Figure 6.5.    





levels of TGF­β levels in patients prior HSCT.  Patients with low‐TGF‐β levels showed a trend towards better overall survival  in  comparison  of  patients  with  high  levels  (44.1%  versus  20.0%; p=0.082)  as  it  is  presented  in  panel  a.  However,  patients  with  low‐TGF‐β levels showed a definitively better DFS than patients with high levels (27.3% versus 10.0%; p=0.026), presented in panel b.           a) Association of TGF‐β and OS  b) Association of TGF‐β and DFS             




Figure 6.5 The levels of TGF­β are associated with relapse risk.  Patients  with  levels  of  TGF‐β  above  the  mean  (258.09ng/ml)  in plasma pre‐conditioning have higher risk of relapse than patients with levels below  the mean p<0.001. The higher  risk of  relapse could be associated  to the immune‐regulating function of TGF‐β.                        




As for the cytokines described previously, TNF‐α, IL‐10 and TGF‐β, patients were grouped based on the mean plasma levels of IFN‐γ; a high‐IFN‐γ group with levels above the mean and a low‐IFN‐γ group with plasma levels lower than the mean. Although IFN‐γ has been reported to be associated with the onset of acute or chronic  GvHD,  this was  not  demonstrated  in  the  analysis  of  this  cohort  of patients.  Moreover,  no  correlation  was  found  with  overall  survival  (OS)  or  disease free survival (DFS) nor were the rates of relapse different between the high‐ or low‐group for IFN‐γ.   The pre‐conditioning plasma levels of the rest of the cytokines analysed (IL‐1β,  IL‐2,  IL‐4,  IL‐12p70,  IL‐15  and  IL‐17)  showed  no  correlation  with transplant  outcome.  However,  IL‐4,  IL‐2  and  IL‐12p70  had  an  impact  on engraftment.  The  high‐IL‐4  group  had  significantly  faster  engraftment  in comparison with the low‐IL‐4 group (15.4 days versus 21.5 days; p=0.002). The  engraftment  was  also  faster  in  the  high  IL‐2  group  than  the  low‐IL‐2 group (16.2 days versus 21.2 days; p=0.029). The same was  found with  IL‐12p70, the high‐IL12p70 group had also a trend towards faster engraftment in comparison with the low‐group (16.20 days versus 21.08 days; p=0.041).  A summary of the results of the impact of cytokines on transplant outcome are presented in Table 6.3 for those cytokines where a significant association was identified.   
















  p value  P value  p value  P value  p value TNF‐α  0.052  0.031  0.031  NS  NS TGF‐β  0.082  0.026  <0.001  NS  NS IFN‐γ  NS  0.081  NS  NS  NS IL‐10  <0.001  0.001  0.010  NS  0.002 IL‐4  NS  NS  NS  NS  0.002 IL‐2  NS  NS  NS  NS  0.029 IL‐12p70  NS  NS  NS  NS  0.041     To summarise, we present here that high levels of regulatory cytokines (IL‐10 and TGF‐β) predispose to a decrease in both overall survival and disease free survival after transplant; this impairment is due to higher relapse rates.  On the other hand, a high level of pro‐inflammatory cytokines such as TNF‐α, is  associated  with  better  transplant  outcome,  without  increasing  the incidence of acute or chronic GvHD. Also, we  found that high  levels of  IL‐2, IL‐4, IL‐10 and IL‐12p70 are associated with a faster engraftment.  These  data  suggests  that  the  analysis  of  cytokines  in  the  pre‐transplant period could be used as a prognostic tool for predicting transplant outcome, 




with  patients  at  higher  risk  of  relapse  having  a  regulatory  pattern  of cytokines,  with  high  TGF‐β  and/or  IL‐10  and  low  TNF‐α  and  IFN‐γ  while patients  at  lower  risk  of  relapse  showed  the  opposite  pattern, with  higher levels of TNF‐α  and  IFN‐γ.     However,  these correlations are not  causation, and both the cytokine levels and the transplant outcome could depend upon some  other  underlying  variable.    Therefore,  a  multivariate  analysis  was performed to calculate the impact of cytokine levels on overall survival (OS), disease  free  survival  (DFS)  and  relapse  simultaneously  with  other  clinical factors,  which  have  previously  been  shown  to  be  important  in  transplant outcome.  The  clinical  factors  analysed  were  the  age  of  the  patient, underlying disease, stage of disease, conditioning regimen used and stem cell source  (Peripheral  blood  mononuclear  cells  (PBMC´s)  vs.  bone  marrow (BM)).    All  of  these  factors  were  statistically  significant  in  an  univariate analysis, as shown in Table 6. 4.            










































Table 6.5 Multivariate analysis for OS Multivariate analysis for Overall Survival (OS) including both clinical factors  and  soluble  factors.  The  most  important  predictive  factor  was  the level of IL‐10. 
Variables for OS  p value  Odds ratio  95.0% CI 
Lower     Upper Patient age  0.023  1.05  1.00659  1.09743  Stage of disease  NS  1.05  0.87109  1.27188  Conditioning regimen  NS  0.41  0.09156  1.91463  Stem cell source  NS  0.43  0.12363  1.54098  TNF‐α NS  0.72  0.26482  1.97103  TGF‐β  NS  2.03  0.65406  6.35291  IL‐10  0.008  4.58  1.48179  14.1852  RIC = reduce intensity conditioning PBMC´s = peripheral blood mononuclear cells BM = bone marrow 





Table 6.6. Multivariate analysis for DFS. Multivariate  analysis  for  disease  free  survival.  Patient  age  was  the most  important prognostic  factor  for DFS,  followed by  type of conditioning (RIC vs. Standard). 
 
 
Variables for DFS  p value  RR  95.0% CI 
Lower      Upper Patient age  0.003  1.06  1.01914  1.10446  Stage of disease  NS  1.13  0.95282  1.35484  Conditioning regimen  0.039  0.20  0.0439  0.92242  Stem cell source  0.080  2.72  0.88458  8.38451  TNF‐α  NS  0.42  0.13753  1.329  TGF‐β  0.075  2.60  0.90714  7.48084  IL‐10  NS  0.59  0.24471  1.45707  IFN‐γ  NS  0.61  0.24202  1.56778  RIC = reduce intensity conditioning PBMC´s = peripheral blood mononuclear cells BM = bone marrow 





Table 6.7  Multivariate analysis for Relapse Multivariate  analysis  to  assess  prognostic  factors  for  the  risk  of relapse. The most important factors for relapse were the levels of TGF‐β and IL‐10. 
 
Variables for Relapse  p value  RR  95.0% CI 













Discussion  The clinical relevance of cytokine levels in the pre‐conditioning period and in the  post‐transplant  period  for  the  onset  of  GvHD  has  been  established  by different  groups  (Holler,  et  al.,  1993)  (Willems,  et  al.,  1994).   While  some cytokines,  such as TNF‐α, have been clearly demonstrated  to play a role  in the  onset  of  GvHD,  in  transplant  related  mortality  (TRM)  and  in  the induction  of  anti‐tumour  T‐cell  responses,  the  role  of  other  cytokines,  and especially the regulatory cytokines, is not yet clear. Here 10 different cytokines (TNF‐α, IFN‐γ, TGF‐β, IL‐1β, IL‐2, IL‐4, IL‐10, IL‐12p70,  IL‐15  and  IL‐17) were measured  in  pre‐conditioning  samples  from patients  undergoing  an  HSCT.    The  primary  goal  was  to  ask  whether  the association  of  high  Treg  levels  with  increased  relapse  mortality  would  be reflected  in  a  similar  association  of  regulatory  cytokines.    A  secondary question was  to  ask whether  there were  any  other  significant  associations between  cytokines  and  outcome  measures  that  might  identify  useful prognostic markers of HSC transplant outcome.  The cytokines were chosen to represent inflammatory, helper and regulatory cytokines and to give some insight into the impact of the major subsets of CD4 T cells on post‐transplant outcome. In  the  initial  study,  comparing  levels  of  expression  in  the  patients  with controls,  it  was  found  that  four  cytokines  had  levels  that  differed significantly  in  the  patient  group,  in  all  cases  being  increased  above  the levels  seen  in  the  controls.    Two  of  these,  TGF‐β and  IL‐10  are  regulatory cytokines, while the other two, TNF‐α and IFN‐γ, are inflammatory cytokines.  Note  that  these were not  found  in  the same patients  instead some patients 




showed  increases  in  both  TGF‐β  and  IL‐10  while  others  had  increases  in TNF‐α and IFN‐γ.  The TGF‐β levels were strongly correlated with the levels of Treg measured in the preceding chapter, consistent with these cells being the source of the cytokine.   The IL‐10 levels did not correlate well with the Treg  levels,  suggesting  that  other  cell  types  could  be  responsible  for  the production of this cytokine. When  the cytokine  levels were compared  to  the outcomes  for  the patients, three  of  these  four  showed  significant  correlations,  with  TGF‐β  and  IL‐10 being  significantly  associated  with  a  worse  outcome  and  an  increased relapse  risk.    Conversely,  high  levels  of  TNF‐α were  associated with  lower relapse mortality and a better overall survival, with perhaps a trend for the association  of  IFN‐γ  in  the  same  direction.    In  addition,  a  number  of  other cytokines showed associations with some aspects of outcome, IL‐2, IL‐4 and IL‐12 all being associated with better engraftment. In  the  multivariate  analysis,  only  IL‐10  and  TGF‐β  showed  significance  as independent risk factors; IL‐10 was strongly associated with reduced overall survival,  and  to  a  lesser  extent  with  relapse,  while  TGF‐β  was  the  most significant factor associated with relapse. Comparing these results with others, there was not an association between the plasma  concentration of TNF‐α  and  the onset  of  aGvHD,  in  accordance with data from Visentainer et al  (Visentainer, et al., 2003). Remember et al.  (Remberger, et al., 1995) and Holler et al. (Holler E. , et al., 1990)  demonstrated  a  correlation  between  higher  pre‐transplant  levels  of TNF‐α  with  moderate  and  severe  GvHD  and  transplant  related  mortality (TRM). Other groups have associated high TNF‐α with  the onset of chronic 




GvHD    (Imamura,  et  al.,  1994).  However,  in  the  cohort  presented  here,  in contrast  to  these reports,  there was not an observable association with the onset  of  either  acute  or  chronic  GvHD.  The  discordance  between  these results  on GvHD with other  groups might be  the  result  of T‐cell  depletion; 60% of  the  patients  included  here were  T‐cell  depleted  and  that  has  been shown to diminish the incidence of GvHD.  On the other hand, high levels of TNF‐α  in our cohort were associated with better  transplant  outcome,  with  better  overall  survival,  improved  disease free survival and consequently less relapse.  TNF‐α induces T‐cell activation and  it  has  been  published  that  TNF‐α  therapy  could  enhance  anti‐tumour responses.  Therefore,  the  lower  relapse  rate  could  be  associated  with antigen‐specific T‐cell activation to mount an effective response to eliminate remaining tumour cells, inducing the graft versus leukaemia effect (GvL).  Since there was no association of TNF‐α with GvHD, these results,  together with the converse association of the regulatory cytokines increasing relapse risk  while  having  no  association  with  GvHD,  suggest  there  should  be different pathways of specific T‐cell activation that can promote either GvL effect or GvHD, and that the pre‐transplant cytokine levels influence the GvL pathway, whilst not affecting the GvHD pathway.  Another  cytokine  closely  involved  in  transplant  outcome  is  IL‐10.  IL‐10  is produce by several cells types (activated T‐cells, B‐cells and monocytes) and it strongly inhibits antigen‐specific T‐cell responses. In  the  context  of  HSCT  it  has  been  shown  that  IL‐10  inhibits  the  onset  of aGvHD and regulates other transplant complications by the inhibition of pro‐inflammatory  cytokine  production  and  therefore  is  associated  with  better 




outcome post‐transplant and lower incidence of aGvHD  (Ju, et al., 2003). The higher  levels  of  IL‐10  production  have  also  been  associated  with  a  lower overall occurrence of transplant‐related complication and a decreased risk of early death  (Baker, et al., 1999). The half‐life of IL‐10 is quite short (4 hours) and  it  is  thought  that  the  protective  effect  of  IL‐10  relies  on  its  continued production by mononuclear cells during the conditioning period. In  the  study presented here,  the  concentration of  IL‐10 prior  to  transplant did  not  show  any  association with  the  occurrence  of  GvHD.  In  contrast  to previous  reports  there  was  no  protective  effect  of  the  higher  IL‐10 production  and  consequent  better  transplant  outcome.  On  the  contrary, higher  levels  of  IL‐10  in  the  pre‐transplant  period  were  associated  with worse outcome due to higher relapse rates. This effect could be explained by the fact that IL‐10 is a modulator of immune responses, its functions includes the  down‐regulation  of  responses  against  allo‐antigens.  In  the  context  of allogeneic‐HSCT  the  allo‐responses  are  associated  with  the  anti‐leukemic effect,  high  levels  of  IL‐10  down‐regulate  the  production  of  pro‐inflammatory  cytokines  that  are  necessary  for  T‐cell  activation  and protective immune responses, thus resulting in an increasing relapse rate.  TGF‐β  as  well  plays  an  important  regulatory  role  in  immune  responses. Elevated  TGF‐β  plasma  levels  before  HSCT  have  been  shown  to  be  a predictive for a higher incidence of GvHD  (Leffell, et al., 2001) (Liem, et al., 1998).    In  the study presented here,  the  levels of TGF‐β prior  to  transplant were  analysed  and  correlated  with  transplant  outcome,  and  showed  that high  levels of TGF‐β  in  the pre‐transplant period have a  strong  correlation with higher relapse rates, similar to the finding for IL‐10. Thus,  the relapse 




free  survival  was  impaired  and  also  the  overall  survival  showed  a  trend towards worse survival.  The mechanism of this effect is not yet clear, but is likely to depend on pre‐existing Treg in the patient surviving the transplant procedure to suppress anti‐tumour responses in the post‐transplant period. The  immune‐suppressive  effect  of  anti‐inflammatory  cytokines,  such  as  IL‐10 and TGF‐β could modulate specific allo‐responses and generate tolerance that could consequently   inhibit anti‐leukaemic responses. In addition, high production  of  TFG‐β  has  been  demonstrated  to  induce  further  Tregs differentiation  that  also  could  further  regulate  allo‐antigen  specific responses. Furthermore, TGF‐β  itself has a  role  in  tumour progression and anti‐tumour  immune response suppression   (Seoane, 2008) (Medicherla, et al., 2007). The  associations  of  the  regulatory  cytokines  reveal  a  subtle  difference,  in that TGF‐β shows an association with relapse, but not with overall survival, while  IL‐10 shows an association with survival more than relapse. Perhaps TGF‐β is associated with the induction of anti‐tumour responses while IL‐10 is associated with their efficacy IL‐10 it is thought to be secreted by tumours to evade immune‐surveillance, which could also explain the lack of an effective response and the recurrence of  the  tumour.      Likewise  it  has  also  been  suggested  that  tumours may  be able  to  induce  the differentiation of Treg,  for example by  the expression of the  enzyme  indoleamine‐2,3‐dioxygenase,  or  IDO  (Curti,  et  al.,  2006).    IDO functions to deplete tryptophan to produce a metabolite, kynurenine.  Either tryptophan  depletion,  monitored  by  the  enzyme  general  control nonrepressed  2  (GCN2)  kinase,  or  kynurenine  and  other  tryptophan 




metabolites, acting through the aryl hydrocarbon receptor, or a combination of both pathways, are able to act on both dendritic cells and T cells directly, to  induce  the differentiation of CD4 T  cells  to Treg  (Munn & Mellor, 2007) (Quintana, et al., 2010).  In  this case,  the elevated  levels of Treg would be a surrogate marker  for  those  tumours  able  to  express  IDO  and  thus  recruit Treg  to  suppress  immune  responses  against  themselves.    Measurement  of IDO  levels  in  tumour  samples  and  their  correlation with  the  levels  of Treg would be required to address this hypothesis, however it may be argued that since  IL‐10  and  Treg  levels were  not  closely  correlated,  and  IL‐10 was  an independent  factor  associated  with  worse  survival,  then  the  results presented here cannot simply be explained  in terms of recruitment of Treg alone.    Instead  it appears  that  it  is  the overall  cytokine environment  in  the patient  that  is  associated with  transplant  outcome,  either  a  pro‐regulatory environment with elevated TGF‐β and/or IL‐10 that is associated with worse overall  survival,  or  a  pro‐inflammatory  environment  with  elevated  TNF‐α and/or IFN‐γ that is associated with better survival. For  the  other  cytokines  that  showed  associations with  transplant  outcome the implications are less obvious.  IFN‐γ has an immunostimulatory function as a mediator of innate immunity.  An association between high levels of IFN‐
γ  has  also  been  associated  with  increased  aGvHD  and  viral  infections. However,  the data presented here did not  show an  association  either with aGvHD  or  with  viral  infections    (Sakata,  et  al.,  2001)  (Visentainer,  et  al., 2003).    While  there  was  a  trend  towards  an  association  with  improved disease‐free survival this did not reach statistical significance. 




IL‐12 has been shown to have an anti‐tumour effect in murine models. Reddy et  al.  published  that  high  levels  of  IL‐12  were  associated  with  better transplant outcomes and increase relapse free survival (Reddy, et al., 2004). They also showed that high levels of IL‐12 pre‐transplant have an increased likelihood of higher levels of IL‐12 post‐transplant. The pre‐transplant levels of  IL‐12p70 were measured  but  in  contrast with  Reddy  did  not  show  any association  between  high  levels  of  this  cytokine  and  transplant  outcome. However, an association of  levels of high  IL‐12p70 with  faster engraftment was observed.  IL‐2 was analysed in the cohort and high levels of IL‐2 in the pre‐transplant period correlated with faster engraftment.  Tanaka and cols. (1997), demonstrated that high levels of IL‐4 were elevated in  the early engraftment phase while  IL‐12 was  lower. Here, we  found that patients  with  higher  levels  of  IL‐4  pre‐transplant  had  faster  engraftment. However, in contrast with them we find that also high levels of IL‐12 in the pre‐transplant  period  had  a  trend  towards  faster  engraftment  that  those patients with lower levels of IL‐12. The mechanisms underlying these latter associations are not clear; IL‐12 is a strong inducer of inflammatory, Th1 responses, while IL‐4 is associated with helper,  Th2  responses  and  IL‐2  drives  proliferation  of  Th0  and  Treg.    A common mechanism  to  explain  all  of  the  associations  is  hard  to  envisage.  Given the low p value for the associations with IL‐2 and IL‐12, it is clear that a larger study is required to clarify their contribution and it is possible that these may in such a wider study lose significance, while the IL‐4 association, which has a greater statistical significance might be retained. 





In  conclusion,  from  these  data  it  is  clear  that  an  imbalance  between  pro‐inflammatory  cytokines  and  immune‐regulating  cytokines  could  create  a microenvironment  that  reduces  specific  allo‐responses  for  anti‐leukemic effect, therefore, increasing the rate of relapse. Although the cohort is small the  impact  of  cytokines  is  very  strong,  showing  a  clear  pattern  of  worse overall  survival  and disease  free  survival  and higher  relapse  rates  in  those patients  in  which  an  immune‐regulatory  environment  is  prevalent.  These results  are  also  consistent  with  previous  results  of  this  thesis,  where  a prevalence of regulatory T‐cells is associated with worse transplant outcome and  higher  relapse  rates,  while  the  opposite  effect  is  seen  when  a  pro‐inflammatory  environment  is  established.  Therefore,  cytokine  monitoring pre‐transplant could be a helpful  tool  for prediction and early  treatment of major  transplant  related  complications,  and  for  monitoring  those  patients with  higher  risk  of  transplant  complications.  Based  on  cytokine  levels patients could also be stratified in higher or lower risk of relapse.  Further analysis including a larger number of patients would be required to demonstrate the clinical benefits of such stratification.   
 
  







Much effort has been expended to improve the outcome of haematopoietic stem 
transplants, yet nearly 30% of patients die after HSCT due to relapse, graft versus 
host disease or infections (Gratwohl, et al., 2005). Improvements in supportive 
care, better prophylaxis and better monitoring of infections have been useful to 
reduce this mortality. However, the identification prior to the transplant of 
patients who are at highest risk of adverse outcomes is potentially an important 
factor to increase the likelihood of success after transplantation.  
The recovery of the T cell pool is one of the key elements related to transplant 
success, therefore, enhancing immune reconstitution is still an area of significant 
research and many strategies have been used to achieve faster T cell recovery 
after HSCT, including application of cytokines and growth factors (Seggewiss & 
Einsele, 2010). Sutherland et al., based on prior experiments in which castration 
of adult mice gave rise to a rapid re-growth of the thymus and increased thymic 
function showed previously that patients treated with LHRH agonists (LHRH-A; 
these act on the hypothalamic-pituitary-gonadal axis to suppress sex steroid 
production) have a faster recovery of the T cell compartment. However, it is not 
only the recovery of cell numbers; it is equally important to recover an adequate 
repertoire of T cells able to recognize an extensive range of antigens and, 
importantly, also able to establish an anti-leukaemic response to prevent relapse. 
In the study from Sutherland et al., it was shown that the treatment with LHRH-A 
not only impacted the T cell recovery, but also wider repertoires were recovered 
in the CD4 compartment in patients that have been transplanted with allogeneic 




grafts. This effect was not seen in the autologous transplant setting, perhaps 
because of differences in T cell depletion in this patient group and a lesser 
reliance on thymic function to repopulate the peripheral T cell repertoire.  In a 
separate study, in which patients were treated with LHRH-A 3 weeks prior to 
HSCT and for 3 months afterwards, patients treated with LHRH-A had better 
disease free survival (DFS) in the autologous setting (p=0.04), although there was 
no significant difference in overall survival, (Sutherland, et al., 2008). Therefore, 
therapies to reactivate the thymus, such as LHRH-A treatment, can improve not 
only the reconstitution of the T cell compartment but also the outcome of the 
transplant. 
Now, we know that immune cells, in particular, from the lymphoid compartment, 
play an important role in the post-transplant period, in infection control, in GvHD 
and in GvL responses that can control relapse.  Thus it is not unreasonable to 
hypothesise that the individual differences in the distribution and activity of these 
cells may influence the post-transplant outcome.  Most studies have focused on 
the post-transplant period, but given that some studies do indicate that T cells 
survive the conditioning process and contribute to immune responses in the 
patient after transplant (Chalandon, et al., 2006), I have chosen to ask the 
question, is there any correlation between the pre-transplant immune state of the 
patient and the transplant outcome?  In other words, can the pre-transplant state 
either persist into the post-transplant period or condition the responses in the 
post-transplant period in such a way as to affect the outcome for the patient? 
Although the most significant consequence from this thesis would be the 
identification of parameters that could be modified in the patients to improve 
their outcome, the identification of pre-transplant immune parameters that do 
correlate with post-transplant outcome would be of benefit. Rosinski et al. 




(Rosinski, et al., 2005) suggested that the immune state in particular of the T cell 
subsets prior to transplant could be beneficial to identify patients at risk of worse 
outcome. Thus, one goal of this thesis therefore was an analysis of the 
immunological state prior to transplant to define biomarkers that might identify 
patients who would need closer monitoring to prevent undesirable complications. 
The primary analysis of the pre-transplant state of the cells of the lymphoid 
compartment was performed using flow cytometry; the cells analysed were the 
CD3+, CD4+ subsets, including regulatory T cells (Tregs) and CD8+ subsets.  In 
addition, the measurement of the levels of TRECs in the peripheral blood was 
used as an indicator of thymic function. Finally, the overall immune environment 
was analysed through the measurement of cytokines prior to transplantation.  
From each of these types of analysis, the results were correlated with the 
outcome, overall survival, disease free survival, relapse or GvHD.  
As mentioned in Chapter 3, the percentages of CD3+ T-cells in the peripheral 
blood were significantly lower in patients pre-transplant than in healthy controls, 
due to a decrease in the CD4+ population and in particular of the naïve subset, 
while the percentages of the CD8 compartment were comparable; similar 
observations were made in the Rosinski study (Rosinski, et al., 2005).  
Rosinski and his group also published that the pre-transplant levels of the 
memory CD4  T-cell (CD4+CD45RA-CD62L-) had a prognostic effect on 
transplant outcome and progression free survival not only in haematological 
malignancies but also in breast cancer, independently of other known factors 
(Rosinski, et al., 2005). However, in this study that effect couldn’t be 
demonstrated. A trend towards better survival was observed in patients who had 
higher levels of both naïve CD4+ and CD8+ T cells. High levels of naive CD4+ 
cells were associated with a decrease in the risk of relapse and with a trend 




towards enhanced disease free survival but this didn’t reach statistical 
significance. The mechanisms for such an effect are not clear.  
One criticism that could be levelled at the study is that, because of the way the 
samples were originally collected, only the percentages of each cell subset could 
be determined and not the absolute counts in the peripheral circulation.  Thus a 
decrease in the percentage of CD3+ cells could simply reflect an increase in a 
CD3- cell subset.  In the case of pretransplant samples this could reflect different 
levels of leukaemic cells, for example. However, if this were the case, one would 
expect to see the different T cell subsets showing parallel decreases.  The fact that 
only the CD4+ T cell subset shows a significant decline in the patient samples 
while the CD8+ subset does not argues that the individual subset changes are real 
events and not artefactual responses to changes in the representation of other 
cells. 
TREC levels prior to transplant were used by Svaldi et al. as a marker to assess 
transplant outcome in patients with multiple myeloma (Svaldi, et al., 2003), 
finding that patients with high TREC levels prior to transplant showed better 
overall survival and disease free survival. We also analysed TREC level to 
evaluate the impact of thymic function on the outcome. However, in contrast to 
the observations of Svaldi, no correlation at all was found between the levels of 
TRECs and transplant outcome.  Svaldi’s study was carried out on patients after 
autologous transplant, while those reported in this thesis received allogeneic 
transplants.  Many factors differ between these two sorts of transplant, including 
the level of myeloablation in the patient and the T cell depletion of the graft, that 
may account for the difference in the results obtained. 
One other subset of cells analysed was the Treg subset, but the identification of 
this population of cells was not easy to perform, because the definition of Treg at 




the time of the study was not conclusive. Therefore, the first set of markers used 
to identify Tregs was the expression of CD4 and CD25, with Tregs being defined 
as a CD4+CD25hi T cell. The percentage of CD4+ lymphocytes expressing high 
levels of CD25 was assessed by flow cytometry, as was shown in Figure 5.1 in 
Chapter 5. An analysis of Treg expression was performed in healthy controls and 
in two patient cohorts, and when they were compared, low levels of Tregs were 
found in both patient groups in comparison to the control group.  Within the 
patient groups, the levels of Tregs were particularly low in patients with CML 
and ALL. 
Outcome of the transplant was also analysed with respect to the Treg levels, and 
according to Zorn et al., an association with the onset of GvHD was expected 
(Zorn, et al., 2005). However, in contrast to their results, in both cohorts a strong 
association with relapse was found. In both cohorts, patients who had increased 
levels of Regulatory T cells (Tregs) pre-transplantation had worse outcome, due 
to higher rates of relapse.  
Since the phenotypic definition of CD4+CD25hi was not considered sufficient to 
identify Treg, to confirm the correlation obtained, another marker to identify 
Tregs was used.  The expression of FOXP3 was assessed by quantitative PCR, 
and again a correlation with outcome was performed, showing the same results, 
that high expression of FOXP3 was associated with worse overall survival due 
higher relapse rates. In the second study cohort, intracellular staining for FoxP3 
protein was carried out, and also showed the same association, high levels being 
associated with higher relapse mortality.   
It is likely that the observed association is due to a reduction in the GvL effect 
mediated by patient Treg. However, this reduction in the GvL response wasn’t 
paralleled, as mentioned before, by any change in GvHD, which might suggest 




that both events have independent mechanisms. Numerous questions arise from 
the analyses described in this thesis, the most important of which is that because 
the analysis was carried out with samples taken prior to transplant, both 
myeloablative conditioning of the patient, and infusion of residual T cell 
depletion agents present in the graft should have eliminated patient immune cells. 
Thus it is difficult to understand the mechanisms by which pre-transplant cell 
levels can influence events after the transplant. However, various studies have 
shown that some T cell depleting agents such as CAMPATH and ATG can spare 
Tregs (Bloom, et al., 2008) (Watanabe, et al., 2006). Also, it has been shown that 
Tregs are preferentially expanded under conditions of lymphopenia, such as 
would exist immediately after the transplant (Cox, et al., 2005). Moreover, a 
detailed analysis of CMV specific T cell responses in patients receiving T cell 
depleted allogeneic transplants has shown that patient CMV specific memory T 
cells can persist through the transplant procedure and establish functional 
immunity in the patient after the transplant (Chalandon, et al., 2006). Thus there 
is a precedent for the concept that patient cells might contribute to immune 
responses in the post-transplant period; in the case of patient Tregs, a greater 
number of Tregs surviving into the post-transplant period being more able to 
regulate anti-leukaemic responses.   
Similar observations on the relationship between high Treg levels and relapse 
have been published by Nadal et al., who found that CML patients who had been 
transplanted and were in remission had significantly fewer Tregs than patients 
who relapse (Nadal, et al., 2007), leading them to suggest that Treg levels could 
be used as a surrogate marker for disease relapse.  Again, no association was 
found with GvHD.  




Two specific events that may contribute to better or worse transplant outcome are 
the Graft versus Leukaemia (GvL) effect and the Graft versus Host Disease 
(GvHD) respectively, both mediated by T cells.  It has been widely considered 
that the two events are linked, and that the GvL response is simply part of a wider 
GvHD response, yet recent data have shown that they might be separate events, 
produced by different cell subsets. In the data presented in this thesis, and in the 
work of Nadal et al (Nadal, et al., 2007), it is clear that the impact of regulatory T 
cells or the regulatory cytokine milieu affects relapse, and hence presumably the 
GvL response, whilst having no effect on GvHD. 
In the study described in this thesis, an analysis of the microenvironment by 
analysing the production of cytokines prior the transplant was also performed, 
and the results showed that an imbalance between pro-inflammatory cytokines 
and regulatory cytokines had an impact on the outcome of the transplant, 
suggesting that a immune-regulating microenvironment could lead to higher rates 
of relapse, may be due to the incapacity of the immune system to mount an 
effective allo-response against tumour cells while an imbalance towards a pro-
inflammatory environment was associated with better overall survival may be 
because a pro-inflammatory environment may enhance anti-tumour responses, 
and therefore lower relapse rate could be associated with antigen-specific T-cell 
activation to mount an effective response to eliminate remaining tumour cells, 
inducing the desired graft versus leukemic effect (GvL).  
Overall, these data, suggest that the immune-regulating environment, created 
either for the patient’s Tregs or tumour induced regulatory cells as a way to evade 
immune surveillance may reduce allo-responses to produce the anti-leukaemic 
effect, leading the patients to higher relapse rates to the disease and have worse 
outcomes after transplant, especially in those patients who have received T cell 




depleting agents. Consequently, as mention in Chapter 6, there should be 
different pathways of specific T-cell activation that can promote either GvL effect 
or GvHD. And understanding the mechanisms by which tumour cells evade 
immunity to relapse or the delay in immune reconstitution will provide better 
tools to develop new therapies to improve transplant outcome. Also finding 
markers to identify a higher risk, will increase the chances to provide adequate 
treatment and therefore to improve survival.  
In recent years, an association between indoleamine 2, 3-dioxygenase (IDO) and 
Tregs has been found, with both the depletion of tryptophan by IDO and the 
production of the metabolite kynurenine being implicated in the induction of 
Treg.  The production of IDO by tumours may be a mechanism to escape immune 
surveillance (Wang, et al., 2009). In this case, the high level of Treg would be a 
surrogate marker for the immunosuppressive phenotype of the tumour, thus 
explaining a correlation with relapse post-transplant.  Studies performed in 
melanoma and breast cancer have shown an association between increase IDO 
expression and higher levels Tregs with poor outcomes (Prendergast, et al., 
2009). Similarly in AML, production of IDO by the tumour is associated with 
higher Treg levels and increased relapse (Curti, et al., 2009).   
In preliminary experiments carried out subsequent to the work in this thesis (P 
Travers, personal communication) there was no association found between high 
Treg levels and IDO levels in the cohort described here.  However, a more in 
depth study should be conducted, analysing Treg levels and both FOXP3 and 
IDO isoform expression in the context of HSCT, to validate the analysis of Tregs 
as a prognostic factor for relapse.  While it may be the case that high Treg levels 
could provide a useful prognostic marker, even if they were produced in response 
to the tumour, the question of whether they are a surrogate marker has more 




significance with respect to potential therapies to reduce relapse rates and 
enhance anti-tumour immune responses.  Depletion of Treg prior to transplant 
may have no effect on patient outcome if the underlying mechanism for the 
elevated levels is their induction by the tumour.  A better strategy in this 
circumstance would be to inhibit the mechanisms used by the tumour to induce 
Treg, for example, to treat with 1-methyltryptophan to inhibit IDO.  
 However, one aspect of the data may argues against the possibility that Treg are 
simply a surrogate marker for an immunosuppressive property of the underlying 
malignancy, and that is the lack of correlation between Treg and TGF-β levels, 
which themselves correlate well, and IL-10 levels.  If, for example, the primary 
association was with the induction of Treg by the underlying tumour, with the 
subsequent production of both TGF-β and IL-10 by the Treg, then all three 
should be correlated.  Treg and TGF-β levels are correlated, suggesting that Treg 
are the primary source of the TGF-β in the patients.  However, IL-10 can be 
produced from cell types other than Treg, and from this study, this IL-10 makes 
an independent contribution to the outcome for the patient.  It can be argued 
therefore that there is unlikely to be a single underlying cause for the associations 
observed and that it is the balance of the immune system in the patients at the 
time of transplant, either pre-regulatory or pro-inflammatory, which biases the 
eventual outcome for the patient. 
This data suggest that the study of the Regulatory T-cells and the analysis of 
cytokine production prior transplantation can be used as a predictor of the 
outcome of the transplant, and can help to stratify patients into different groups, 
those who are in higher risk and need closer monitoring, and those who are in low 
risk to relapse.  




In this study no functional analysis were performed, due the lack of appropriate 
material, but for further studies, functional analysis on the regulatory T cells 
should be performed to confirm their suppressive activity; a complete analysis 
measuring IDO expression with suppressive function of Tregs should also be 
performed. 
 
A better study design 
The main cohort of samples used in the studies reported in this thesis were 
collected as part of an ongoing study in which transplant outcome measures are 
compared against genetic polymorphisms in a variety of genes.  For that reason, 
no particular attention was paid to the number or status of the immune cells in the 
patient samples and the only attempt to retain viable cells was for the purpose of 
generating immortalised cell lines by EBV transformation of B cells. In 
retrospect, the collection and storage criteria of this study are too limited and 
restrict the conclusions that can be drawn.  For any future study, careful 
consideration would need to be given to the timing and the nature of samples 
collected, and how they are to be stored.   
Ideally a presentation sample would be collected, to allow characteristics of the 
malignant cells to be determined; this may not be feasible since the decision to 
proceed to transplant is often made at a later stage in the treatment of the 
individual patient.   
The minimum sample collection would therefore be of a pre-transplant, 
preconditioning sample.  In a prospective study, the analyses would be carried out 
on this sample without long term storage, giving the most accurate measurements 
of true pre-transplant cell and cytokine subsets.  Irrespective of whether the full 
analysis is to be made with fresh or frozen samples, a critical measurement that 




must be made at thus point is that the sample should have a full blood count, 
giving accurate numbers of CD3+ T lymphocytes and preferably numbers of 
CD4+ and CD8+ T lymphocytes.  Commercial flow cytometry kits such as 
TruCount (BD Biosciences) exist to provide this information from a small 
amount (50μl) of fresh blood.  This information can also be used as a crosscheck 
to determine whether there is preferential loss of CD4 or CD8 T cells on freezing 
and thawing; the percentage of CD4 and CD8 cells in the fresh and thawed 
samples should be the same. 
A separate tube should be collected to provide a sample of serum or plasma to be 
used for the detection of cytokines.  The recommendation from a leading 
company in the field of multi-analyte profiling, MyriadRBM, is that unless the 
specific markers of interest are known to differ between plasma and serum (for 
example, fibrinogen) then it is more important that all samples are of the same 
type.   
The main sample should be collected in citrate or EDTA collection tubes and the 
peripheral blood mononuclear cell fraction purified by standard procedures.  The 
cell number present should be counted.  The cells may be used fresh for analysis 
of T cell subsets or, if to be stored, should be pelleted in aliquots of known cell 
number and resuspended in standard heat-inactivated FCS/10% DMSO freezing 
mix before freezing initially at -80°C and then in liquid nitrogen vapour phase for 
long term storage.  Ideally, in a prospective study, the cells would be analysed 
fresh ex vivo rather than after freezing and thawing. 
In general, the tests carried out would be the same as those described within the 
thesis, though with the advantage that since absolute cell numbers would be 
known, the potential artefacts arising from variations in the numbers of tumour 
cells present in the sample can be avoided.  Additional phenotypic 




characterisation of Treg would be carried out, since the initial study treated only 
CD4+CD25hi cells as Treg; now that phenotype would be extended to include the 
expression of glucocorticoid-induced TNF receptor (GITR+) and low levels of the 
IL7 receptor α chain (CD127lo).  As was carried out for the second cohort 
described in this thesis, intracellular staining of FoxP3 protein would also be used 
to define the population of Treg. 
Cell surface markers of recent thymic emigrants have been defined, such as for 
example, CD103 (McFarland, et al., 2000) for CD8 T cells and protein tyrosine 
kinase 7 (PTK7) for CD4 T cells (Haines, et al., 2009).  Measurement of CD103+ 
naïve CD8 T cells and PTK7+ naïve CD4 T cells (ie 
CCR7+CD62L+CD27+CD45RA+) can complement TREC measurements to 
define the level of thymic output. 
In the initial cohort, rtPCR was used to estimate the relative level of expression of 
FoxP3 in the samples; this strategy could also be adapted to estimate the level of 
other functional CD4 subsets in addition to Treg. TBX21 (the human orthologue 
of Tbet), GATA3 and RORγ are the key transcription factors that define Th1, Th2 
and Th17 effector cell subpopulations, and quantitation of the levels of transcripts 
of these can indicate the functional balance of the immune response in the 
patients.  Such measurements would be interpreted together with the 
measurement of a wider range of cytokines to give a more comprehensive picture 
of the status of the immune system in the patient prior to transplant.   
In the studies reported in this thesis, the levels of 10 cytokines (IL-1α, IL-2, IL-4, 
IL-10, IL-12p70, IL-15, IL-17, IFN-γ, TNF-α, and TGF-β) were measured in 
pre-transplant plasma samples. In a future study, plasma/serum samples would be 
analysed for a larger panel of cytokines.  Although some of these can be made by 
more than one cell type, they can largely be grouped into the following functional 




classes, and the patterns of expression, together with the relative levels of the 
effector cell specific transcription factors, can give information on the underlying 
patterns of immune function in the patient at the time of sampling: 
 
Monokines: IL-1, IL6, MIP-1a, MIP-1b, MCAF, IP10, PDGF-BB, G-CSF 
Inflammatory responses: IL1ra, bFGF 
Th1: IL-2, IL-3, IL-12, IFN-γ, TNF-α 
Th2: IL-4, IL-5, IL-6, IL-10, IL-13 
Th17: IL-17 
Treg: IL-10, TGF-β 
 
These changes will improve the quality of the data.  In retrospect, it is clear that 
for the individual disease entities the patient numbers are not sufficient to allow a 
statistically significant result to be obtained.  Any future study should therefore 
include greater patient numbers, or perhaps focused on a single disease entity, 
although the proposed mechanism is likely to apply to all diseases.  In theory, this 
mechanism should apply to autologous transplants as well as to allogeneic ones, 
although the intrinsic immunogenicity of the tumour in the allogeneic setting may 
be an essential component; any anti-tumour response in the autologous setting is 
almost entirely an anti self-response. While there are clear deficiencies in the way 
the samples were collected and stored, which limit the conclusions from this 
study, none of these are fatal flaws and the results obtained are self consistent and 
replicated within the separate cohort of Australian patients.  It does therefore 
make a useful and potentially valuable contribution to the understanding of the 
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